All Transactions Announced Date,Target/Issuer,Exchange:Ticker,Transaction Types,Transaction Status,"Total Transaction Value (CADmm, Historical rate)",Buyers/Investors,Sellers,CIQ Transaction ID,Industry Classifications [Target/Issuer],Geographic Locations [Target/Issuer],Business Description [Target/Issuer],Exchange Country [Primary Listing] [Target/Issuer],Exchange Country [Secondary Listings] [Target/Issuer]
11/26/2019,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Announced, 0.4 ,-,-,IQTR645639965,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
11/21/2019,Biomark Diagnostics Inc (DB:20B),DB:20B,Private Placement,Announced, 0.5 ,-,-,IQTR645116375,Health Care (Primary),Canada (Primary),"Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a research collaboration with the University of Maryland School of Medicine related to the discovery and validation of biomarkers using a combinatorial technology approach. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",-,"CNSX:BUX
Company: Biomark Diagnostics Inc
(IQT275753722) - Canada"
11/15/2019,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Private Placement,Closed, 0.331 ,-,-,IQTR644720256,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
11/14/2019,Cotinga Pharmaceuticals Inc. (TSXV:COT),TSXV:COT,Private Placement,Announced, 0.2 ,-,-,IQTR644243205,Health Care (Primary),Canada (Primary),"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","TSXV:COT
Company: Cotinga Pharmaceuticals Inc.
(IQT29927531) - Canada",-
11/13/2019,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Announced, 6.5 ,-,-,IQTR644092947,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
11/06/2019,Valeo Pharma Inc. (CNSX:VPH),CNSX:VPH,Private Placement,Announced, 4.0 ,-,-,IQTR643168074,Health Care (Primary),Canada (Primary),"Valeo Pharma Inc. acquires and markets specialty products, and markets and distributes third-party pharmaceutical products. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; M-Eslon, an extended release morphine sulphate used for pain management; and M-Ediat, an immediate release morphine sulphate used for pain management. The company also offers Utrogestan, a micronized progesterone indicated for luteal phase support during in vitro fertilization cycles; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson’s disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada.","CNSX:VPH
Company: Valeo Pharma Inc.
(IQT602790307) - Canada",-
11/05/2019,Zymeworks Inc. (NYSE:ZYME),NYSE:ZYME,Public Offering,Announced, 98.78 ,-,-,IQTR643082436,Health Care (Primary),Canada (Primary),"Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; and ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnership with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.",-,"TSX:ZYME
Company: Zymeworks Inc.
(IQT428079716) - Canada"
11/04/2019,Must Capital Inc. (TSXV:MUST.H),TSXV:MUST.H,Private Placement,Closed, 0.05 ,-,-,IQTR642949832,Health Care (Primary),Canada (Primary),"Must Capital Inc. does not have significant operations. Previously, the company was developed 3D medical imaging software platform for legal, insurance, and medical professions. The company was formerly known as Intrinsic4D Inc. and changed its name to Must Capital Inc. in January 2019. The company was incorporated in 2010 and is based in Toronto, Canada.","TSXV:MUST.H
Company: Must Capital Inc.
(IQT244323131) - Canada",-
11/01/2019,Aquarius Surgical Technologies Inc. (CNSX:ASTI),CNSX:ASTI,Private Placement,Announced, 3.0 ,-,-,IQTR642488089,Health Care (Primary),Canada (Primary),"Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America. It provides multi-diode laser systems and related fibre-optic delivery devices for minimally invasive treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance, as well as consumables. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.","CNSX:ASTI
Company: Aquarius Surgical Technologies Inc.
(IQT536082025) - Canada",-
11/01/2019,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Announced, 3.0 ,-,-,IQTR643095510,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
10/30/2019,Lexaria Bioscience Corp. (OTCPK:LXRP),OTCPK:LXRP,Private Placement,Announced, 1.32 ,-,-,IQTR642263874,Health Care (Primary),Canada (Primary),"Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.",-,"CNSX:LXX
Company: Lexaria Bioscience Corp.
(IQT241590134) - Canada"
10/29/2019,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 0.177 ,-,-,IQTR642914681,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
10/28/2019,Sienna Senior Living Inc. (TSX:SIA),TSX:SIA,Private Placement,Closed, 150.0 ,-,-,IQTR642006941,Health Care (Primary),Canada (Primary),"Sienna Senior Living Inc., through its subsidiaries, provides senior housing and long-term care (LTC) services in Canada. It operates through LTC and Retirement segments. The company offers a range of seniors’ living options, including independent and assisted living, memory care, long-term care, and specialized programs and services, as well as provides management services. As of December 31, 2018, it owned and operated a total of 70 seniors’ living residences comprising 27 retirement residences, 35 LTC residences, and 8 seniors’ living residences. The company was formerly known as Leisureworld Senior Care Corporation and changed its name to Sienna Senior Living Inc. in May 2015. Sienna Senior Living Inc. was founded in 1972 and is headquartered in Markham, Canada.","TSX:SIA
Company: Sienna Senior Living Inc.
(IQT99930472) - Canada",-
10/22/2019,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Public Offering,Announced, 40.63 ,-,-,IQTR641388853,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
10/11/2019,Telo Genomics Corp. (TSXV:TELO),TSXV:TELO,Private Placement,Closed, 1.74 ,-,-,IQTR640275696,Health Care (Primary),Canada (Primary),"Telo Genomics Corp., a personalized medicine company, focuses on the development and commercialization of predictive technological products. Its proprietary software platform predicts the course of certain diseases and personalizes the treatment for individual patients. The company’s TeloView software platform measures the stage of the disease, rate of progression of the disease, how different diseases will respond to various therapies, and drug efficacy and toxicity. It is developing five diagnostic and prognostic products for cancers and neurological disorders, including Hodgkin’s lymphoma, prostate cancer, multiple myeloma, lung cancer, and Alzheimer’s diseases. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. is headquartered in Toronto, Canada.","TSXV:TELO
Company: Telo Genomics Corp.
(IQT401930792) - Canada",-
10/09/2019,Rapid Dose Therapeutics Corp. (CNSX:DOSE),CNSX:DOSE,Private Placement,Closed, 0.893 ,-,-,IQTR640058068,Health Care (Primary),Canada (Primary),"Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada. The company’s over the counter products include QuickStrip, a processed oral film that contains the active molecule embedded in the delivery matrix; QuickStrip energy; vitamin B12; and QuickStrip sleep that delivers melatonin to your system. It also PharmaStrip delivery system. The company serves pharmaceutical and healthcare manufacturing industry. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.","CNSX:DOSE
Company: Rapid Dose Therapeutics Corp.
(IQT595207521) - Canada",-
10/07/2019,KDA Group Inc. (TSXV:KDA),TSXV:KDA,Private Placement,Closed, 4.93 ,-,-,IQTR639715215,Health Care (Primary),Canada (Primary),"KDA Group Inc. provides pharmacy personnel replacement and vocational training services to health industry in the Province of Quebec, Canada. The company operates through Pharmacy Services and Pharmaceutical Solutions segments. It primarily offers replacement pharmacists and technical assistants. The company also provides consulting services to assist in optimizing pharmacy operations, including container-content verification delegation, optimization of laboratory operations, professional services and care plans, and inventory management. In addition, it is involved in the distribution of generic pharmaceutical products. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.","TSXV:KDA
Company: KDA Group Inc.
(IQT282005982) - Canada",-
10/07/2019,Aquarius Surgical Technologies Inc. (CNSX:ASTI),CNSX:ASTI,Private Placement,Announced, 3.0 ,-,-,IQTR639716750,Health Care (Primary),Canada (Primary),"Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America. It provides multi-diode laser systems and related fibre-optic delivery devices for minimally invasive treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance, as well as consumables. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.","CNSX:ASTI
Company: Aquarius Surgical Technologies Inc.
(IQT536082025) - Canada",-
10/01/2019,Medicenna Therapeutics Corp. (TSX:MDNA),TSX:MDNA,Public Offering,Closed, 6.0 ,-,-,IQTR639082663,Health Care (Primary),Canada (Primary),"Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.","TSX:MDNA
Company: Medicenna Therapeutics Corp.
(IQT421396443) - Canada",-
09/27/2019,Resverlogix Corp. (TSX:RVX),TSX:RVX,Private Placement,Closed, 15.92 ,-,-,IQTR638597253,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
09/26/2019,Cognetivity Neurosciences Ltd. (CNSX:CGN),CNSX:CGN,Private Placement,Closed, 0.164 ,-,-,IQTR638550602,Health Care (Primary),Canada (Primary),"Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops integrated cognitive assessment, a cognitive testing platform, which includes visual stimulus based diagnostic test and artificial intelligence tools to support the early detection and monitoring of cognitive impairment in neurodegenerative diseases, such as Alzheimer’s and dementia. The company is headquartered in Vancouver, Canada.","CNSX:CGN
Company: Cognetivity Neurosciences Ltd.
(IQT556284961) - Canada",-
09/24/2019,Premier Health Group Inc. (CNSX:PHGI),CNSX:PHGI,Private Placement,Closed, 2.1 ,-,-,IQTR638203000,Health Care (Primary),Canada (Primary),"Premier Health Group Inc., together with its subsidiaries, operates and manages primary care clinics in Canada and the Dominican Republic. It operates four primary care clinics based in the Lower Mainland in British Columbia. The company also focuses on developing proprietary technology through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company was formerly known as Premier Health Services Inc. and changed its name to Premier Health Group Inc. in September 2015. Premier Health Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.","CNSX:PHGI
Company: Premier Health Group Inc.
(IQT316965305) - Canada",-
09/23/2019,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Announced, 32.9 ,-,-,IQTR638083729,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
09/20/2019,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 0.568 ,Stratpath Management Inc.,-,IQTR637843558,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
09/19/2019,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Private Placement,Announced, 2.25 ,-,-,IQTR637706169,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
09/16/2019,SQI Diagnostics Inc. (TSXV:SQD),TSXV:SQD,Private Placement,Closed, 3.23 ,-,-,IQTR637177201,Health Care (Primary),Canada (Primary),"SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.","TSXV:SQD
Company: SQI Diagnostics Inc.
(IQT34231255) - Canada",-
09/13/2019,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.55 ,-,-,IQTR636919887,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
09/13/2019,Aurinia Pharmaceuticals Inc. (TSX:AUP),TSX:AUP,Public Offering,Announced, 53.05 ,-,-,IQTR636953574,Health Care (Primary),Canada (Primary),"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","TSX:AUP
Company: Aurinia Pharmaceuticals Inc.
(IQT2622592) - Canada",-
09/12/2019,Profound Medical Corp. (TSX:PRN),TSX:PRN,Public Offering,Closed, 9.04 ,-,-,IQTR636831006,Health Care (Primary),Canada (Primary),"Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.","TSX:PRN
Company: Profound Medical Corp.
(IQT269189531) - Canada",-
09/12/2019,Profound Medical Corp. (TSX:PRN),TSX:PRN,Public Offering,Closed, 0.957 ,-,-,IQTR637408022,Health Care (Primary),Canada (Primary),"Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.","TSX:PRN
Company: Profound Medical Corp.
(IQT269189531) - Canada",-
09/10/2019,Vaxil Bio Ltd. (TSXV:VXL),TSXV:VXL,Private Placement,Announced, 0.75 ,-,-,IQTR636575767,Health Care (Primary),Canada (Primary),"Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company’s lead product is ImMucin that has completed a Phase1/2 clinical trial, which is used for the treatment of multiple myeloma. It is also involved in developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.","TSXV:VXL
Company: Vaxil Bio Ltd.
(IQT115279018) - Canada",-
09/10/2019,EXMceuticals Inc. (CNSX:EXM),CNSX:EXM,Private Placement,Closed, 2.0 ,-,-,IQTR636641418,Health Care (Primary),Canada (Primary),"EXMceuticals Inc. engages in the sustainable cultivation, processing, and export of non-psychotropic and psychotropic pharmaceutical-grade cannabinoid ingredients from Africa. If focuses on offering Cannabidiol (CBD), a non-psychoactive cannabinoid that has been proven effective against acne, anxiety, depression, epilepsy, and degenerative diseases, such as Parkinson’s; and Tetrahydrocannabinol (THC), a psychoactive cannabinoid ingredient that has been proven effective in the fields of pain management, appetite control, anxiety, and managing side effects of chemotherapy. The company was founded in 2017 and is headquartered in Vancouver, Canada.","CNSX:EXM
Company: EXMceuticals Inc.
(IQT595175052) - Canada",-
09/09/2019,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 0.221 ,-,-,IQTR636558509,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
09/03/2019,BELLUS Health Inc. (TSX:BLU),TSX:BLU,Public Offering,Closed, 92.06 ,-,-,IQTR635507059,Health Care (Primary),Canada (Primary),"BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer’s disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.","TSX:BLU
Company: BELLUS Health Inc.
(IQT45480612) - Canada",-
08/29/2019,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Announced, 46.54 ,-,-,IQTR635055643,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
08/28/2019,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Announced, 2.0 ,-,-,IQTR634890946,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
08/23/2019,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Public Offering,Closed, 47.81 ,-,-,IQTR634241377,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
08/21/2019,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 6.24 ,-,-,IQTR633969506,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
08/21/2019,Devonian Health Group Inc. (TSXV:GSD),TSXV:GSD,Private Placement,Announced, 5.0 ,-,-,IQTR634023542,Health Care (Primary),Canada (Primary),"Devonian Health Group Inc., a pharmaceutical company, engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase II clinical trials for the treatment of ulcerative colitis and atopic dermatitis. It also develops value-added products for dermo-cosmetics. The company was incorporated in 2013 and is headquartered in Québec, Canada.","TSXV:GSD
Company: Devonian Health Group Inc.
(IQT431508091) - Canada",-
08/19/2019,iCo Therapeutics Inc. (TSXV:ICO),TSXV:ICO,Private Placement,Closed, 2.06 ,-,-,IQTR633682829,Health Care (Primary),Canada (Primary),"iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in clinical stage for the treatment of systemic fungal and parasitic infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.","TSXV:ICO
Company: iCo Therapeutics Inc.
(IQT39861103) - Canada",-
08/16/2019,VentriPoint Diagnostics Ltd. (TSXV:VPT),TSXV:VPT,Private Placement,Closed, 0.703 ,-,-,IQTR633624110,Health Care (Primary),Canada (Primary),"Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe. The company offers Ventripoint Medical System, a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company is headquartered in Toronto, Canada.","TSXV:VPT
Company: VentriPoint Diagnostics Ltd.
(IQT37361106) - Canada",-
08/16/2019,Camarico Investment Group Ltd. (CNSX:CIG),CNSX:CIG,Private Placement,Announced, 5.0 ,-,-,IQTR633726461,Health Care (Primary),Canada (Primary),"Camarico Investment Group Ltd., together with its subsidiaries, engages in the acquisition, exploration, and development of oil and gas properties in Canada. The company is also involved in the oil and gas production business; and disposal/injection operations. In addition, it produces methanol and converts methanol to other products. Further, the company engages in the procurement, terminaling, sale, and transportation of petroleum, natural gas, fuel, and petrochemical commodities in North America. The company was formerly known as Cerus Energy Group Ltd. and changed its name to Camarico Investment Group Ltd. in June 2019. Camarico Investment Group Ltd. was incorporated in 1996 and is headquartered in Nanton, Canada.","CNSX:CIG
Company: Camarico Investment Group Ltd.
(IQT23498757) - Canada",-
08/14/2019,Cognetivity Neurosciences Ltd. (CNSX:CGN),CNSX:CGN,Private Placement,Closed, 0.168 ,-,-,IQTR633348903,Health Care (Primary),Canada (Primary),"Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops integrated cognitive assessment, a cognitive testing platform, which includes visual stimulus based diagnostic test and artificial intelligence tools to support the early detection and monitoring of cognitive impairment in neurodegenerative diseases, such as Alzheimer’s and dementia. The company is headquartered in Vancouver, Canada.","CNSX:CGN
Company: Cognetivity Neurosciences Ltd.
(IQT556284961) - Canada",-
08/13/2019,Oncolytics Biotech Inc. (TSX:ONC),TSX:ONC,Public Offering,Closed, 4.97 ,-,-,IQTR633122941,Health Care (Primary),Canada (Primary),"Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.","TSX:ONC
Company: Oncolytics Biotech Inc.
(IQT2635856) - Canada",-
08/12/2019,TSO3 Inc. (TSX:TOS),TSX:TOS,Merger/Acquisition,Closed, 65.11 ,9402-4874 Québec Inc.,-,IQTR632925410,Health Care (Primary),Canada (Primary),"TSO3 Inc. engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices worldwide. Its principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States. In addition, it offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices. TSO3 Inc. was founded in 1998 and is headquartered in Quebec, Canada. As of October 1, 2019, TSO3 Inc. operates as a subsidiary of 9402-4874 Québec Inc.","TSX:TOS
Company: TSO3 Inc.
(IQT4056377) - Canada",-
08/12/2019,EGF Theramed Health Corp. (CNSX:TMED),CNSX:TMED,Private Placement,Closed, 0.35 ,-,-,IQTR633629119,Health Care (Primary),Canada (Primary),"EGF Theramed Health Corp. operates as a technology company that provides automated biomedical care online services for common health problems. It provides Fully Automated Signal Transduction, a medical device, which monitors blood pressure, as well as enables physiologically interactive health apps used in testing, tracking, and treating common health conditions. The company also offers Electro-Physiologically Interactive Computing (EPIC) system, an online system. Its EPIC serves people interested in normalizing blood pressure, blood glucose, and body weight and skin conditions. The company was formerly known as Theramed Health Corporation and changed its name to EGF Theramed Health Corp. in October 2019. EGF Theramed Health Corp. was incorporated in 2011 and is headquartered in Richmond, Canada.","CNSX:TMED
Company: EGF Theramed Health Corp.
(IQT246550060) - Canada",-
08/09/2019,Aquarius Surgical Technologies Inc. (CNSX:ASTI),CNSX:ASTI,Private Placement,Announced, 2.5 ,-,-,IQTR632726892,Health Care (Primary),Canada (Primary),"Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America. It provides multi-diode laser systems and related fibre-optic delivery devices for minimally invasive treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance, as well as consumables. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.","CNSX:ASTI
Company: Aquarius Surgical Technologies Inc.
(IQT536082025) - Canada",-
08/01/2019,Covalon Technologies Ltd. (TSXV:COV),TSXV:COV,Private Placement,Closed, 5.5 ,Chord Management Inc; Almada Inc.,-,IQTR631623912,Health Care (Primary),Canada (Primary),"Covalon Technologies Ltd., an advanced medical technologies company, researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has three proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products that treat chronic and infected wounds, such as diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform, which is used in a family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. It sells wound care dressing, surgical and peri-operative, and infection management products under the Covalon brand name. The company also offers development contracts, licensing agreements, and distribution contracts services. It provides its technologies, products, and services to various health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.","TSXV:COV
Company: Covalon Technologies Ltd.
(IQT13433026) - Canada",-
08/01/2019,Correvio Pharma Corp. (TSX:CORV),TSX:CORV,Public Offering,Closed, 15.87 ,-,-,IQTR631662097,Health Care (Primary),Canada (Primary),"Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.","TSX:CORV
Company: Correvio Pharma Corp.
(IQT2598163) - Canada",-
07/26/2019,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Closed, 0.264 ,Corner Market Capital Corporation,-,IQTR631276974,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
07/25/2019,WELL Health Technologies Corp. (TSXV:WELL),TSXV:WELL,Private Placement,Closed, 15.01 ,Impactreneur Capital Corp.; Argentum Consulting Inc.; West Bellevue Limited,-,IQTR630875212,Health Care (Primary),Canada (Primary),"WELL Health Technologies Corp. owns and operates a portfolio of primary healthcare facilities. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. As at December 31, 2018, it operated 19 medical clinics. WELL Health Technologies Corp. is headquartered in Vancouver, Canada.","TSXV:WELL
Company: WELL Health Technologies Corp.
(IQT434799348) - Canada",-
07/25/2019,Sernova Corp. (TSXV:SVA),TSXV:SVA,Private Placement,Closed, 4.68 ,-,-,IQTR630875227,Health Care (Primary),Canada (Primary),"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as hemophilia A and thyroid diseases. Sernova Corp. is headquartered in London, Canada.","TSXV:SVA
Company: Sernova Corp.
(IQT29198402) - Canada",-
07/23/2019,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 0.846 ,-,-,IQTR630510580,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
07/23/2019,Antibe Therapeutics Inc. (TSXV:ATE),TSXV:ATE,Public Offering,Closed, 8.05 ,-,-,IQTR630565794,Health Care (Primary),Canada (Primary),"Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company’s lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.","TSXV:ATE
Company: Antibe Therapeutics Inc.
(IQT241870185) - Canada",-
07/11/2019,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Closed, 3.71 ,-,-,IQTR629179498,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
07/10/2019,Hemp For Health Inc. (CNSX:HFH),CNSX:HFH,Private Placement,Closed, 0.078 ,-,-,IQTR645214638,Health Care (Primary),Canada (Primary),"Hemp for Health Inc. engages in cultivating and distributing hemp-based CBD products in Italy. It is growing hemp on 100 hectares in the Tuscany region of Italy. The company was formerly known as Euro Grow Ltd. and changed its name to Hemp for Health Inc. in May 2019. Hemp for Health Inc. was incorporated in 2018 and is headquartered in Vancouver, Canada.","CNSX:HFH
Company: Hemp For Health Inc.
(IQT629834290) - Canada",-
07/09/2019,Sirona Biochem Corp. (TSXV:SBM),TSXV:SBM,Private Placement,Closed, 1.5 ,-,-,IQTR628731210,Health Care (Primary),Canada (Primary),"Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.","TSXV:SBM
Company: Sirona Biochem Corp.
(IQT58893998) - Canada",-
07/08/2019,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Private Placement,Announced, 13.09 ,-,-,IQTR628636261,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
07/03/2019,Ortho Regenerative Technologies Inc. (CNSX:ORTH),CNSX:ORTH,Private Placement,Closed, 1.64 ,-,-,IQTR626954110,Health Care (Primary),Canada (Primary),"Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a freeze-dried formulation for rotator cuff repair; and Ortho-M, a biopolymer for bilateral meniscus repair. It also develops Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.","CNSX:ORTH
Company: Ortho Regenerative Technologies Inc.
(IQT539889813) - Canada",-
07/02/2019,SQI Diagnostics Inc. (TSXV:SQD),TSXV:SQD,Private Placement,Closed, 1.75 ,Hanover Investors Management LLP,-,IQTR626724675,Health Care (Primary),Canada (Primary),"SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.","TSXV:SQD
Company: SQI Diagnostics Inc.
(IQT34231255) - Canada",-
06/26/2019,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Closed, 1.17 ,-,-,IQTR625963562,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
06/25/2019,Theralase Technologies Inc. (TSXV:TLT),TSXV:TLT,Public Offering,Closed, 15.0 ,-,-,IQTR626007663,Health Care (Primary),Canada (Primary),"Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Anti-Cancer Therapy and Medical Laser Technology. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.","TSXV:TLT
Company: Theralase Technologies Inc.
(IQT12454055) - Canada",-
06/18/2019,Zymeworks Inc. (NYSE:ZYME),NYSE:ZYME,Public Offering,Closed, 233.65 ,-,-,IQTR622876221,Health Care (Primary),Canada (Primary),"Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; and ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnership with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.",-,"TSX:ZYME
Company: Zymeworks Inc.
(IQT428079716) - Canada"
06/13/2019,Aquarius Surgical Technologies Inc. (CNSX:ASTI),CNSX:ASTI,Private Placement,Announced, 3.0 ,-,-,IQTR621123148,Health Care (Primary),Canada (Primary),"Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America. It provides multi-diode laser systems and related fibre-optic delivery devices for minimally invasive treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance, as well as consumables. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.","CNSX:ASTI
Company: Aquarius Surgical Technologies Inc.
(IQT536082025) - Canada",-
06/06/2019,Med BioGene Inc. (TSXV:MBI.H),TSXV:MBI.H,Private Placement,Closed, 0.225 ,-,-,IQTR619247754,Health Care (Primary),Canada (Primary),"Med BioGene Inc., a life science company, focuses on the development and commercialization of genomic-based clinical tests for cancer. Its product is the GeneFx Lung, which tests early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy. Med BioGene Inc. has a collaboration agreement with the University Health Network in Toronto. The company was founded in 2002 and is headquartered in Vancouver, Canada.","TSXV:MBI.H
Company: Med BioGene Inc.
(IQT27127728) - Canada",-
05/30/2019,WELL Health Technologies Corp. (TSXV:WELL),TSXV:WELL,Private Placement,Closed, 10.5 ,West Bellevue Limited,-,IQTR616504632,Health Care (Primary),Canada (Primary),"WELL Health Technologies Corp. owns and operates a portfolio of primary healthcare facilities. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. As at December 31, 2018, it operated 19 medical clinics. WELL Health Technologies Corp. is headquartered in Vancouver, Canada.","TSXV:WELL
Company: WELL Health Technologies Corp.
(IQT434799348) - Canada",-
05/29/2019,Aptose Biosciences Inc. (TSX:APS),TSX:APS,Public Offering,Closed, 24.98 ,-,-,IQTR616071921,Health Care (Primary),Canada (Primary),"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.","TSX:APS
Company: Aptose Biosciences Inc.
(IQT35573257) - Canada",-
05/24/2019,Aptose Biosciences Inc. (TSX:APS),TSX:APS,Public Offering,Announced, 53.82 ,-,-,IQTR615619959,Health Care (Primary),Canada (Primary),"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.","TSX:APS
Company: Aptose Biosciences Inc.
(IQT35573257) - Canada",-
05/23/2019,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Closed, 0.136 ,-,-,IQTR616898992,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
05/21/2019,EGF Theramed Health Corp. (CNSX:TMED),CNSX:TMED,Private Placement,Announced, 1.0 ,-,-,IQTR614317293,Health Care (Primary),Canada (Primary),"EGF Theramed Health Corp. operates as a technology company that provides automated biomedical care online services for common health problems. It provides Fully Automated Signal Transduction, a medical device, which monitors blood pressure, as well as enables physiologically interactive health apps used in testing, tracking, and treating common health conditions. The company also offers Electro-Physiologically Interactive Computing (EPIC) system, an online system. Its EPIC serves people interested in normalizing blood pressure, blood glucose, and body weight and skin conditions. The company was formerly known as Theramed Health Corporation and changed its name to EGF Theramed Health Corp. in October 2019. EGF Theramed Health Corp. was incorporated in 2011 and is headquartered in Richmond, Canada.","CNSX:TMED
Company: EGF Theramed Health Corp.
(IQT246550060) - Canada",-
05/17/2019,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 1.0 ,-,-,IQTR613966726,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
05/15/2019,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Public Offering,Closed, 38.0 ,-,-,IQTR613661762,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
05/14/2019,Neovasc Inc. (TSX:NVCN),TSX:NVCN,Private Placement,Closed, 15.45 ,-,-,IQTR613408758,Health Care (Primary),Canada (Primary),"Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.","TSX:NVCN
Company: Neovasc Inc.
(IQT46472100) - Canada",-
05/14/2019,HLS Therapeutics Inc. (TSX:HLS),TSX:HLS,Public Offering,Closed, 43.5 ,-,-,IQTR613491594,Health Care (Primary),Canada (Primary),"HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It markets Clozaril, a pharmaceutical product used in the treatment of schizophrenia in Canada and the United States. The company also holds the U.S. marketing rights to Absorica, a commercial stage dermatology product. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company is based in Toronto, Canada.","TSX:HLS
Company: HLS Therapeutics Inc.
(IQT555924350) - Canada",-
05/14/2019,Resverlogix Corp. (TSX:RVX),TSX:RVX,Public Offering,Closed, 15.2 ,-,-,IQTR613491869,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
05/10/2019,H-Source Holdings Ltd. (TSXV:HSI),TSXV:HSI,Private Placement,Closed, 3.74 ,-,-,IQTR613242092,Health Care (Primary),Canada (Primary),"H-Source Holdings Ltd., a technology company, operates in the healthcare industry. It offers a hospital-to-hospital transaction platform that provides a marketplace for members to buy, sell, and transfer excess inventory supplies and capital equipment with each other. The company’s platform allows members to conduct transactions within integrated delivery networks and group purchasing organizations. H-Source Holdings Ltd. is headquartered in Vancouver, Canada.","TSXV:HSI
Company: H-Source Holdings Ltd.
(IQT377711030) - Canada",-
05/10/2019,Aptose Biosciences Inc. (TSX:APS),TSX:APS,Public Offering,Announced, 26.86 ,-,-,IQTR613260472,Health Care (Primary),Canada (Primary),"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.","TSX:APS
Company: Aptose Biosciences Inc.
(IQT35573257) - Canada",-
05/09/2019,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed," 1,012.3 ",-,-,IQTR613018538,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
05/09/2019,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed," 1,012.3 ",-,-,IQTR613018572,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
05/06/2019,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Announced, 2.5 ,-,-,IQTR612721825,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
05/03/2019,Hemostemix Inc. (TSXV:HEM),TSXV:HEM,Private Placement,Closed, 0.525 ,-,-,IQTR612388774,Health Care (Primary),Canada (Primary),"Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cells products, such as synergetic cell populations, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.","TSXV:HEM
Company: Hemostemix Inc.
(IQT278407492) - Canada",-
05/01/2019,Aptose Biosciences Inc. (TSX:APS),TSX:APS,Public Offering,Announced, 16.19 ,-,-,IQTR612428857,Health Care (Primary),Canada (Primary),"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.","TSX:APS
Company: Aptose Biosciences Inc.
(IQT35573257) - Canada",-
05/01/2019,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Private Placement,Closed, 1.41 ,-,-,IQTR612745120,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
04/30/2019,Valeo Pharma Inc. (CNSX:VPH),CNSX:VPH,Public Offering,Closed, 3.1 ,-,-,IQTR612057678,Health Care (Primary),Canada (Primary),"Valeo Pharma Inc. acquires and markets specialty products, and markets and distributes third-party pharmaceutical products. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; M-Eslon, an extended release morphine sulphate used for pain management; and M-Ediat, an immediate release morphine sulphate used for pain management. The company also offers Utrogestan, a micronized progesterone indicated for luteal phase support during in vitro fertilization cycles; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson’s disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada.","CNSX:VPH
Company: Valeo Pharma Inc.
(IQT602790307) - Canada",-
04/29/2019,Greenbrook TMS Inc. (TSX:GTMS),TSX:GTMS,Public Offering,Closed, 11.38 ,-,-,IQTR611938445,Health Care (Primary),Canada (Primary),"Greenbrook TMS Inc. operates outpatient mental health services centers in the United States. The company’s Greenbrook centers offer transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy that provides electromagnetic stimulation to brain regions associated with mood regulation for the treatment of major depressive disorders. As of May 10, 2019, it operated 71 company-operated treatment centers in the United States. The company was founded in 2011 and is headquartered in Toronto, Canada.","TSX:GTMS
Company: Greenbrook TMS Inc.
(IQT584768492) - Canada",-
04/29/2019,XORTX Therapeutics Inc. (CNSX:XRX),CNSX:XRX,Private Placement,Announced, 5.0 ,-,-,IQTR611950759,Health Care (Primary),Canada (Primary),"XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.","CNSX:XRX
Company: XORTX Therapeutics Inc.
(IQT549277332) - Canada",-
04/29/2019,Greenbrook TMS Inc. (TSX:GTMS),TSX:GTMS,Private Placement,Closed, 17.5 ,1315 Capital LLC,-,IQTR611979504,Health Care (Primary),Canada (Primary),"Greenbrook TMS Inc. operates outpatient mental health services centers in the United States. The company’s Greenbrook centers offer transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy that provides electromagnetic stimulation to brain regions associated with mood regulation for the treatment of major depressive disorders. As of May 10, 2019, it operated 71 company-operated treatment centers in the United States. The company was founded in 2011 and is headquartered in Toronto, Canada.","TSX:GTMS
Company: Greenbrook TMS Inc.
(IQT584768492) - Canada",-
04/26/2019,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Closed, 0.283 ,-,-,IQTR611787807,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
04/23/2019,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Private Placement,Closed, 49.01 ,-,-,IQTR625700207,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
04/18/2019,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 2.03 ,-,-,IQTR611076211,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
04/18/2019,Geyser Brands Inc. (TSXV:GYSR),TSXV:GYSR,Private Placement,Closed, 0.31 ,-,-,IQTR611390711,Health Care (Primary),Canada (Primary),"Geyser Brands Inc., a consumer healthcare company, builds health-based hemp and CBD consumer products in the nutraceutical, cosmetics, food and beverage, and pet sectors worldwide. The company is based in Vancouver, Canada.","TSXV:GYSR
Company: Geyser Brands Inc.
(IQT596162061) - Canada",-
04/15/2019,Hemostemix Inc. (TSXV:HEM),TSXV:HEM,Private Placement,Announced, 6.0 ,-,-,IQTR610515539,Health Care (Primary),Canada (Primary),"Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cells products, such as synergetic cell populations, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.","TSXV:HEM
Company: Hemostemix Inc.
(IQT278407492) - Canada",-
04/12/2019,"Abacus Health Products, Inc. (CNSX:ABCS)",CNSX:ABCS,Public Offering,Closed, 40.35 ,-,-,IQTR610220575,Health Care (Primary),Canada (Primary),"Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.","CNSX:ABCS
Company: Abacus Health Products, Inc.
(IQT600224541) - Canada",-
04/09/2019,Biomark Diagnostics Inc (DB:20B),DB:20B,Private Placement,Closed, 0.2 ,-,-,IQTR609758075,Health Care (Primary),Canada (Primary),"Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a research collaboration with the University of Maryland School of Medicine related to the discovery and validation of biomarkers using a combinatorial technology approach. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",-,"CNSX:BUX
Company: Biomark Diagnostics Inc
(IQT275753722) - Canada"
04/03/2019,Premier Health Group Inc. (CNSX:PHGI),CNSX:PHGI,Private Placement,Closed, 2.49 ,-,-,IQTR608702056,Health Care (Primary),Canada (Primary),"Premier Health Group Inc., together with its subsidiaries, operates and manages primary care clinics in Canada and the Dominican Republic. It operates four primary care clinics based in the Lower Mainland in British Columbia. The company also focuses on developing proprietary technology through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company was formerly known as Premier Health Services Inc. and changed its name to Premier Health Group Inc. in September 2015. Premier Health Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.","CNSX:PHGI
Company: Premier Health Group Inc.
(IQT316965305) - Canada",-
04/03/2019,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Public Offering,Closed, 3.16 ,-,-,IQTR608703245,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
03/29/2019,Acerus Pharmaceuticals Corporation (TSX:ASP),TSX:ASP,Private Placement,Closed, 4.53 ,First Generation Capital Inc.,-,IQTR608184903,Health Care (Primary),Canada (Primary),"Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.","TSX:ASP
Company: Acerus Pharmaceuticals Corporation
(IQT137641837) - Canada",-
03/27/2019,Avivagen Inc. (TSXV:VIV),TSXV:VIV,Private Placement,Closed, 5.37 ,-,-,IQTR607807124,Health Care (Primary),Canada (Primary),"Avivagen Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal’s own health defenses. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. The company is headquartered in Ottawa, Canada.","TSXV:VIV
Company: Avivagen Inc.
(IQT23428260) - Canada",-
03/19/2019,Cotinga Pharmaceuticals Inc. (TSXV:COT),TSXV:COT,Private Placement,Announced, 1.0 ,-,-,IQTR606881801,Health Care (Primary),Canada (Primary),"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","TSXV:COT
Company: Cotinga Pharmaceuticals Inc.
(IQT29927531) - Canada",-
03/18/2019,StillCanna Inc. (CNSX:STIL),CNSX:STIL,Private Placement,Closed, 24.37 ,-,-,IQTR606809507,Health Care (Primary),Canada (Primary),"StillCanna Inc., a life sciences company, focuses on cannabidiol extraction in Europe. The company was formerly known as EVI Global Group Developments Corp. and changed its name to StillCanna Inc. in March 2019. The company is headquartered in Vancouver, Canada.","CNSX:STIL
Company: StillCanna Inc.
(IQT312257169) - Canada",-
03/15/2019,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.609 ,-,-,IQTR606682148,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
03/14/2019,EXMceuticals Inc. (CNSX:EXM),CNSX:EXM,Private Placement,Closed, 3.52 ,-,-,IQTR606468033,Health Care (Primary),Canada (Primary),"EXMceuticals Inc. engages in the sustainable cultivation, processing, and export of non-psychotropic and psychotropic pharmaceutical-grade cannabinoid ingredients from Africa. If focuses on offering Cannabidiol (CBD), a non-psychoactive cannabinoid that has been proven effective against acne, anxiety, depression, epilepsy, and degenerative diseases, such as Parkinson’s; and Tetrahydrocannabinol (THC), a psychoactive cannabinoid ingredient that has been proven effective in the fields of pain management, appetite control, anxiety, and managing side effects of chemotherapy. The company was founded in 2017 and is headquartered in Vancouver, Canada.","CNSX:EXM
Company: EXMceuticals Inc.
(IQT595175052) - Canada",-
03/14/2019,NervGen Pharma Corp. (TSXV:NGEN),TSXV:NGEN,Private Placement,Closed, 0.74 ,-,-,IQTR606532558,Health Care (Primary),Canada (Primary),"NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.","TSXV:NGEN
Company: NervGen Pharma Corp.
(IQT604727914) - Canada",-
03/13/2019,Correvio Pharma Corp. (TSX:CORV),TSX:CORV,Public Offering,Announced, 16.01 ,-,-,IQTR606371284,Health Care (Primary),Canada (Primary),"Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.","TSX:CORV
Company: Correvio Pharma Corp.
(IQT2598163) - Canada",-
03/12/2019,Neovasc Inc. (TSX:NVCN),TSX:NVCN,Public Offering,Closed, 6.67 ,-,-,IQTR606139876,Health Care (Primary),Canada (Primary),"Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.","TSX:NVCN
Company: Neovasc Inc.
(IQT46472100) - Canada",-
03/07/2019,Must Capital Inc. (TSXV:MUST.H),TSXV:MUST.H,Private Placement,Closed, 0.19 ,-,-,IQTR605797390,Health Care (Primary),Canada (Primary),"Must Capital Inc. does not have significant operations. Previously, the company was developed 3D medical imaging software platform for legal, insurance, and medical professions. The company was formerly known as Intrinsic4D Inc. and changed its name to Must Capital Inc. in January 2019. The company was incorporated in 2010 and is based in Toronto, Canada.","TSXV:MUST.H
Company: Must Capital Inc.
(IQT244323131) - Canada",-
03/05/2019,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 33.48 ,-,-,IQTR605368820,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
02/28/2019,IMV Inc. (TSX:IMV),TSX:IMV,Public Offering,Closed, 26.71 ,-,-,IQTR604737506,Health Care (Primary),Canada (Primary),"IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company’s DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.","TSX:IMV
Company: IMV Inc.
(IQT71987179) - Canada",-
02/26/2019,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 2.97 ,-,-,IQTR604328616,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
02/25/2019,Neovasc Inc. (TSX:NVCN),TSX:NVCN,Public Offering,Closed, 6.59 ,-,-,IQTR604209450,Health Care (Primary),Canada (Primary),"Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.","TSX:NVCN
Company: Neovasc Inc.
(IQT46472100) - Canada",-
02/22/2019,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed, 659.08 ,-,-,IQTR604101846,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
02/21/2019,Trillium Therapeutics Inc. (TSX:TRIL),TSX:TRIL,Public Offering,Closed, 19.77 ,-,-,IQTR603748961,Health Care (Primary),Canada (Primary),"Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.","TSX:TRIL
Company: Trillium Therapeutics Inc.
(IQT13556077) - Canada",-
02/20/2019,SQI Diagnostics Inc. (TSXV:SQD),TSXV:SQD,Private Placement,Closed, 2.26 ,Hanover Investors Management LLP; Cumberland Private Wealth Management Inc.,-,IQTR603375486,Health Care (Primary),Canada (Primary),"SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.","TSXV:SQD
Company: SQI Diagnostics Inc.
(IQT34231255) - Canada",-
02/19/2019,Canada House Wellness Group Inc. (CNSX:CHV),CNSX:CHV,Private Placement,Closed, 3.3 ,-,-,IQTR603159327,Health Care (Primary),Canada (Primary),"Canada House Wellness Group Inc., through its subsidiaries, provides patient-specific cannabinoid therapy products and services. It offers its products and services through clinics and licensed producers. Canada House Wellness Group Inc. has a strategic partnership with Peak Pharma Solutions Inc. The company is headquartered in Pickering, Canada.","CNSX:CHV
Company: Canada House Wellness Group Inc.
(IQT417812352) - Canada",-
02/19/2019,WELL Health Technologies Corp. (TSXV:WELL),TSXV:WELL,Private Placement,Closed, 2.73 ,Horizons Ventures Limited,-,IQTR603187196,Health Care (Primary),Canada (Primary),"WELL Health Technologies Corp. owns and operates a portfolio of primary healthcare facilities. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. As at December 31, 2018, it operated 19 medical clinics. WELL Health Technologies Corp. is headquartered in Vancouver, Canada.","TSXV:WELL
Company: WELL Health Technologies Corp.
(IQT434799348) - Canada",-
02/15/2019,Sirona Biochem Corp. (TSXV:SBM),TSXV:SBM,Private Placement,Closed, 1.78 ,-,-,IQTR602885638,Health Care (Primary),Canada (Primary),"Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.","TSXV:SBM
Company: Sirona Biochem Corp.
(IQT58893998) - Canada",-
02/14/2019,Acasti Pharma Inc. (TSXV:ACST),TSXV:ACST,Public Offering,Announced,-,-,-,IQTR602452909,Health Care (Primary),Canada (Primary),"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","TSXV:ACST
Company: Acasti Pharma Inc.
(IQT129334454) - Canada",-
02/14/2019,Biocure Technology Inc. (CNSX:CURE),CNSX:CURE,Private Placement,Effective, 3.0 ,-,-,IQTR602470350,Health Care (Primary),Canada (Primary),"Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab in South Korea. The company is developing Interferons- ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing CAR T Cell Therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; a hair growth production product; and a breast cancer detection kit. Biocure Technology Inc. is headquartered in Vancouver, Canada.","CNSX:CURE
Company: Biocure Technology Inc.
(IQT545093978) - Canada",-
02/12/2019,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 0.195 ,-,-,IQTR602308875,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
02/11/2019,Cognetivity Neurosciences Ltd. (CNSX:CGN),CNSX:CGN,Private Placement,Announced, 2.5 ,-,-,IQTR601985292,Health Care (Primary),Canada (Primary),"Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops integrated cognitive assessment, a cognitive testing platform, which includes visual stimulus based diagnostic test and artificial intelligence tools to support the early detection and monitoring of cognitive impairment in neurodegenerative diseases, such as Alzheimer’s and dementia. The company is headquartered in Vancouver, Canada.","CNSX:CGN
Company: Cognetivity Neurosciences Ltd.
(IQT556284961) - Canada",-
02/08/2019,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Announced,-,-,-,IQTR607642194,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
02/04/2019,Antibe Therapeutics Inc. (TSXV:ATE),TSXV:ATE,Public Offering,Closed, 5.0 ,-,-,IQTR600965977,Health Care (Primary),Canada (Primary),"Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company’s lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.","TSXV:ATE
Company: Antibe Therapeutics Inc.
(IQT241870185) - Canada",-
02/04/2019,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Announced, 0.75 ,Corner Market Capital Corporation,-,IQTR600971880,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
01/31/2019,Resverlogix Corp. (TSX:RVX),TSX:RVX,Private Placement,Closed,-,"Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399)",-,IQTR600485153,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
01/31/2019,iCo Therapeutics Inc. (TSXV:ICO),TSXV:ICO,Private Placement,Closed, 1.25 ,-,-,IQTR600505972,Health Care (Primary),Canada (Primary),"iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in clinical stage for the treatment of systemic fungal and parasitic infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.","TSXV:ICO
Company: iCo Therapeutics Inc.
(IQT39861103) - Canada",-
01/25/2019,Lexaria Bioscience Corp. (OTCPK:LXRP),OTCPK:LXRP,Private Placement,Closed, 0.174 ,-,-,IQTR600121885,Health Care (Primary),Canada (Primary),"Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.",-,"CNSX:LXX
Company: Lexaria Bioscience Corp.
(IQT241590134) - Canada"
01/24/2019,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 0.5 ,-,-,IQTR599537055,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
01/22/2019,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Closed, 2.2 ,-,-,IQTR599397398,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
01/18/2019,Vitalhub Corp. (TSXV:VHI),TSXV:VHI,Private Placement,Closed, 3.3 ,-,-,IQTR598855410,Health Care (Primary),Canada (Primary),"VitalHub Corp., together with its subsidiaries, develops and supports healthcare information systems in the mental health, long term care, community health service, and hospital sectors in Canada and the United States. Its technologies include blockchain, mobile and Web-based assessment, and electronic healthcare record solutions. The company is based in Toronto, Canada.","TSXV:VHI
Company: Vitalhub Corp.
(IQT411552553) - Canada",-
01/18/2019,Preferred Dental Technologies Inc. (CNSX:PDTI),CNSX:PDTI,Private Placement,Effective, 0.25 ,-,-,IQTR598871554,Health Care (Primary),Canada (Primary),"Preferred Dental Technologies Inc. develops and commercializes various technologies in the dental implant industry. It offers EAS components for custom dental abutments for dental implants. The company is headquartered in Winnipeg, Canada.","CNSX:PDTI
Company: Preferred Dental Technologies Inc.
(IQT529428534) - Canada",-
01/15/2019,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 0.028 ,-,-,IQTR599272169,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
01/09/2019,VentriPoint Diagnostics Ltd. (TSXV:VPT),TSXV:VPT,Private Placement,Closed, 1.51 ,-,-,IQTR597667127,Health Care (Primary),Canada (Primary),"Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe. The company offers Ventripoint Medical System, a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company is headquartered in Toronto, Canada.","TSXV:VPT
Company: VentriPoint Diagnostics Ltd.
(IQT37361106) - Canada",-
01/09/2019,Theralase Technologies Inc. (TSXV:TLT),TSXV:TLT,Private Placement,Closed, 1.43 ,-,-,IQTR597670050,Health Care (Primary),Canada (Primary),"Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Anti-Cancer Therapy and Medical Laser Technology. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.","TSXV:TLT
Company: Theralase Technologies Inc.
(IQT12454055) - Canada",-
12/21/2018,"Abacus Health Products, Inc. (CNSX:ABCS)",CNSX:ABCS,Private Placement,Closed, 19.88 ,-,-,IQTR596020290,Health Care (Primary),Canada (Primary),"Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.","CNSX:ABCS
Company: Abacus Health Products, Inc.
(IQT600224541) - Canada",-
12/20/2018,Willow Biosciences Inc. (CNSX:WLLW),CNSX:WLLW,Private Placement,Closed, 29.22 ,"Tuatara Capital, L.P.",-,IQTR595707443,Health Care (Primary),Canada (Primary),"Willow Biosciences Inc. engages in the biosynthetic production of plant-derived compounds. The company, through its integrated suite of technologies, developing manufacturing processes for various active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management, and CNS disorders. It also owns proprietary yeast-based lab strains in the cannabinoid field that produce CBD, tetrahydrocannabinol, and cannabigerol, as well as cannabinoids. The company was founded in 2019 and is headquartered in Calgary, Canada.","CNSX:WLLW
Company: Willow Biosciences Inc.
(IQT610453680) - Canada",-
12/20/2018,Geyser Brands Inc. (TSXV:GYSR),TSXV:GYSR,Private Placement,Closed, 0.421 ,-,-,IQTR597027553,Health Care (Primary),Canada (Primary),"Geyser Brands Inc., a consumer healthcare company, builds health-based hemp and CBD consumer products in the nutraceutical, cosmetics, food and beverage, and pet sectors worldwide. The company is based in Vancouver, Canada.","TSXV:GYSR
Company: Geyser Brands Inc.
(IQT596162061) - Canada",-
12/19/2018,Gaia Grow Corp. (TSXV:GAIA),TSXV:GAIA,Private Placement,Closed, 4.51 ,-,-,IQTR595616751,Health Care (Primary),Canada (Primary),"Gaia Grow Corp., through its subsidiaries, focuses on the cultivation and sale of industrial hemp for medical uses in Canada. The company is headquartered in Vancouver, Canada.","TSXV:GAIA
Company: Gaia Grow Corp.
(IQT630614170) - Canada",-
12/17/2018,KDA Group Inc. (TSXV:KDA),TSXV:KDA,Private Placement,Closed, 3.22 ,-,-,IQTR595472250,Health Care (Primary),Canada (Primary),"KDA Group Inc. provides pharmacy personnel replacement and vocational training services to health industry in the Province of Quebec, Canada. The company operates through Pharmacy Services and Pharmaceutical Solutions segments. It primarily offers replacement pharmacists and technical assistants. The company also provides consulting services to assist in optimizing pharmacy operations, including container-content verification delegation, optimization of laboratory operations, professional services and care plans, and inventory management. In addition, it is involved in the distribution of generic pharmaceutical products. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.","TSXV:KDA
Company: KDA Group Inc.
(IQT282005982) - Canada",-
12/13/2018,Avicanna Inc. (TSX:AVCN),TSX:AVCN,Private Placement,Closed, 22.15 ,-,-,IQTR630401644,Health Care (Primary),Canada (Primary),"Avicanna Inc. focuses on the research and development, cultivation, manufacture, and commercialization of plant-derived cannabinoid-based products and extracts in North America, Latin America, Europe, and Asia. It intends to offer plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and extracts. The company was founded in 2016 and is headquartered in Toronto, Canada.","TSX:AVCN
Company: Avicanna Inc.
(IQT628278928) - Canada",-
12/12/2018,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.333 ,-,-,IQTR594820365,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
12/10/2018,BELLUS Health Inc. (TSX:BLU),TSX:BLU,Public Offering,Closed, 35.0 ,-,-,IQTR594501044,Health Care (Primary),Canada (Primary),"BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer’s disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.","TSX:BLU
Company: BELLUS Health Inc.
(IQT45480612) - Canada",-
12/07/2018,Cronos Group Inc. (TSX:CRON),TSX:CRON,Private Placement,Closed," 2,376.09 ",Altria Summit LLC,-,IQTR594204822,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
12/06/2018,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 2.26 ,-,-,IQTR594128051,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
12/06/2018,H-Source Holdings Ltd. (TSXV:HSI),TSXV:HSI,Private Placement,Closed, 0.4 ,-,-,IQTR594224113,Health Care (Primary),Canada (Primary),"H-Source Holdings Ltd., a technology company, operates in the healthcare industry. It offers a hospital-to-hospital transaction platform that provides a marketplace for members to buy, sell, and transfer excess inventory supplies and capital equipment with each other. The company’s platform allows members to conduct transactions within integrated delivery networks and group purchasing organizations. H-Source Holdings Ltd. is headquartered in Vancouver, Canada.","TSXV:HSI
Company: H-Source Holdings Ltd.
(IQT377711030) - Canada",-
11/30/2018,Aurinia Pharmaceuticals Inc. (TSX:AUP),TSX:AUP,Public Offering,Closed, 39.69 ,-,-,IQTR593534016,Health Care (Primary),Canada (Primary),"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","TSX:AUP
Company: Aurinia Pharmaceuticals Inc.
(IQT2622592) - Canada",-
11/27/2018,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Public Offering,Announced, 50.0 ,-,-,IQTR593224334,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
11/23/2018,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Announced, 2.5 ,-,-,IQTR600186151,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
11/19/2018,NervGen Pharma Corp. (TSXV:NGEN),TSXV:NGEN,Public Offering,Closed, 10.0 ,-,-,IQTR592003729,Health Care (Primary),Canada (Primary),"NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.","TSXV:NGEN
Company: NervGen Pharma Corp.
(IQT604727914) - Canada",-
11/16/2018,NanoSphere Health Sciences Inc. (CNSX:NSHS),CNSX:NSHS,Private Placement,Closed, 3.34 ,-,-,IQTR591709230,Health Care (Primary),Canada (Primary),"NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing nutritive elements and medicants through licensing arrangements. It focuses on developing cannabinoid, nutraceutical, and cosmeceutical and drug formulations. The company is headquartered in Vancouver, Canada.","CNSX:NSHS
Company: NanoSphere Health Sciences Inc.
(IQT537616648) - Canada",-
11/09/2018,Mondias Natural Products Inc. (TSXV:NHP),TSXV:NHP,Private Placement,Closed, 1.39 ,-,-,IQTR590998573,Health Care (Primary),Canada (Primary),"Mondias Natural Products Inc. develops and commercializes evidence-based botanical products for the health care and agriculture markets in Canada. It is developing botanical based specialty fertilizers for enhancing plant growth and crop yield; botanical agents to prevent and treat fungal infections of plants; oral and topical botanical drugs and agents to manage unmet medical needs, such as fungal infections of nails and skin, as well as insomnia; and products for the management of conditions, such as acne and wound healing. Mondias Natural Products Inc. is headquartered in Saint-Hubert, Canada.","TSXV:NHP
Company: Mondias Natural Products Inc.
(IQT590306183) - Canada",-
11/08/2018,Medicenna Therapeutics Corp. (TSX:MDNA),TSX:MDNA,Public Offering,Closed, 4.0 ,-,-,IQTR590728153,Health Care (Primary),Canada (Primary),"Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.","TSX:MDNA
Company: Medicenna Therapeutics Corp.
(IQT421396443) - Canada",-
11/06/2018,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 1.03 ,-,-,IQTR590419433,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
11/02/2018,Resverlogix Corp. (TSX:RVX),TSX:RVX,Private Placement,Closed, 13.5 ,-,-,IQTR590077362,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
10/30/2018,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.342 ,-,-,IQTR589614829,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
10/24/2018,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.5 ,-,-,IQTR588440009,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
10/24/2018,Oncolytics Biotech Inc. (TSX:ONC),TSX:ONC,Public Offering,Announced, 39.12 ,-,-,IQTR588699155,Health Care (Primary),Canada (Primary),"Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.","TSX:ONC
Company: Oncolytics Biotech Inc.
(IQT2635856) - Canada",-
10/17/2018,IntelGenx Technologies Corp. (OTCPK:IGXT),OTCPK:IGXT,Public Offering,Closed, 15.73 ,-,-,IQTR587098689,Health Care (Primary),Canada (Primary),"IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer’s disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",-,"TSXV:IGX
Company: IntelGenx Technologies Corp.
(IQT59707332) - Canada"
10/16/2018,Sirona Biochem Corp. (TSXV:SBM),TSXV:SBM,Private Placement,Closed, 0.71 ,-,-,IQTR587132120,Health Care (Primary),Canada (Primary),"Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.","TSXV:SBM
Company: Sirona Biochem Corp.
(IQT58893998) - Canada",-
10/16/2018,Lexaria Bioscience Corp. (OTCPK:LXRP),OTCPK:LXRP,Private Placement,Closed, 1.99 ,-,-,IQTR587659802,Health Care (Primary),Canada (Primary),"Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.",-,"CNSX:LXX
Company: Lexaria Bioscience Corp.
(IQT241590134) - Canada"
10/12/2018,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Private Placement,Closed, 4.7 ,-,-,IQTR586555866,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
10/11/2018,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Closed, 0.519 ,-,-,IQTR586356345,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
10/03/2018,Acasti Pharma Inc. (TSXV:ACST),TSXV:ACST,Public Offering,Closed, 24.0 ,-,-,IQTR585210199,Health Care (Primary),Canada (Primary),"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","TSXV:ACST
Company: Acasti Pharma Inc.
(IQT129334454) - Canada",-
10/03/2018,Acasti Pharma Inc. (TSXV:ACST),TSXV:ACST,Public Offering,Closed, 21.39 ,-,-,IQTR585210215,Health Care (Primary),Canada (Primary),"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","TSXV:ACST
Company: Acasti Pharma Inc.
(IQT129334454) - Canada",-
09/28/2018,Oncolytics Biotech Inc. (TSX:ONC),TSX:ONC,Public Offering,Announced, 34.79 ,-,-,IQTR584048045,Health Care (Primary),Canada (Primary),"Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.","TSX:ONC
Company: Oncolytics Biotech Inc.
(IQT2635856) - Canada",-
09/28/2018,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 1.15 ,-,-,IQTR592394099,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
09/20/2018,Canada House Wellness Group Inc. (CNSX:CHV),CNSX:CHV,Private Placement,Announced, 25.0 ,Alumina Partners LLC,-,IQTR581917583,Health Care (Primary),Canada (Primary),"Canada House Wellness Group Inc., through its subsidiaries, provides patient-specific cannabinoid therapy products and services. It offers its products and services through clinics and licensed producers. Canada House Wellness Group Inc. has a strategic partnership with Peak Pharma Solutions Inc. The company is headquartered in Pickering, Canada.","CNSX:CHV
Company: Canada House Wellness Group Inc.
(IQT417812352) - Canada",-
09/20/2018,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Public Offering,Closed, 16.78 ,-,-,IQTR582019403,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
09/19/2018,IntelGenx Technologies Corp. (OTCPK:IGXT),OTCPK:IGXT,Private Placement,Closed, 1.32 ,"Tilray, Inc. (NasdaqGS:TLRY)",-,IQTR581855391,Health Care (Primary),Canada (Primary),"IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer’s disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",-,"TSXV:IGX
Company: IntelGenx Technologies Corp.
(IQT59707332) - Canada"
09/18/2018,HealthSpace Data Systems Ltd. (CNSX:HS),CNSX:HS,Private Placement,Closed, 0.5 ,-,-,IQTR581540778,Health Care (Primary),Canada (Primary),"HealthSpace Data Systems Ltd. develops and sells information and communication management systems for health inspection departments of federal, provincial, state, and municipal governments in Canada and the United States. Its products include HSCloud product, an enterprise software system for license, invoice, and inspection data for use by government agencies; HealthSpace Touch, an application designed for data collection, electronically capture signatures, and insert photos and email inspection reports for health inspectors; and HealthSpace EnviroIntel EHS Manager, an internet-based client/server application used to fill out forms, request information, and view data, including reports. The company also offers HealthSpace Cloud, a customizable cloud-based portal for managing applications, licenses, permits, and other data; and HealthSpace Data that provides environmental health reporting, analytics, and monitoring platform. HealthSpace Data Systems Ltd. was founded in 1998 and is headquartered in Chilliwack, Canada.","CNSX:HS
Company: HealthSpace Data Systems Ltd.
(IQT317841012) - Canada",-
09/17/2018,Cardiol Therapeutics Inc. (TSX:CRDL),TSX:CRDL,Public Offering,Closed, 15.0 ,-,-,IQTR581408837,Health Care (Primary),Canada (Primary),"Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company develops CTX01, a proprietary formulation of pharmaceutical cannabidiol for the treatment of heart failure with preserved ejection fraction; CTX02, a proprietary formulation of methotrexate for the treatment of heart failure; and CTX03 is a proprietary nanoformulation of encapsulated Cyclosporine A for the treatment of heart failure. It also develops CRxIMT, an anti-tumor immunotherapy for the treatment of Glioblastoma Multiforme; and CardiolRx, a pharmaceutical cannabidiol product. The company was incorporated in 2017 and is headquartered in Oakville, Canada.","TSX:CRDL
Company: Cardiol Therapeutics Inc.
(IQT562976995) - Canada",-
09/12/2018,NervGen Pharma Corp. (TSXV:NGEN),TSXV:NGEN,Private Placement,Closed, 0.145 ,-,-,IQTR581862980,Health Care (Primary),Canada (Primary),"NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.","TSXV:NGEN
Company: NervGen Pharma Corp.
(IQT604727914) - Canada",-
09/11/2018,Lotus Ventures Inc. (CNSX:J),CNSX:J,Private Placement,Closed, 2.82 ,-,-,IQTR584696365,Health Care (Primary),Canada (Primary),"Lotus Ventures Inc. produces and sells medical marijuana. The company is based in Vancouver, Canada.","CNSX:J
Company: Lotus Ventures Inc.
(IQT274566928) - Canada",-
09/10/2018,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.456 ,-,-,IQTR580652031,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
09/10/2018,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Private Placement,Closed, 0.658 ,-,-,IQTR580711682,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
09/07/2018,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Public Offering,Announced, 10.0 ,-,-,IQTR580397307,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
09/07/2018,KDA Group Inc. (TSXV:KDA),TSXV:KDA,Private Placement,Closed, 2.09 ,-,-,IQTR589638672,Health Care (Primary),Canada (Primary),"KDA Group Inc. provides pharmacy personnel replacement and vocational training services to health industry in the Province of Quebec, Canada. The company operates through Pharmacy Services and Pharmaceutical Solutions segments. It primarily offers replacement pharmacists and technical assistants. The company also provides consulting services to assist in optimizing pharmacy operations, including container-content verification delegation, optimization of laboratory operations, professional services and care plans, and inventory management. In addition, it is involved in the distribution of generic pharmaceutical products. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.","TSXV:KDA
Company: KDA Group Inc.
(IQT282005982) - Canada",-
09/06/2018,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Announced, 2.5 ,-,-,IQTR580221499,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
09/06/2018,StillCanna Inc. (CNSX:STIL),CNSX:STIL,Private Placement,Closed, 4.0 ,-,-,IQTR580221611,Health Care (Primary),Canada (Primary),"StillCanna Inc., a life sciences company, focuses on cannabidiol extraction in Europe. The company was formerly known as EVI Global Group Developments Corp. and changed its name to StillCanna Inc. in March 2019. The company is headquartered in Vancouver, Canada.","CNSX:STIL
Company: StillCanna Inc.
(IQT312257169) - Canada",-
09/06/2018,Medexus Pharmaceuticals Inc. (TSXV:MDP),TSXV:MDP,Private Placement,Closed, 61.95 ,Lumira Ventures; Goodwood Inc.; 9346-4626 Québec Inc.,-,IQTR580310634,Health Care (Primary),Canada (Primary),"Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company’s primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Otixal, a prescription product for the treatment of acute otitis media with tympanostomy tubes in pediatric patients; Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; and Rupall, an allergy medication. It also offers Metoject Subcutaneous for the treatment of rheumatoid arthritis, psoriasis, and psoriatic arthritis; and distributes pharmaceutical products, such as Treosulfan and Gliolan. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is headquartered in Verdun, Canada.","TSXV:MDP
Company: Medexus Pharmaceuticals Inc.
(IQT253516634) - Canada",-
08/31/2018,Apteryx Imaging Inc. (TSXV:XRAY),TSXV:XRAY,Private Placement,Closed, 5.48 ,Polar Asset Management Partners Inc.; Ewing Morris & Co. Investment Partners,-,IQTR579590435,Health Care (Primary),Canada (Primary),"Apteryx Imaging Inc. provides diagnostic imaging software and device technologies for dentists and oral health specialists. Its imaging software products include XrayVision 4 that provides image enhancement and analysis tools with open-architecture technology allowing integration with the imaging systems from various manufacturers; XVWeb, a DICOM server that accepts images from various DICOM-compliant imaging software; XVWeb 3D, a cloud solution for 3D dental imaging; XVlite, a dental imaging software package; and XrayVision DCV, a DICOM-based dental imaging suite. The company’s imaging hardware products comprise TUXEDO intraoral sensors; LED IC100 intraoral cameras; and RAYSCAN panoramic + cephalometric imaging solutions. It also offers VELscope Vx system, a device for the enhanced visualization of mucosal abnormalities, such as oral cancer and premalignant dysplasia; VELscope Vx imaging adapter for fluorescence and white-light clinical imaging; Vx VELcaps to prevent patient cross contamination; Vx VELsheaths, a single use plastic sheath to prevent patient cross contamination; and VELscope Vx Value Bundle, a portable handheld device used to conduct oral tissue examinations. Apteryx Imaging Inc. has a partnership agreement with 4th-IR AG to develop a suite of cloud-based AI solutions. The company was formerly known as LED Medical Diagnostics Inc. and changed its name to Apteryx Imaging Inc. in September 2019. Apteryx Imaging Inc. was founded in 2002 and is headquartered in Vancouver, Canada.","TSXV:XRAY
Company: Apteryx Imaging Inc.
(IQT143328534) - Canada",-
08/31/2018,"Abacus Health Products, Inc. (CNSX:ABCS)",CNSX:ABCS,Private Placement,Closed, 3.97 ,-,-,IQTR581685711,Health Care (Primary),Canada (Primary),"Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.","CNSX:ABCS
Company: Abacus Health Products, Inc.
(IQT600224541) - Canada",-
08/31/2018,Rapid Dose Therapeutics Corp. (CNSX:DOSE),CNSX:DOSE,Private Placement,Closed, 5.4 ,Aphria Inc. (TSX:APHA),-,IQTR590253239,Health Care (Primary),Canada (Primary),"Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada. The company’s over the counter products include QuickStrip, a processed oral film that contains the active molecule embedded in the delivery matrix; QuickStrip energy; vitamin B12; and QuickStrip sleep that delivers melatonin to your system. It also PharmaStrip delivery system. The company serves pharmaceutical and healthcare manufacturing industry. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.","CNSX:DOSE
Company: Rapid Dose Therapeutics Corp.
(IQT595207521) - Canada",-
08/30/2018,Resverlogix Corp. (TSX:RVX),TSX:RVX,Private Placement,Closed, 26.0 ,-,-,IQTR579448215,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
08/28/2018,Theralase Technologies Inc. (TSXV:TLT),TSXV:TLT,Private Placement,Closed, 1.1 ,-,-,IQTR579180353,Health Care (Primary),Canada (Primary),"Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Anti-Cancer Therapy and Medical Laser Technology. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.","TSXV:TLT
Company: Theralase Technologies Inc.
(IQT12454055) - Canada",-
08/24/2018,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.112 ,-,-,IQTR578742447,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
08/16/2018,"Agility Health, Inc. (TSXV:AHI.H)",TSXV:AHI.H,Private Placement,Announced, 2.0 ,-,-,IQTR577817715,Health Care (Primary),Canada (Primary),"Agility Health, Inc. does not have significant operations. It focuses on identifying an active business. Previously, the company provided rehabilitation services through its clinics in Canada. Agility Health, Inc. was founded in 1968 and is headquartered in Hamilton, Canada.","TSXV:AHI.H
Company: Agility Health, Inc.
(IQT141105226) - Canada",-
08/15/2018,VentriPoint Diagnostics Ltd. (TSXV:VPT),TSXV:VPT,Private Placement,Closed, 1.01 ,-,-,IQTR577642534,Health Care (Primary),Canada (Primary),"Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe. The company offers Ventripoint Medical System, a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company is headquartered in Toronto, Canada.","TSXV:VPT
Company: VentriPoint Diagnostics Ltd.
(IQT37361106) - Canada",-
08/13/2018,Izotropic Corporation (CNSX:IZO),CNSX:IZO,Private Placement,Closed, 0.1 ,-,-,IQTR577411551,Health Care (Primary),Canada (Primary),"Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3-D breast CT imaging technology for early diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.","CNSX:IZO
Company: Izotropic Corporation
(IQT552160890) - Canada",-
08/13/2018,ADVANZ PHARMA Corp. (TSX:ADVZ),TSX:ADVZ,Private Placement,Effective, 1.54 ,-,-,IQTR577431581,Health Care (Primary),Canada (Primary),"ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, ADVANZ PHARMA International and ADVANZ PHARMA North America. The ADVANZ PHARMA International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment’s products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; Zapain, a combination of codeine phosphate and paracetamol for severe pain reliefs, such as back pain, toothache, severe sprains and strains, and pain after operations. The ADVANZ PHARMA North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. The company sells its products through direct sales and local distribution relationships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.","TSX:ADVZ
Company: ADVANZ PHARMA Corp.
(IQT253396955) - Canada",-
08/09/2018,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Private Placement,Closed, 0.775 ,-,-,IQTR576878740,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
08/08/2018,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.818 ,-,-,IQTR576834170,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
08/02/2018,EGF Theramed Health Corp. (CNSX:TMED),CNSX:TMED,Private Placement,Announced, 5.0 ,-,-,IQTR576303908,Health Care (Primary),Canada (Primary),"EGF Theramed Health Corp. operates as a technology company that provides automated biomedical care online services for common health problems. It provides Fully Automated Signal Transduction, a medical device, which monitors blood pressure, as well as enables physiologically interactive health apps used in testing, tracking, and treating common health conditions. The company also offers Electro-Physiologically Interactive Computing (EPIC) system, an online system. Its EPIC serves people interested in normalizing blood pressure, blood glucose, and body weight and skin conditions. The company was formerly known as Theramed Health Corporation and changed its name to EGF Theramed Health Corp. in October 2019. EGF Theramed Health Corp. was incorporated in 2011 and is headquartered in Richmond, Canada.","CNSX:TMED
Company: EGF Theramed Health Corp.
(IQT246550060) - Canada",-
08/01/2018,TSO3 Inc. (TSX:TOS),TSX:TOS,Private Placement,Closed, 26.01 ,-,-,IQTR576058123,Health Care (Primary),Canada (Primary),"TSO3 Inc. engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices worldwide. Its principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States. In addition, it offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices. TSO3 Inc. was founded in 1998 and is headquartered in Quebec, Canada. As of October 1, 2019, TSO3 Inc. operates as a subsidiary of 9402-4874 Québec Inc.","TSX:TOS
Company: TSO3 Inc.
(IQT4056377) - Canada",-
07/31/2018,SQI Diagnostics Inc. (TSXV:SQD),TSXV:SQD,Private Placement,Closed, 3.52 ,-,-,IQTR575920364,Health Care (Primary),Canada (Primary),"SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.","TSXV:SQD
Company: SQI Diagnostics Inc.
(IQT34231255) - Canada",-
07/25/2018,Valeo Pharma Inc. (CNSX:VPH),CNSX:VPH,Private Placement,Closed, 1.4 ,-,-,IQTR603308895,Health Care (Primary),Canada (Primary),"Valeo Pharma Inc. acquires and markets specialty products, and markets and distributes third-party pharmaceutical products. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; M-Eslon, an extended release morphine sulphate used for pain management; and M-Ediat, an immediate release morphine sulphate used for pain management. The company also offers Utrogestan, a micronized progesterone indicated for luteal phase support during in vitro fertilization cycles; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson’s disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada.","CNSX:VPH
Company: Valeo Pharma Inc.
(IQT602790307) - Canada",-
07/23/2018,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Public Offering,Closed, 0.8 ,-,-,IQTR574915614,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
07/19/2018,Devonian Health Group Inc. (TSXV:GSD),TSXV:GSD,Private Placement,Announced, 5.0 ,Aspri Pharma Canada Inc.,-,IQTR574612600,Health Care (Primary),Canada (Primary),"Devonian Health Group Inc., a pharmaceutical company, engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase II clinical trials for the treatment of ulcerative colitis and atopic dermatitis. It also develops value-added products for dermo-cosmetics. The company was incorporated in 2013 and is headquartered in Québec, Canada.","TSXV:GSD
Company: Devonian Health Group Inc.
(IQT431508091) - Canada",-
07/17/2018,Kane Biotech Inc. (TSXV:KNE),TSXV:KNE,Private Placement,Closed, 0.5 ,-,-,IQTR574431591,Health Care (Primary),Canada (Primary),"Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.","TSXV:KNE
Company: Kane Biotech Inc.
(IQT5532100) - Canada",-
07/16/2018,"Agility Health, Inc. (TSXV:AHI.H)",TSXV:AHI.H,Private Placement,Closed, 0.15 ,-,-,IQTR574246999,Health Care (Primary),Canada (Primary),"Agility Health, Inc. does not have significant operations. It focuses on identifying an active business. Previously, the company provided rehabilitation services through its clinics in Canada. Agility Health, Inc. was founded in 1968 and is headquartered in Hamilton, Canada.","TSXV:AHI.H
Company: Agility Health, Inc.
(IQT141105226) - Canada",-
07/13/2018,Neovasc Inc. (TSX:NVCN),TSX:NVCN,Public Offering,Announced,-,-,-,IQTR574208943,Health Care (Primary),Canada (Primary),"Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.","TSX:NVCN
Company: Neovasc Inc.
(IQT46472100) - Canada",-
07/13/2018,Element Lifestyle Retirement Inc. (TSXV:ELM),TSXV:ELM,Private Placement,Announced, 1.8 ,-,-,IQTR576145425,Health Care (Primary),Canada (Primary),"Element Lifestyle Retirement Inc. develops and operates senior retirement communities in British Columbia, Canada. It provides development consulting services, such as property selection, assembly and acquisition, building and community design, municipal approval and land entitlement processes, financing, marketing, sales and leasing, and construction project management. The company also offers long-term management services for the facilities, which include management of the administration, operation, and financing of retirement communities and physical facilities. Element Lifestyle Retirement Inc. was incorporated in 2007 and is headquartered in Vancouver, Canada.","TSXV:ELM
Company: Element Lifestyle Retirement Inc.
(IQT142268555) - Canada",-
07/10/2018,Correvio Pharma Corp. (TSX:CORV),TSX:CORV,Public Offering,Closed, 17.28 ,-,-,IQTR573533265,Health Care (Primary),Canada (Primary),"Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.","TSX:CORV
Company: Correvio Pharma Corp.
(IQT2598163) - Canada",-
07/09/2018,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 1.0 ,-,-,IQTR573472448,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
06/28/2018,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 25.14 ,-,-,IQTR572375272,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
06/28/2018,Enlighta Inc. (TSXV:NLTA),TSXV:NLTA,Private Placement,Effective, 2.64 ,-,-,IQTR572406958,Health Care (Primary),Canada (Primary),"Enlighta Inc. operates as a healthcare and medical digital, green, and clean technology company. The company, through a joint venture with Fischer Institute of Physical Therapy and Performance, provides physical therapy services and rehabilitative medicine treatments. It also has a patent pending portfolio of 10 OTC nutraceutical formulations. The company was formerly known as HooXi Network Inc. and changed its name to Enlighta Inc. in July 2019. Enlighta Inc. is based in Richmond, Canada.","TSXV:NLTA
Company: Enlighta Inc.
(IQT253108413) - Canada",-
06/26/2018,Sernova Corp. (TSXV:SVA),TSXV:SVA,Private Placement,Closed, 2.75 ,-,-,IQTR571992583,Health Care (Primary),Canada (Primary),"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as hemophilia A and thyroid diseases. Sernova Corp. is headquartered in London, Canada.","TSXV:SVA
Company: Sernova Corp.
(IQT29198402) - Canada",-
06/25/2018,H-Source Holdings Ltd. (TSXV:HSI),TSXV:HSI,Private Placement,Closed, 1.15 ,-,-,IQTR571918570,Health Care (Primary),Canada (Primary),"H-Source Holdings Ltd., a technology company, operates in the healthcare industry. It offers a hospital-to-hospital transaction platform that provides a marketplace for members to buy, sell, and transfer excess inventory supplies and capital equipment with each other. The company’s platform allows members to conduct transactions within integrated delivery networks and group purchasing organizations. H-Source Holdings Ltd. is headquartered in Vancouver, Canada.","TSXV:HSI
Company: H-Source Holdings Ltd.
(IQT377711030) - Canada",-
06/19/2018,Trillium Therapeutics Inc. (TSX:TRIL),TSX:TRIL,Public Offering,Announced, 33.18 ,-,-,IQTR571255000,Health Care (Primary),Canada (Primary),"Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.","TSX:TRIL
Company: Trillium Therapeutics Inc.
(IQT13556077) - Canada",-
06/14/2018,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.06 ,-,-,IQTR571051811,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
06/13/2018,Microbix Biosystems Inc. (TSX:MBX),TSX:MBX,Private Placement,Closed, 0.099 ,-,-,IQTR570908063,Health Care (Primary),Canada (Primary),"Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for diagnostic assays. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.","TSX:MBX
Company: Microbix Biosystems Inc.
(IQT2630461) - Canada",-
06/08/2018,Aptose Biosciences Inc. (TSX:APS),TSX:APS,Public Offering,Announced, 25.92 ,-,-,IQTR570297886,Health Care (Primary),Canada (Primary),"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.","TSX:APS
Company: Aptose Biosciences Inc.
(IQT35573257) - Canada",-
06/07/2018,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.941 ,-,-,IQTR570181656,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
06/06/2018,Zymeworks Inc. (NYSE:ZYME),NYSE:ZYME,Public Offering,Closed, 109.83 ,-,-,IQTR569968991,Health Care (Primary),Canada (Primary),"Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; and ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnership with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.",-,"TSX:ZYME
Company: Zymeworks Inc.
(IQT428079716) - Canada"
06/06/2018,Acerus Pharmaceuticals Corporation (TSX:ASP),TSX:ASP,Public Offering,Closed, 5.75 ,-,-,IQTR569988681,Health Care (Primary),Canada (Primary),"Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.","TSX:ASP
Company: Acerus Pharmaceuticals Corporation
(IQT137641837) - Canada",-
06/01/2018,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Closed, 3.0 ,"Lind Asset Management XI, LLC",-,IQTR569306512,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
05/31/2018,Oncolytics Biotech Inc. (TSX:ONC),TSX:ONC,Public Offering,Closed, 10.36 ,-,-,IQTR569119095,Health Care (Primary),Canada (Primary),"Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.","TSX:ONC
Company: Oncolytics Biotech Inc.
(IQT2635856) - Canada",-
05/30/2018,Theratechnologies Inc. (TSX:TH),TSX:TH,Public Offering,Closed, 66.37 ,-,-,IQTR568886710,Health Care (Primary),Canada (Primary),"Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.","TSX:TH
Company: Theratechnologies Inc.
(IQT2657754) - Canada",-
05/28/2018,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.8 ,-,-,IQTR568107741,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
05/25/2018,Ortho Regenerative Technologies Inc. (CNSX:ORTH),CNSX:ORTH,Private Placement,Closed, 1.5 ,-,-,IQTR567936084,Health Care (Primary),Canada (Primary),"Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a freeze-dried formulation for rotator cuff repair; and Ortho-M, a biopolymer for bilateral meniscus repair. It also develops Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.","CNSX:ORTH
Company: Ortho Regenerative Technologies Inc.
(IQT539889813) - Canada",-
05/24/2018,Cardiol Therapeutics Inc. (TSX:CRDL),TSX:CRDL,Private Placement,Closed, 10.5 ,-,-,IQTR567906882,Health Care (Primary),Canada (Primary),"Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company develops CTX01, a proprietary formulation of pharmaceutical cannabidiol for the treatment of heart failure with preserved ejection fraction; CTX02, a proprietary formulation of methotrexate for the treatment of heart failure; and CTX03 is a proprietary nanoformulation of encapsulated Cyclosporine A for the treatment of heart failure. It also develops CRxIMT, an anti-tumor immunotherapy for the treatment of Glioblastoma Multiforme; and CardiolRx, a pharmaceutical cannabidiol product. The company was incorporated in 2017 and is headquartered in Oakville, Canada.","TSX:CRDL
Company: Cardiol Therapeutics Inc.
(IQT562976995) - Canada",-
05/16/2018,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Effective, 0.5 ,-,-,IQTR565579211,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
05/09/2018,Preferred Dental Technologies Inc. (CNSX:PDTI),CNSX:PDTI,Private Placement,Closed, 0.3 ,-,-,IQTR570512303,Health Care (Primary),Canada (Primary),"Preferred Dental Technologies Inc. develops and commercializes various technologies in the dental implant industry. It offers EAS components for custom dental abutments for dental implants. The company is headquartered in Winnipeg, Canada.","CNSX:PDTI
Company: Preferred Dental Technologies Inc.
(IQT529428534) - Canada",-
05/08/2018,Theralase Technologies Inc. (TSXV:TLT),TSXV:TLT,Private Placement,Closed, 1.02 ,-,-,IQTR563343404,Health Care (Primary),Canada (Primary),"Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Anti-Cancer Therapy and Medical Laser Technology. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.","TSXV:TLT
Company: Theralase Technologies Inc.
(IQT12454055) - Canada",-
05/08/2018,IntelGenx Technologies Corp. (OTCPK:IGXT),OTCPK:IGXT,Private Placement,Closed, 4.15 ,-,-,IQTR564039837,Health Care (Primary),Canada (Primary),"IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer’s disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",-,"TSXV:IGX
Company: IntelGenx Technologies Corp.
(IQT59707332) - Canada"
05/07/2018,Biocure Technology Inc. (CNSX:CURE),CNSX:CURE,Private Placement,Effective, 0.75 ,-,-,IQTR562773941,Health Care (Primary),Canada (Primary),"Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab in South Korea. The company is developing Interferons- ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing CAR T Cell Therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; a hair growth production product; and a breast cancer detection kit. Biocure Technology Inc. is headquartered in Vancouver, Canada.","CNSX:CURE
Company: Biocure Technology Inc.
(IQT545093978) - Canada",-
05/04/2018,Premier Health Group Inc. (CNSX:PHGI),CNSX:PHGI,Private Placement,Closed, 3.56 ,-,-,IQTR562146249,Health Care (Primary),Canada (Primary),"Premier Health Group Inc., together with its subsidiaries, operates and manages primary care clinics in Canada and the Dominican Republic. It operates four primary care clinics based in the Lower Mainland in British Columbia. The company also focuses on developing proprietary technology through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company was formerly known as Premier Health Services Inc. and changed its name to Premier Health Group Inc. in September 2015. Premier Health Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.","CNSX:PHGI
Company: Premier Health Group Inc.
(IQT316965305) - Canada",-
05/01/2018,IntelGenx Technologies Corp. (OTCPK:IGXT),OTCPK:IGXT,Private Placement,Closed, 4.15 ,-,-,IQTR561455777,Health Care (Primary),Canada (Primary),"IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer’s disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",-,"TSXV:IGX
Company: IntelGenx Technologies Corp.
(IQT59707332) - Canada"
05/01/2018,ADVANZ PHARMA Corp. (TSX:ADVZ),TSX:ADVZ,Private Placement,Closed, 775.11 ,GSO Capital Partners LP,-,IQTR561674025,Health Care (Primary),Canada (Primary),"ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, ADVANZ PHARMA International and ADVANZ PHARMA North America. The ADVANZ PHARMA International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment’s products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; Zapain, a combination of codeine phosphate and paracetamol for severe pain reliefs, such as back pain, toothache, severe sprains and strains, and pain after operations. The ADVANZ PHARMA North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. The company sells its products through direct sales and local distribution relationships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.","TSX:ADVZ
Company: ADVANZ PHARMA Corp.
(IQT253396955) - Canada",-
04/30/2018,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.605 ,-,-,IQTR561151918,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
04/30/2018,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Closed, 7.24 ,-,-,IQTR561354440,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
04/27/2018,Premier Health Group Inc. (CNSX:PHGI),CNSX:PHGI,Private Placement,Effective, 1.0 ,-,-,IQTR560740298,Health Care (Primary),Canada (Primary),"Premier Health Group Inc., together with its subsidiaries, operates and manages primary care clinics in Canada and the Dominican Republic. It operates four primary care clinics based in the Lower Mainland in British Columbia. The company also focuses on developing proprietary technology through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company was formerly known as Premier Health Services Inc. and changed its name to Premier Health Group Inc. in September 2015. Premier Health Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.","CNSX:PHGI
Company: Premier Health Group Inc.
(IQT316965305) - Canada",-
04/25/2018,Chartwell Retirement Residences (TSX:CSH.UN),TSX:CSH.UN,Private Placement,Closed, 150.0 ,-,-,IQTR560503895,Health Care (Primary),Canada (Primary),"Chartwell is an unincorporated, open-ended real estate trust which indirectly owns and operates a complete range of seniors housing communities, from independent supportive living through assisted living to long term care. It is the largest operator in the Canadian seniors living sector with over 200 quality retirement communities in four provinces. Chartwell is committed to its vision of Making People's Lives BETTER and to providing a happier, healthier and more fulfilling life experience for its residents.","TSX:CSH.UN
Company: Chartwell Retirement Residences
(IQT7768795) - Canada",-
04/24/2018,WELL Health Technologies Corp. (TSXV:WELL),TSXV:WELL,Private Placement,Closed, 5.24 ,Argentum Consulting Inc.,-,IQTR560407229,Health Care (Primary),Canada (Primary),"WELL Health Technologies Corp. owns and operates a portfolio of primary healthcare facilities. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. As at December 31, 2018, it operated 19 medical clinics. WELL Health Technologies Corp. is headquartered in Vancouver, Canada.","TSXV:WELL
Company: WELL Health Technologies Corp.
(IQT434799348) - Canada",-
04/23/2018,Spectral Medical Inc. (TSX:EDT),TSX:EDT,Private Placement,Closed, 5.31 ,-,-,IQTR560249043,Health Care (Primary),Canada (Primary),"Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops continuous renal replacement therapy, an open platform for other hemoperfusion cartridges. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.","TSX:EDT
Company: Spectral Medical Inc.
(IQT2651919) - Canada",-
04/23/2018,Acasti Pharma Inc. (TSXV:ACST),TSXV:ACST,Public Offering,Closed, 10.01 ,-,-,IQTR560263192,Health Care (Primary),Canada (Primary),"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","TSXV:ACST
Company: Acasti Pharma Inc.
(IQT129334454) - Canada",-
04/20/2018,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Private Placement,Closed, 0.718 ,-,-,IQTR560010143,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
04/19/2018,Therma Bright Inc. (TSXV:THRM),TSXV:THRM,Private Placement,Closed, 0.579 ,-,-,IQTR559777633,Health Care (Primary),Canada (Primary),"Therma Bright Inc. develops and markets thermal therapy technology that provides topical relief to skin irritations resulting from insect bites, stings, and prevention of cold sores. It offers InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.","TSXV:THRM
Company: Therma Bright Inc.
(IQT2623116) - Canada",-
04/18/2018,Must Capital Inc. (TSXV:MUST.H),TSXV:MUST.H,Merger/Acquisition,Closed,-,"Scharfe Holdings, Inc.","Mosaic Makro Medical Partners, LLC",IQTR559618038,Health Care (Primary),Canada (Primary),"Must Capital Inc. does not have significant operations. Previously, the company was developed 3D medical imaging software platform for legal, insurance, and medical professions. The company was formerly known as Intrinsic4D Inc. and changed its name to Must Capital Inc. in January 2019. The company was incorporated in 2010 and is based in Toronto, Canada.","TSXV:MUST.H
Company: Must Capital Inc.
(IQT244323131) - Canada",-
04/18/2018,Must Capital Inc. (TSXV:MUST.H),TSXV:MUST.H,Merger/Acquisition,Closed,-,2444444 Ontario Inc.,"Scharfe Holdings, Inc.",IQTR559636155,Health Care (Primary),Canada (Primary),"Must Capital Inc. does not have significant operations. Previously, the company was developed 3D medical imaging software platform for legal, insurance, and medical professions. The company was formerly known as Intrinsic4D Inc. and changed its name to Must Capital Inc. in January 2019. The company was incorporated in 2010 and is based in Toronto, Canada.","TSXV:MUST.H
Company: Must Capital Inc.
(IQT244323131) - Canada",-
04/11/2018,Akumin Inc. (TSX:AKU),TSX:AKU,Public Offering,Closed, 44.97 ,-,-,IQTR558878676,Health Care (Primary),Canada (Primary),"Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2018, the company operated 95 imaging centers located in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, arthrography, biopsy, and other diagnostic or interventional radiology procedures; and online medical bill payment services. Akumin Inc. is headquartered in Toronto, Canada.","TSX:AKU
Company: Akumin Inc.
(IQT528412037) - Canada",-
04/11/2018,Resverlogix Corp. (TSX:RVX),TSX:RVX,Private Placement,Closed, 33.2 ,-,-,IQTR558911078,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
04/09/2018,Camarico Investment Group Ltd. (CNSX:CIG),CNSX:CIG,Private Placement,Closed, 2.13 ,-,-,IQTR558636546,Health Care (Primary),Canada (Primary),"Camarico Investment Group Ltd., together with its subsidiaries, engages in the acquisition, exploration, and development of oil and gas properties in Canada. The company is also involved in the oil and gas production business; and disposal/injection operations. In addition, it produces methanol and converts methanol to other products. Further, the company engages in the procurement, terminaling, sale, and transportation of petroleum, natural gas, fuel, and petrochemical commodities in North America. The company was formerly known as Cerus Energy Group Ltd. and changed its name to Camarico Investment Group Ltd. in June 2019. Camarico Investment Group Ltd. was incorporated in 1996 and is headquartered in Nanton, Canada.","CNSX:CIG
Company: Camarico Investment Group Ltd.
(IQT23498757) - Canada",-
04/05/2018,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 4.26 ,"Fulcher, N. W. Limited",-,IQTR558255588,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
04/03/2018,Imagin Medical Inc. (CNSX:IME),CNSX:IME,Private Placement,Closed, 3.94 ,-,-,IQTR558022860,Health Care (Primary),Canada (Primary),"Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.","CNSX:IME
Company: Imagin Medical Inc.
(IQT302480186) - Canada",-
04/03/2018,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Announced,-,-,-,IQTR565652963,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
03/28/2018,Aptose Biosciences Inc. (TSX:APS),TSX:APS,Public Offering,Announced, 30.0 ,-,-,IQTR557481220,Health Care (Primary),Canada (Primary),"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.","TSX:APS
Company: Aptose Biosciences Inc.
(IQT35573257) - Canada",-
03/26/2018,Sona Nanotech Inc. (CNSX:SONA),CNSX:SONA,Private Placement,Closed, 2.0 ,-,-,IQTR557298900,Health Care (Primary),Canada (Primary),"Sona Nanotech Inc. manufactures gold nanorod products for diagnostic test products and medical treatment applications. Its products portfolio comprises Gemini 650NM, Gemini 700NM, Gemini 750NM, Gemini 800NM, Gemini 850NM, Gemini 900NM, Gemini 950NM, and Gemini 1050NM, as well as Gemini nanorods kit. The company has collaborations with Soma Bioscience Ltd. to produce diagnostic tests; Anteo Diagnostics Limited to develop products that improve the development and performance of lateral flow immunoassays; and University of Birmingham to develop nanorods for tissue imaging. Sona Nanotech Inc. is based in Halifax, Canada.","CNSX:SONA
Company: Sona Nanotech Inc.
(IQT585396616) - Canada",-
03/26/2018,Extendicare Inc. (TSX:EXE),TSX:EXE,Public Offering,Closed, 110.0 ,-,-,IQTR557320567,Health Care (Primary),Canada (Primary),"Extendicare Inc. provides care and services for seniors in Canada. The company offers long term care services; retirement living services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management and consulting services to third-party owners. It also provides third-party liability insurance products in the United States. As of February 28, 2019, it operated 120 senior care and retirement living centers, including 67 owned and 53 managed centers, as well as home health care operations under the Extendicare, Esprit Lifestyle, and ParaMed brands. Extendicare Inc. was founded in 1968 and is based in Markham, Canada.","TSX:EXE
Company: Extendicare Inc.
(IQT208467081) - Canada",-
03/21/2018,Cronos Group Inc. (TSX:CRON),TSX:CRON,Public Offering,Closed, 127.74 ,-,-,IQTR556866920,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
03/19/2018,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Public Offering,Closed, 2.36 ,-,-,IQTR556613917,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
03/19/2018,Aquarius Surgical Technologies Inc. (CNSX:ASTI),CNSX:ASTI,Private Placement,Closed, 0.517 ,-,-,IQTR556696977,Health Care (Primary),Canada (Primary),"Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America. It provides multi-diode laser systems and related fibre-optic delivery devices for minimally invasive treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance, as well as consumables. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.","CNSX:ASTI
Company: Aquarius Surgical Technologies Inc.
(IQT536082025) - Canada",-
03/19/2018,Correvio Pharma Corp. (TSX:CORV),TSX:CORV,Private Placement,Closed, 24.5 ,Cipher Pharmaceuticals Inc. (TSX:CPH),-,IQTR590435555,Health Care (Primary),Canada (Primary),"Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.","TSX:CORV
Company: Correvio Pharma Corp.
(IQT2598163) - Canada",-
03/16/2018,Greenbrook TMS Inc. (TSX:GTMS),TSX:GTMS,Private Placement,Closed, 25.95 ,-,-,IQTR584702761,Health Care (Primary),Canada (Primary),"Greenbrook TMS Inc. operates outpatient mental health services centers in the United States. The company’s Greenbrook centers offer transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy that provides electromagnetic stimulation to brain regions associated with mood regulation for the treatment of major depressive disorders. As of May 10, 2019, it operated 71 company-operated treatment centers in the United States. The company was founded in 2011 and is headquartered in Toronto, Canada.","TSX:GTMS
Company: Greenbrook TMS Inc.
(IQT584768492) - Canada",-
03/13/2018,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Public Offering,Closed, 4.58 ,-,-,IQTR556095295,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
03/12/2018,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed," 1,925.46 ",-,-,IQTR555852247,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
03/09/2018,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 0.789 ,-,-,IQTR555649633,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
03/07/2018,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Private Placement,Closed, 0.407 ,-,-,IQTR555172988,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
03/07/2018,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 5.35 ,Mario Family Partners; Brio Capital L.P.; Efrat Investments,-,IQTR555210769,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
03/06/2018,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 15.0 ,-,-,IQTR554976594,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
03/01/2018,Imagin Medical Inc. (CNSX:IME),CNSX:IME,Private Placement,Closed, 0.24 ,-,-,IQTR554780189,Health Care (Primary),Canada (Primary),"Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.","CNSX:IME
Company: Imagin Medical Inc.
(IQT302480186) - Canada",-
02/27/2018,Profound Medical Corp. (TSX:PRN),TSX:PRN,Public Offering,Closed, 30.0 ,-,-,IQTR554348540,Health Care (Primary),Canada (Primary),"Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.","TSX:PRN
Company: Profound Medical Corp.
(IQT269189531) - Canada",-
02/23/2018,Pascal Biosciences Inc. (TSXV:PAS),TSXV:PAS,Private Placement,Closed, 5.17 ,-,-,IQTR553840008,Health Care (Primary),Canada (Primary),"Pascal Biosciences Inc., a biopharmaceutical company, researches and develops products for the treatment of cancer, and for the enhancement of immune system. Its development portfolio includes PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule to enhance the efficacy of checkpoint inhibitors. The company is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas. The company has a research collaboration agreement with Y-Biologics for the discovery and development of novel bispecific antibodies for the treatment of leukemia. Pascal Biosciences Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:PAS
Company: Pascal Biosciences Inc.
(IQT206253827) - Canada",-
02/23/2018,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 0.513 ,"Fulcher, N. W. Limited",-,IQTR553951666,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
02/22/2018,Izotropic Corporation (CNSX:IZO),CNSX:IZO,Public Offering,Closed, 0.2 ,-,-,IQTR554073959,Health Care (Primary),Canada (Primary),"Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3-D breast CT imaging technology for early diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.","CNSX:IZO
Company: Izotropic Corporation
(IQT552160890) - Canada",-
02/09/2018,Lotus Ventures Inc. (CNSX:J),CNSX:J,Private Placement,Closed, 1.0 ,Auxly Cannabis Group Inc. (TSXV:XLY),-,IQTR552456781,Health Care (Primary),Canada (Primary),"Lotus Ventures Inc. produces and sells medical marijuana. The company is based in Vancouver, Canada.","CNSX:J
Company: Lotus Ventures Inc.
(IQT274566928) - Canada",-
02/09/2018,Akumin Inc. (TSX:AKU),TSX:AKU,Merger/Acquisition,Closed, 2.35 ,Z Strategies Inc.,-,IQTR552598575,Health Care (Primary),Canada (Primary),"Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2018, the company operated 95 imaging centers located in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, arthrography, biopsy, and other diagnostic or interventional radiology procedures; and online medical bill payment services. Akumin Inc. is headquartered in Toronto, Canada.","TSX:AKU
Company: Akumin Inc.
(IQT528412037) - Canada",-
02/08/2018,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 0.6 ,-,-,IQTR552273943,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
02/06/2018,Rapid Dose Therapeutics Corp. (CNSX:DOSE),CNSX:DOSE,Private Placement,Closed, 0.139 ,-,-,IQTR552074492,Health Care (Primary),Canada (Primary),"Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada. The company’s over the counter products include QuickStrip, a processed oral film that contains the active molecule embedded in the delivery matrix; QuickStrip energy; vitamin B12; and QuickStrip sleep that delivers melatonin to your system. It also PharmaStrip delivery system. The company serves pharmaceutical and healthcare manufacturing industry. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.","CNSX:DOSE
Company: Rapid Dose Therapeutics Corp.
(IQT595207521) - Canada",-
02/05/2018,EXMceuticals Inc. (CNSX:EXM),CNSX:EXM,Private Placement,Effective, 4.0 ,-,-,IQTR552043368,Health Care (Primary),Canada (Primary),"EXMceuticals Inc. engages in the sustainable cultivation, processing, and export of non-psychotropic and psychotropic pharmaceutical-grade cannabinoid ingredients from Africa. If focuses on offering Cannabidiol (CBD), a non-psychoactive cannabinoid that has been proven effective against acne, anxiety, depression, epilepsy, and degenerative diseases, such as Parkinson’s; and Tetrahydrocannabinol (THC), a psychoactive cannabinoid ingredient that has been proven effective in the fields of pain management, appetite control, anxiety, and managing side effects of chemotherapy. The company was founded in 2017 and is headquartered in Vancouver, Canada.","CNSX:EXM
Company: EXMceuticals Inc.
(IQT595175052) - Canada",-
01/31/2018,KDA Group Inc. (TSXV:KDA),TSXV:KDA,Private Placement,Closed, 0.19 ,-,-,IQTR551613260,Health Care (Primary),Canada (Primary),"KDA Group Inc. provides pharmacy personnel replacement and vocational training services to health industry in the Province of Quebec, Canada. The company operates through Pharmacy Services and Pharmaceutical Solutions segments. It primarily offers replacement pharmacists and technical assistants. The company also provides consulting services to assist in optimizing pharmacy operations, including container-content verification delegation, optimization of laboratory operations, professional services and care plans, and inventory management. In addition, it is involved in the distribution of generic pharmaceutical products. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.","TSXV:KDA
Company: KDA Group Inc.
(IQT282005982) - Canada",-
01/30/2018,Imagin Medical Inc. (CNSX:IME),CNSX:IME,Private Placement,Closed, 0.2 ,-,-,IQTR551612869,Health Care (Primary),Canada (Primary),"Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.","CNSX:IME
Company: Imagin Medical Inc.
(IQT302480186) - Canada",-
01/29/2018,Avicanna Inc. (TSX:AVCN),TSX:AVCN,Private Placement,Closed, 4.75 ,-,-,IQTR551038679,Health Care (Primary),Canada (Primary),"Avicanna Inc. focuses on the research and development, cultivation, manufacture, and commercialization of plant-derived cannabinoid-based products and extracts in North America, Latin America, Europe, and Asia. It intends to offer plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and extracts. The company was founded in 2016 and is headquartered in Toronto, Canada.","TSX:AVCN
Company: Avicanna Inc.
(IQT628278928) - Canada",-
01/26/2018,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 1.25 ,-,-,IQTR551017762,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
01/25/2018,IMV Inc. (TSX:IMV),TSX:IMV,Public Offering,Closed, 12.5 ,-,-,IQTR550756845,Health Care (Primary),Canada (Primary),"IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company’s DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.","TSX:IMV
Company: IMV Inc.
(IQT71987179) - Canada",-
01/25/2018,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Public Offering,Closed, 0.3 ,-,-,IQTR550812829,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
01/22/2018,Sienna Senior Living Inc. (TSX:SIA),TSX:SIA,Public Offering,Closed, 160.01 ,-,-,IQTR550355121,Health Care (Primary),Canada (Primary),"Sienna Senior Living Inc., through its subsidiaries, provides senior housing and long-term care (LTC) services in Canada. It operates through LTC and Retirement segments. The company offers a range of seniors’ living options, including independent and assisted living, memory care, long-term care, and specialized programs and services, as well as provides management services. As of December 31, 2018, it owned and operated a total of 70 seniors’ living residences comprising 27 retirement residences, 35 LTC residences, and 8 seniors’ living residences. The company was formerly known as Leisureworld Senior Care Corporation and changed its name to Sienna Senior Living Inc. in May 2015. Sienna Senior Living Inc. was founded in 1972 and is headquartered in Markham, Canada.","TSX:SIA
Company: Sienna Senior Living Inc.
(IQT99930472) - Canada",-
01/19/2018,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 1.46 ,-,-,IQTR550758675,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
01/16/2018,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 5.09 ,YOFOTO (China) Health Industry Co. Ltd.,-,IQTR549766604,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
01/16/2018,Must Capital Inc. (TSXV:MUST.H),TSXV:MUST.H,Private Placement,Effective, 0.1 ,-,-,IQTR549871255,Health Care (Primary),Canada (Primary),"Must Capital Inc. does not have significant operations. Previously, the company was developed 3D medical imaging software platform for legal, insurance, and medical professions. The company was formerly known as Intrinsic4D Inc. and changed its name to Must Capital Inc. in January 2019. The company was incorporated in 2010 and is based in Toronto, Canada.","TSXV:MUST.H
Company: Must Capital Inc.
(IQT244323131) - Canada",-
01/15/2018,Canntab Therapeutics Limited (CNSX:PILL),CNSX:PILL,Private Placement,Closed, 5.01 ,-,-,IQTR559080645,Health Care (Primary),Canada (Primary),"Canntab Therapeutics Limited researches and develops advanced pharmaceutical grade formulations of cannabinoids and terpenes in Canada. It offers sustained release, immediate release, modified release, flash melt, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.","CNSX:PILL
Company: Canntab Therapeutics Limited
(IQT558198016) - Canada",-
01/11/2018,Aurora Spine Corporation (TSXV:ASG),TSXV:ASG,Private Placement,Closed, 0.927 ,-,-,IQTR549208367,Health Care (Primary),Canada (Primary),"Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. The company offers interspinous process lumbar fusion devices for patients suffering from degenerative disc diseases; Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae and bone grows to complete the fusion process; sterile-packed titanium plasma spray coated spinal infusion implants for bone growth; and 3D Printed Stand Alone ALIF Cage, an integrated plate and spacer system that helps to preserve the natural anatomic profile, and provide spinal column support and stability. The company was incorporated in 2013 and is headquartered in Toronto, Canada.","TSXV:ASG
Company: Aurora Spine Corporation
(IQT245521185) - Canada",-
01/11/2018,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Private Placement,Closed, 0.3 ,-,-,IQTR549210210,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
01/08/2018,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Closed, 1.66 ,-,-,IQTR548811858,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
01/05/2018,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Private Placement,Closed, 0.841 ,-,-,IQTR548758287,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
01/04/2018,Pascal Biosciences Inc. (TSXV:PAS),TSXV:PAS,Private Placement,Effective, 0.13 ,-,-,IQTR548564005,Health Care (Primary),Canada (Primary),"Pascal Biosciences Inc., a biopharmaceutical company, researches and develops products for the treatment of cancer, and for the enhancement of immune system. Its development portfolio includes PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule to enhance the efficacy of checkpoint inhibitors. The company is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas. The company has a research collaboration agreement with Y-Biologics for the discovery and development of novel bispecific antibodies for the treatment of leukemia. Pascal Biosciences Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:PAS
Company: Pascal Biosciences Inc.
(IQT206253827) - Canada",-
01/02/2018,Cronos Group Inc. (TSX:CRON),TSX:CRON,Public Offering,Closed, 40.0 ,-,-,IQTR548322814,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
12/31/2017,Cotinga Pharmaceuticals Inc. (TSXV:COT),TSXV:COT,Private Placement,Closed, 2.01 ,-,-,IQTR562361387,Health Care (Primary),Canada (Primary),"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","TSXV:COT
Company: Cotinga Pharmaceuticals Inc.
(IQT29927531) - Canada",-
12/29/2017,Zecotek Photonics Inc. (TSXV:ZMS),TSXV:ZMS,Private Placement,Closed, 4.83 ,-,-,IQTR548227697,Health Care (Primary),Canada (Primary),"Zecotek Photonics Inc., a photonics technology company, develops various photonics technologies and products for commercial and research applications in medical, bio-science, high-energy physics, pharmaceutical research, material processing, engineering and industrial design, and multi-media markets. The company operates through three divisions: Zecotek Imaging China, Zecotek Optronics Systems, and Zecotek Autotronics. Its imaging systems include lutetium fine silicate scintillation crystals; solid-state micro-pixel avalanche photo diode photo detectors and transistors; and integrated detector modules. The company also develops glasses-free 3D displays; and 3D auto-stereoscopic displays, and 3D printers and related technologies for applications in healthcare, scientific, and industrial markets. Zecotek Photonics Inc. in Asia and North America. Its strategic partners primarily include Nucare Ltd., University of Washington, and University of California. The company was formerly known as Zecotek Medical Systems Inc. and changed its name to Zecotek Photonics Inc. in November 2007. Zecotek Photonics Inc. was incorporated in 1983 and is headquartered in Richmond, Canada.","TSXV:ZMS
Company: Zecotek Photonics Inc.
(IQT39242544) - Canada",-
12/22/2017,H-Source Holdings Ltd. (TSXV:HSI),TSXV:HSI,Private Placement,Closed, 1.73 ,-,-,IQTR547591653,Health Care (Primary),Canada (Primary),"H-Source Holdings Ltd., a technology company, operates in the healthcare industry. It offers a hospital-to-hospital transaction platform that provides a marketplace for members to buy, sell, and transfer excess inventory supplies and capital equipment with each other. The company’s platform allows members to conduct transactions within integrated delivery networks and group purchasing organizations. H-Source Holdings Ltd. is headquartered in Vancouver, Canada.","TSXV:HSI
Company: H-Source Holdings Ltd.
(IQT377711030) - Canada",-
12/22/2017,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.751 ,-,-,IQTR547620146,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
12/21/2017,Enlighta Inc. (TSXV:NLTA),TSXV:NLTA,Private Placement,Closed, 0.387 ,-,-,IQTR547433842,Health Care (Primary),Canada (Primary),"Enlighta Inc. operates as a healthcare and medical digital, green, and clean technology company. The company, through a joint venture with Fischer Institute of Physical Therapy and Performance, provides physical therapy services and rehabilitative medicine treatments. It also has a patent pending portfolio of 10 OTC nutraceutical formulations. The company was formerly known as HooXi Network Inc. and changed its name to Enlighta Inc. in July 2019. Enlighta Inc. is based in Richmond, Canada.","TSXV:NLTA
Company: Enlighta Inc.
(IQT253108413) - Canada",-
12/15/2017,StillCanna Inc. (CNSX:STIL),CNSX:STIL,Private Placement,Closed, 0.273 ,-,-,IQTR546979233,Health Care (Primary),Canada (Primary),"StillCanna Inc., a life sciences company, focuses on cannabidiol extraction in Europe. The company was formerly known as EVI Global Group Developments Corp. and changed its name to StillCanna Inc. in March 2019. The company is headquartered in Vancouver, Canada.","CNSX:STIL
Company: StillCanna Inc.
(IQT312257169) - Canada",-
12/15/2017,EGF Theramed Health Corp. (CNSX:TMED),CNSX:TMED,Private Placement,Closed, 2.5 ,-,-,IQTR546990972,Health Care (Primary),Canada (Primary),"EGF Theramed Health Corp. operates as a technology company that provides automated biomedical care online services for common health problems. It provides Fully Automated Signal Transduction, a medical device, which monitors blood pressure, as well as enables physiologically interactive health apps used in testing, tracking, and treating common health conditions. The company also offers Electro-Physiologically Interactive Computing (EPIC) system, an online system. Its EPIC serves people interested in normalizing blood pressure, blood glucose, and body weight and skin conditions. The company was formerly known as Theramed Health Corporation and changed its name to EGF Theramed Health Corp. in October 2019. EGF Theramed Health Corp. was incorporated in 2011 and is headquartered in Richmond, Canada.","CNSX:TMED
Company: EGF Theramed Health Corp.
(IQT246550060) - Canada",-
12/15/2017,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Closed, 0.726 ,Sinalta Investments Ltd,-,IQTR547007149,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
12/15/2017,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Public Offering,Closed, 31.03 ,-,-,IQTR547073007,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
12/12/2017,Reliq Health Technologies Inc. (TSXV:RHT),TSXV:RHT,Private Placement,Closed, 10.0 ,-,-,IQTR546508949,Health Care (Primary),Canada (Primary),"Reliq Health Technologies Inc., a healthcare technology company, engages in the development of mobile software solutions for community care market. It offers iUGO Health technology platform, a hardware and software solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.","TSXV:RHT
Company: Reliq Health Technologies Inc.
(IQT26049870) - Canada",-
12/12/2017,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Public Offering,Closed,-,-,-,IQTR546516861,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
12/08/2017,Vitalhub Corp. (TSXV:VHI),TSXV:VHI,Private Placement,Closed, 2.0 ,-,-,IQTR546139718,Health Care (Primary),Canada (Primary),"VitalHub Corp., together with its subsidiaries, develops and supports healthcare information systems in the mental health, long term care, community health service, and hospital sectors in Canada and the United States. Its technologies include blockchain, mobile and Web-based assessment, and electronic healthcare record solutions. The company is based in Toronto, Canada.","TSXV:VHI
Company: Vitalhub Corp.
(IQT411552553) - Canada",-
12/05/2017,Vaxil Bio Ltd. (TSXV:VXL),TSXV:VXL,Private Placement,Closed, 1.81 ,-,-,IQTR545770096,Health Care (Primary),Canada (Primary),"Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company’s lead product is ImMucin that has completed a Phase1/2 clinical trial, which is used for the treatment of multiple myeloma. It is also involved in developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.","TSXV:VXL
Company: Vaxil Bio Ltd.
(IQT115279018) - Canada",-
12/05/2017,HealthSpace Data Systems Ltd. (CNSX:HS),CNSX:HS,Private Placement,Closed, 1.06 ,Vanbex Capital,-,IQTR545788748,Health Care (Primary),Canada (Primary),"HealthSpace Data Systems Ltd. develops and sells information and communication management systems for health inspection departments of federal, provincial, state, and municipal governments in Canada and the United States. Its products include HSCloud product, an enterprise software system for license, invoice, and inspection data for use by government agencies; HealthSpace Touch, an application designed for data collection, electronically capture signatures, and insert photos and email inspection reports for health inspectors; and HealthSpace EnviroIntel EHS Manager, an internet-based client/server application used to fill out forms, request information, and view data, including reports. The company also offers HealthSpace Cloud, a customizable cloud-based portal for managing applications, licenses, permits, and other data; and HealthSpace Data that provides environmental health reporting, analytics, and monitoring platform. HealthSpace Data Systems Ltd. was founded in 1998 and is headquartered in Chilliwack, Canada.","CNSX:HS
Company: HealthSpace Data Systems Ltd.
(IQT317841012) - Canada",-
12/04/2017,BELLUS Health Inc. (TSX:BLU),TSX:BLU,Public Offering,Closed, 20.0 ,-,-,IQTR545713001,Health Care (Primary),Canada (Primary),"BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer’s disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.","TSX:BLU
Company: BELLUS Health Inc.
(IQT45480612) - Canada",-
12/04/2017,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed," 1,880.18 ",-,-,IQTR545749337,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
11/30/2017,Avivagen Inc. (TSXV:VIV),TSXV:VIV,Private Placement,Closed, 4.09 ,Dancap Family Investment Office,-,IQTR545394382,Health Care (Primary),Canada (Primary),"Avivagen Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal’s own health defenses. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. The company is headquartered in Ottawa, Canada.","TSXV:VIV
Company: Avivagen Inc.
(IQT23428260) - Canada",-
11/30/2017,WELL Health Technologies Corp. (TSXV:WELL),TSXV:WELL,Private Placement,Closed, 4.5 ,-,-,IQTR545476637,Health Care (Primary),Canada (Primary),"WELL Health Technologies Corp. owns and operates a portfolio of primary healthcare facilities. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. As at December 31, 2018, it operated 19 medical clinics. WELL Health Technologies Corp. is headquartered in Vancouver, Canada.","TSXV:WELL
Company: WELL Health Technologies Corp.
(IQT434799348) - Canada",-
11/29/2017,NanoSphere Health Sciences Inc. (CNSX:NSHS),CNSX:NSHS,Private Placement,Closed, 5.91 ,-,-,IQTR545430129,Health Care (Primary),Canada (Primary),"NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing nutritive elements and medicants through licensing arrangements. It focuses on developing cannabinoid, nutraceutical, and cosmeceutical and drug formulations. The company is headquartered in Vancouver, Canada.","CNSX:NSHS
Company: NanoSphere Health Sciences Inc.
(IQT537616648) - Canada",-
11/27/2017,Telo Genomics Corp. (TSXV:TELO),TSXV:TELO,Private Placement,Closed, 1.62 ,-,-,IQTR545009595,Health Care (Primary),Canada (Primary),"Telo Genomics Corp., a personalized medicine company, focuses on the development and commercialization of predictive technological products. Its proprietary software platform predicts the course of certain diseases and personalizes the treatment for individual patients. The company’s TeloView software platform measures the stage of the disease, rate of progression of the disease, how different diseases will respond to various therapies, and drug efficacy and toxicity. It is developing five diagnostic and prognostic products for cancers and neurological disorders, including Hodgkin’s lymphoma, prostate cancer, multiple myeloma, lung cancer, and Alzheimer’s diseases. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. is headquartered in Toronto, Canada.","TSXV:TELO
Company: Telo Genomics Corp.
(IQT401930792) - Canada",-
11/27/2017,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Closed, 0.3 ,-,-,IQTR545019032,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
11/27/2017,Canntab Therapeutics Limited (CNSX:PILL),CNSX:PILL,Private Placement,Closed, 5.01 ,Telferscot Resources Inc.,-,IQTR545044963,Health Care (Primary),Canada (Primary),"Canntab Therapeutics Limited researches and develops advanced pharmaceutical grade formulations of cannabinoids and terpenes in Canada. It offers sustained release, immediate release, modified release, flash melt, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.","CNSX:PILL
Company: Canntab Therapeutics Limited
(IQT558198016) - Canada",-
11/16/2017,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 0.475 ,-,-,IQTR544102320,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
11/16/2017,Lotus Ventures Inc. (CNSX:J),CNSX:J,Private Placement,Closed, 5.02 ,-,-,IQTR544432768,Health Care (Primary),Canada (Primary),"Lotus Ventures Inc. produces and sells medical marijuana. The company is based in Vancouver, Canada.","CNSX:J
Company: Lotus Ventures Inc.
(IQT274566928) - Canada",-
11/15/2017,Trillium Therapeutics Inc. (TSX:TRIL),TSX:TRIL,Private Placement,Closed, 25.39 ,-,-,IQTR543916847,Health Care (Primary),Canada (Primary),"Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.","TSX:TRIL
Company: Trillium Therapeutics Inc.
(IQT13556077) - Canada",-
11/15/2017,Chartwell Retirement Residences (TSX:CSH.UN),TSX:CSH.UN,Public Offering,Closed, 245.02 ,-,-,IQTR543937680,Health Care (Primary),Canada (Primary),"Chartwell is an unincorporated, open-ended real estate trust which indirectly owns and operates a complete range of seniors housing communities, from independent supportive living through assisted living to long term care. It is the largest operator in the Canadian seniors living sector with over 200 quality retirement communities in four provinces. Chartwell is committed to its vision of Making People's Lives BETTER and to providing a happier, healthier and more fulfilling life experience for its residents.","TSX:CSH.UN
Company: Chartwell Retirement Residences
(IQT7768795) - Canada",-
11/15/2017,Preferred Dental Technologies Inc. (CNSX:PDTI),CNSX:PDTI,Private Placement,Effective, 0.052 ,-,-,IQTR543975575,Health Care (Primary),Canada (Primary),"Preferred Dental Technologies Inc. develops and commercializes various technologies in the dental implant industry. It offers EAS components for custom dental abutments for dental implants. The company is headquartered in Winnipeg, Canada.","CNSX:PDTI
Company: Preferred Dental Technologies Inc.
(IQT529428534) - Canada",-
11/14/2017,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 23.0 ,-,-,IQTR543768526,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
11/13/2017,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed, 956.12 ,-,-,IQTR543567518,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
11/10/2017,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Private Placement,Closed, 1.6 ,-,-,IQTR543502891,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
11/09/2017,Neovasc Inc. (TSX:NVCN),TSX:NVCN,Public Offering,Closed, 47.59 ,-,-,IQTR543231289,Health Care (Primary),Canada (Primary),"Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.","TSX:NVCN
Company: Neovasc Inc.
(IQT46472100) - Canada",-
11/09/2017,Neovasc Inc. (TSX:NVCN),TSX:NVCN,Private Placement,Closed, 34.64 ,-,-,IQTR543355324,Health Care (Primary),Canada (Primary),"Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.","TSX:NVCN
Company: Neovasc Inc.
(IQT46472100) - Canada",-
11/08/2017,ZoomMed Inc. (TSXV:ZMD.H),TSXV:ZMD.H,Private Placement,Closed, 0.5 ,-,-,IQTR543228959,Health Care (Primary),Canada (Primary),"ZoomMed Inc., together with its subsidiaries, develops and markets a range of computer applications designed for healthcare professionals primarily in the United States and the United Kingdom. The company builds and operates a clinical information exchange platform between physicians, pharmacists, and various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical companies, laboratories, physiotherapy clinics, and other organizations. It also offers ZRx Prescriber, a technological Web application that enables physicians to generate prescriptions. ZoomMed Inc. was incorporated in 2005 and is headquartered in Brossard, Canada.","TSXV:ZMD.H
Company: ZoomMed Inc.
(IQT22495974) - Canada",-
11/06/2017,Canada House Wellness Group Inc. (CNSX:CHV),CNSX:CHV,Private Placement,Closed, 8.61 ,-,-,IQTR542766975,Health Care (Primary),Canada (Primary),"Canada House Wellness Group Inc., through its subsidiaries, provides patient-specific cannabinoid therapy products and services. It offers its products and services through clinics and licensed producers. Canada House Wellness Group Inc. has a strategic partnership with Peak Pharma Solutions Inc. The company is headquartered in Pickering, Canada.","CNSX:CHV
Company: Canada House Wellness Group Inc.
(IQT417812352) - Canada",-
11/03/2017,SQI Diagnostics Inc. (TSXV:SQD),TSXV:SQD,Private Placement,Closed, 4.5 ,-,-,IQTR542604466,Health Care (Primary),Canada (Primary),"SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.","TSXV:SQD
Company: SQI Diagnostics Inc.
(IQT34231255) - Canada",-
10/31/2017,Cognetivity Neurosciences Ltd. (CNSX:CGN),CNSX:CGN,Private Placement,Closed, 4.17 ,-,-,IQTR556581719,Health Care (Primary),Canada (Primary),"Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops integrated cognitive assessment, a cognitive testing platform, which includes visual stimulus based diagnostic test and artificial intelligence tools to support the early detection and monitoring of cognitive impairment in neurodegenerative diseases, such as Alzheimer’s and dementia. The company is headquartered in Vancouver, Canada.","CNSX:CGN
Company: Cognetivity Neurosciences Ltd.
(IQT556284961) - Canada",-
10/30/2017,Vitalhub Corp. (TSXV:VHI),TSXV:VHI,Private Placement,Closed, 2.22 ,-,-,IQTR542091624,Health Care (Primary),Canada (Primary),"VitalHub Corp., together with its subsidiaries, develops and supports healthcare information systems in the mental health, long term care, community health service, and hospital sectors in Canada and the United States. Its technologies include blockchain, mobile and Web-based assessment, and electronic healthcare record solutions. The company is based in Toronto, Canada.","TSXV:VHI
Company: Vitalhub Corp.
(IQT411552553) - Canada",-
10/27/2017,Ortho Regenerative Technologies Inc. (CNSX:ORTH),CNSX:ORTH,Private Placement,Closed, 1.07 ,-,-,IQTR542141447,Health Care (Primary),Canada (Primary),"Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a freeze-dried formulation for rotator cuff repair; and Ortho-M, a biopolymer for bilateral meniscus repair. It also develops Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.","CNSX:ORTH
Company: Ortho Regenerative Technologies Inc.
(IQT539889813) - Canada",-
10/24/2017,Sirona Biochem Corp. (TSXV:SBM),TSXV:SBM,Private Placement,Closed, 0.635 ,-,-,IQTR541439437,Health Care (Primary),Canada (Primary),"Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.","TSXV:SBM
Company: Sirona Biochem Corp.
(IQT58893998) - Canada",-
10/23/2017,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Private Placement,Closed, 113.2 ,"Thomvest Ventures, Inc.",-,IQTR541286560,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
10/23/2017,Appili Therapeutics Inc. (TSXV:APLI),TSXV:APLI,Private Placement,Closed, 7.4 ,Innovacorp; NSBI Venture Capital,-,IQTR541286685,Health Care (Primary),Canada (Primary),"Appili Therapeutics Inc., a pharmaceutical company, acquires, develops, and commercializes therapeutics in the area of infectious disease in Canada. The company focuses on building and advancing a portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-1501, a taste-masked oral liquid formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was founded in 2015 and is headquartered in Halifax, Canada.","TSXV:APLI
Company: Appili Therapeutics Inc.
(IQT607127273) - Canada",-
10/23/2017,Vitalhub Corp. (TSXV:VHI),TSXV:VHI,Private Placement,Closed, 0.085 ,-,-,IQTR541310265,Health Care (Primary),Canada (Primary),"VitalHub Corp., together with its subsidiaries, develops and supports healthcare information systems in the mental health, long term care, community health service, and hospital sectors in Canada and the United States. Its technologies include blockchain, mobile and Web-based assessment, and electronic healthcare record solutions. The company is based in Toronto, Canada.","TSXV:VHI
Company: Vitalhub Corp.
(IQT411552553) - Canada",-
10/23/2017,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 0.5 ,-,-,IQTR541395194,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
10/20/2017,Titan Medical Inc. (TSX:TMD),TSX:TMD,Private Placement,Closed, 3.35 ,-,-,IQTR541224198,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
10/19/2017,Cronos Group Inc. (TSX:CRON),TSX:CRON,Public Offering,Closed, 15.0 ,-,-,IQTR541089224,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
10/19/2017,Microbix Biosystems Inc. (TSX:MBX),TSX:MBX,Private Placement,Closed, 3.5 ,-,-,IQTR541120406,Health Care (Primary),Canada (Primary),"Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for diagnostic assays. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.","TSX:MBX
Company: Microbix Biosystems Inc.
(IQT2630461) - Canada",-
10/19/2017,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 3.91 ,-,-,IQTR541207395,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
10/18/2017,Aurora Spine Corporation (TSXV:ASG),TSXV:ASG,Private Placement,Closed, 0.156 ,-,-,IQTR541308810,Health Care (Primary),Canada (Primary),"Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. The company offers interspinous process lumbar fusion devices for patients suffering from degenerative disc diseases; Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae and bone grows to complete the fusion process; sterile-packed titanium plasma spray coated spinal infusion implants for bone growth; and 3D Printed Stand Alone ALIF Cage, an integrated plate and spacer system that helps to preserve the natural anatomic profile, and provide spinal column support and stability. The company was incorporated in 2013 and is headquartered in Toronto, Canada.","TSXV:ASG
Company: Aurora Spine Corporation
(IQT245521185) - Canada",-
10/17/2017,Apteryx Imaging Inc. (TSXV:XRAY),TSXV:XRAY,Private Placement,Closed, 2.5 ,-,-,IQTR540858254,Health Care (Primary),Canada (Primary),"Apteryx Imaging Inc. provides diagnostic imaging software and device technologies for dentists and oral health specialists. Its imaging software products include XrayVision 4 that provides image enhancement and analysis tools with open-architecture technology allowing integration with the imaging systems from various manufacturers; XVWeb, a DICOM server that accepts images from various DICOM-compliant imaging software; XVWeb 3D, a cloud solution for 3D dental imaging; XVlite, a dental imaging software package; and XrayVision DCV, a DICOM-based dental imaging suite. The company’s imaging hardware products comprise TUXEDO intraoral sensors; LED IC100 intraoral cameras; and RAYSCAN panoramic + cephalometric imaging solutions. It also offers VELscope Vx system, a device for the enhanced visualization of mucosal abnormalities, such as oral cancer and premalignant dysplasia; VELscope Vx imaging adapter for fluorescence and white-light clinical imaging; Vx VELcaps to prevent patient cross contamination; Vx VELsheaths, a single use plastic sheath to prevent patient cross contamination; and VELscope Vx Value Bundle, a portable handheld device used to conduct oral tissue examinations. Apteryx Imaging Inc. has a partnership agreement with 4th-IR AG to develop a suite of cloud-based AI solutions. The company was formerly known as LED Medical Diagnostics Inc. and changed its name to Apteryx Imaging Inc. in September 2019. Apteryx Imaging Inc. was founded in 2002 and is headquartered in Vancouver, Canada.","TSXV:XRAY
Company: Apteryx Imaging Inc.
(IQT143328534) - Canada",-
10/16/2017,Sienna Senior Living Inc. (TSX:SIA),TSX:SIA,Public Offering,Closed, 100.01 ,-,-,IQTR540781219,Health Care (Primary),Canada (Primary),"Sienna Senior Living Inc., through its subsidiaries, provides senior housing and long-term care (LTC) services in Canada. It operates through LTC and Retirement segments. The company offers a range of seniors’ living options, including independent and assisted living, memory care, long-term care, and specialized programs and services, as well as provides management services. As of December 31, 2018, it owned and operated a total of 70 seniors’ living residences comprising 27 retirement residences, 35 LTC residences, and 8 seniors’ living residences. The company was formerly known as Leisureworld Senior Care Corporation and changed its name to Sienna Senior Living Inc. in May 2015. Sienna Senior Living Inc. was founded in 1972 and is headquartered in Markham, Canada.","TSX:SIA
Company: Sienna Senior Living Inc.
(IQT99930472) - Canada",-
10/13/2017,Resverlogix Corp. (TSX:RVX),TSX:RVX,Private Placement,Closed, 87.0 ,"Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399)",-,IQTR540568470,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
10/13/2017,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 1.0 ,-,-,IQTR540729908,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
10/11/2017,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Public Offering,Closed, 4.99 ,-,-,IQTR540317726,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
10/11/2017,Reliq Health Technologies Inc. (TSXV:RHT),TSXV:RHT,Private Placement,Closed, 5.0 ,-,-,IQTR540360822,Health Care (Primary),Canada (Primary),"Reliq Health Technologies Inc., a healthcare technology company, engages in the development of mobile software solutions for community care market. It offers iUGO Health technology platform, a hardware and software solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.","TSXV:RHT
Company: Reliq Health Technologies Inc.
(IQT26049870) - Canada",-
10/10/2017,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 1.15 ,-,-,IQTR540197817,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
10/06/2017,HealthSpace Data Systems Ltd. (CNSX:HS),CNSX:HS,Private Placement,Closed, 0.85 ,-,-,IQTR539881593,Health Care (Primary),Canada (Primary),"HealthSpace Data Systems Ltd. develops and sells information and communication management systems for health inspection departments of federal, provincial, state, and municipal governments in Canada and the United States. Its products include HSCloud product, an enterprise software system for license, invoice, and inspection data for use by government agencies; HealthSpace Touch, an application designed for data collection, electronically capture signatures, and insert photos and email inspection reports for health inspectors; and HealthSpace EnviroIntel EHS Manager, an internet-based client/server application used to fill out forms, request information, and view data, including reports. The company also offers HealthSpace Cloud, a customizable cloud-based portal for managing applications, licenses, permits, and other data; and HealthSpace Data that provides environmental health reporting, analytics, and monitoring platform. HealthSpace Data Systems Ltd. was founded in 1998 and is headquartered in Chilliwack, Canada.","CNSX:HS
Company: HealthSpace Data Systems Ltd.
(IQT317841012) - Canada",-
10/03/2017,Telo Genomics Corp. (TSXV:TELO),TSXV:TELO,Private Placement,Closed, 0.5 ,ScreenCell SA,-,IQTR539456716,Health Care (Primary),Canada (Primary),"Telo Genomics Corp., a personalized medicine company, focuses on the development and commercialization of predictive technological products. Its proprietary software platform predicts the course of certain diseases and personalizes the treatment for individual patients. The company’s TeloView software platform measures the stage of the disease, rate of progression of the disease, how different diseases will respond to various therapies, and drug efficacy and toxicity. It is developing five diagnostic and prognostic products for cancers and neurological disorders, including Hodgkin’s lymphoma, prostate cancer, multiple myeloma, lung cancer, and Alzheimer’s diseases. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. is headquartered in Toronto, Canada.","TSXV:TELO
Company: Telo Genomics Corp.
(IQT401930792) - Canada",-
10/02/2017,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed," 1,250.9 ",-,-,IQTR539329459,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
09/29/2017,Acasti Pharma Inc. (TSXV:ACST),TSXV:ACST,Public Offering,Closed, 12.73 ,-,-,IQTR539296625,Health Care (Primary),Canada (Primary),"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","TSXV:ACST
Company: Acasti Pharma Inc.
(IQT129334454) - Canada",-
09/26/2017,Imagin Medical Inc. (CNSX:IME),CNSX:IME,Private Placement,Closed, 1.09 ,-,-,IQTR538853460,Health Care (Primary),Canada (Primary),"Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.","CNSX:IME
Company: Imagin Medical Inc.
(IQT302480186) - Canada",-
09/20/2017,Cotinga Pharmaceuticals Inc. (TSXV:COT),TSXV:COT,Private Placement,Closed, 2.07 ,-,-,IQTR538089825,Health Care (Primary),Canada (Primary),"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","TSXV:COT
Company: Cotinga Pharmaceuticals Inc.
(IQT29927531) - Canada",-
09/20/2017,Profound Medical Corp. (TSX:PRN),TSX:PRN,Private Placement,Closed, 1.1 ,-,-,IQTR540691139,Health Care (Primary),Canada (Primary),"Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.","TSX:PRN
Company: Profound Medical Corp.
(IQT269189531) - Canada",-
09/15/2017,Sona Nanotech Inc. (CNSX:SONA),CNSX:SONA,Private Placement,Closed, 0.26 ,-,-,IQTR537884053,Health Care (Primary),Canada (Primary),"Sona Nanotech Inc. manufactures gold nanorod products for diagnostic test products and medical treatment applications. Its products portfolio comprises Gemini 650NM, Gemini 700NM, Gemini 750NM, Gemini 800NM, Gemini 850NM, Gemini 900NM, Gemini 950NM, and Gemini 1050NM, as well as Gemini nanorods kit. The company has collaborations with Soma Bioscience Ltd. to produce diagnostic tests; Anteo Diagnostics Limited to develop products that improve the development and performance of lateral flow immunoassays; and University of Birmingham to develop nanorods for tissue imaging. Sona Nanotech Inc. is based in Halifax, Canada.","CNSX:SONA
Company: Sona Nanotech Inc.
(IQT585396616) - Canada",-
09/15/2017,Cardiol Therapeutics Inc. (TSX:CRDL),TSX:CRDL,Private Placement,Closed, 2.25 ,-,-,IQTR539201269,Health Care (Primary),Canada (Primary),"Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company develops CTX01, a proprietary formulation of pharmaceutical cannabidiol for the treatment of heart failure with preserved ejection fraction; CTX02, a proprietary formulation of methotrexate for the treatment of heart failure; and CTX03 is a proprietary nanoformulation of encapsulated Cyclosporine A for the treatment of heart failure. It also develops CRxIMT, an anti-tumor immunotherapy for the treatment of Glioblastoma Multiforme; and CardiolRx, a pharmaceutical cannabidiol product. The company was incorporated in 2017 and is headquartered in Oakville, Canada.","TSX:CRDL
Company: Cardiol Therapeutics Inc.
(IQT562976995) - Canada",-
09/14/2017,Cronos Group Inc. (TSX:CRON),TSX:CRON,Private Placement,Closed, 15.0 ,-,-,IQTR537567319,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
09/05/2017,Resverlogix Corp. (TSX:RVX),TSX:RVX,Private Placement,Closed, 5.13 ,-,-,IQTR536572907,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
08/31/2017,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 1.31 ,-,-,IQTR536192708,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
08/24/2017,Profound Medical Corp. (TSX:PRN),TSX:PRN,Public Offering,Closed, 10.0 ,-,-,IQTR535336974,Health Care (Primary),Canada (Primary),"Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.","TSX:PRN
Company: Profound Medical Corp.
(IQT269189531) - Canada",-
08/23/2017,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Closed, 0.45 ,-,-,IQTR535290028,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
08/16/2017,Mondias Natural Products Inc. (TSXV:NHP),TSXV:NHP,Private Placement,Closed, 1.39 ,-,-,IQTR534554688,Health Care (Primary),Canada (Primary),"Mondias Natural Products Inc. develops and commercializes evidence-based botanical products for the health care and agriculture markets in Canada. It is developing botanical based specialty fertilizers for enhancing plant growth and crop yield; botanical agents to prevent and treat fungal infections of plants; oral and topical botanical drugs and agents to manage unmet medical needs, such as fungal infections of nails and skin, as well as insomnia; and products for the management of conditions, such as acne and wound healing. Mondias Natural Products Inc. is headquartered in Saint-Hubert, Canada.","TSXV:NHP
Company: Mondias Natural Products Inc.
(IQT590306183) - Canada",-
08/14/2017,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 0.99 ,"Fulcher, N. W. Limited",-,IQTR534270845,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
08/14/2017,Eastwood Bio-Medical Canada Inc. (TSXV:EBM),TSXV:EBM,Private Placement,Closed, 0.099 ,-,-,IQTR534272509,Health Care (Primary),Canada (Primary),"Eastwood Bio-Medical Canada Inc. researches and develops natural health products in North America and Asia. The company distributes Eleotin products and related products. Its Eleotin brand of products provide natural sourced solutions for metabolic syndromes, such as blood glucose control, obesity, and hypertension. The company’s products include Eleotin Kalimera Hypno, a melatonin product used to help with the body's sleep-wake cycles; Eleotin MCE, which addresses sexual health; Eleotin Waikiki, a combination of coral calcium and vitamin D; and Eleotin Mb teas, which are health drink powders. It is also developing Eleotin Katharos, an anti-oxidant product for heavy metals and smog in the environment. The company was incorporated in 2010 and is based in Richmond, Canada. Eastwood Bio-Medical Canada Inc. is a subsidiary of Eastwood Bio-Medical Research Inc.","TSXV:EBM
Company: Eastwood Bio-Medical Canada Inc.
(IQT261566801) - Canada",-
08/11/2017,Canada House Wellness Group Inc. (CNSX:CHV),CNSX:CHV,Private Placement,Closed, 0.403 ,Quinsam Capital Corporation (CNSX:QCA),-,IQTR534206081,Health Care (Primary),Canada (Primary),"Canada House Wellness Group Inc., through its subsidiaries, provides patient-specific cannabinoid therapy products and services. It offers its products and services through clinics and licensed producers. Canada House Wellness Group Inc. has a strategic partnership with Peak Pharma Solutions Inc. The company is headquartered in Pickering, Canada.","CNSX:CHV
Company: Canada House Wellness Group Inc.
(IQT417812352) - Canada",-
08/02/2017,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 0.649 ,-,-,IQTR533134901,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
07/24/2017,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 0.2 ,-,-,IQTR531920438,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
07/20/2017,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Closed, 4.79 ,-,-,IQTR531471317,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
07/20/2017,Lotus Ventures Inc. (CNSX:J),CNSX:J,Private Placement,Closed, 2.53 ,-,-,IQTR531776914,Health Care (Primary),Canada (Primary),"Lotus Ventures Inc. produces and sells medical marijuana. The company is based in Vancouver, Canada.","CNSX:J
Company: Lotus Ventures Inc.
(IQT274566928) - Canada",-
07/18/2017,Zecotek Photonics Inc. (TSXV:ZMS),TSXV:ZMS,Private Placement,Closed, 2.46 ,-,-,IQTR531364467,Health Care (Primary),Canada (Primary),"Zecotek Photonics Inc., a photonics technology company, develops various photonics technologies and products for commercial and research applications in medical, bio-science, high-energy physics, pharmaceutical research, material processing, engineering and industrial design, and multi-media markets. The company operates through three divisions: Zecotek Imaging China, Zecotek Optronics Systems, and Zecotek Autotronics. Its imaging systems include lutetium fine silicate scintillation crystals; solid-state micro-pixel avalanche photo diode photo detectors and transistors; and integrated detector modules. The company also develops glasses-free 3D displays; and 3D auto-stereoscopic displays, and 3D printers and related technologies for applications in healthcare, scientific, and industrial markets. Zecotek Photonics Inc. in Asia and North America. Its strategic partners primarily include Nucare Ltd., University of Washington, and University of California. The company was formerly known as Zecotek Medical Systems Inc. and changed its name to Zecotek Photonics Inc. in November 2007. Zecotek Photonics Inc. was incorporated in 1983 and is headquartered in Richmond, Canada.","TSXV:ZMS
Company: Zecotek Photonics Inc.
(IQT39242544) - Canada",-
07/13/2017,Element Lifestyle Retirement Inc. (TSXV:ELM),TSXV:ELM,Private Placement,Closed, 2.51 ,-,-,IQTR531801309,Health Care (Primary),Canada (Primary),"Element Lifestyle Retirement Inc. develops and operates senior retirement communities in British Columbia, Canada. It provides development consulting services, such as property selection, assembly and acquisition, building and community design, municipal approval and land entitlement processes, financing, marketing, sales and leasing, and construction project management. The company also offers long-term management services for the facilities, which include management of the administration, operation, and financing of retirement communities and physical facilities. Element Lifestyle Retirement Inc. was incorporated in 2007 and is headquartered in Vancouver, Canada.","TSXV:ELM
Company: Element Lifestyle Retirement Inc.
(IQT142268555) - Canada",-
07/12/2017,Devonian Health Group Inc. (TSXV:GSD),TSXV:GSD,Private Placement,Closed, 0.13 ,-,-,IQTR530207612,Health Care (Primary),Canada (Primary),"Devonian Health Group Inc., a pharmaceutical company, engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase II clinical trials for the treatment of ulcerative colitis and atopic dermatitis. It also develops value-added products for dermo-cosmetics. The company was incorporated in 2013 and is headquartered in Québec, Canada.","TSXV:GSD
Company: Devonian Health Group Inc.
(IQT431508091) - Canada",-
07/12/2017,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Public Offering,Closed,-,-,-,IQTR530420809,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
07/11/2017,Hemostemix Inc. (TSXV:HEM),TSXV:HEM,Public Offering,Closed, 2.49 ,-,-,IQTR530096951,Health Care (Primary),Canada (Primary),"Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cells products, such as synergetic cell populations, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.","TSXV:HEM
Company: Hemostemix Inc.
(IQT278407492) - Canada",-
07/06/2017,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Private Placement,Closed, 8.58 ,"Thomvest Ventures, Inc.",-,IQTR529782177,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
06/29/2017,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Effective, 12.98 ,Milost Global Inc.,-,IQTR528875972,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
06/19/2017,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Closed, 0.27 ,-,-,IQTR434747600,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
06/19/2017,Element Lifestyle Retirement Inc. (TSXV:ELM),TSXV:ELM,Private Placement,Closed, 2.51 ,-,-,IQTR434808053,Health Care (Primary),Canada (Primary),"Element Lifestyle Retirement Inc. develops and operates senior retirement communities in British Columbia, Canada. It provides development consulting services, such as property selection, assembly and acquisition, building and community design, municipal approval and land entitlement processes, financing, marketing, sales and leasing, and construction project management. The company also offers long-term management services for the facilities, which include management of the administration, operation, and financing of retirement communities and physical facilities. Element Lifestyle Retirement Inc. was incorporated in 2007 and is headquartered in Vancouver, Canada.","TSXV:ELM
Company: Element Lifestyle Retirement Inc.
(IQT142268555) - Canada",-
06/15/2017,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Public Offering,Closed, 53.13 ,-,-,IQTR434693019,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
06/14/2017,XORTX Therapeutics Inc. (CNSX:XRX),CNSX:XRX,Private Placement,Closed, 1.96 ,Cato BioVentures,-,IQTR434263624,Health Care (Primary),Canada (Primary),"XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.","CNSX:XRX
Company: XORTX Therapeutics Inc.
(IQT549277332) - Canada",-
06/09/2017,Reliq Health Technologies Inc. (TSXV:RHT),TSXV:RHT,Private Placement,Closed, 0.763 ,-,-,IQTR433690543,Health Care (Primary),Canada (Primary),"Reliq Health Technologies Inc., a healthcare technology company, engages in the development of mobile software solutions for community care market. It offers iUGO Health technology platform, a hardware and software solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.","TSXV:RHT
Company: Reliq Health Technologies Inc.
(IQT26049870) - Canada",-
06/08/2017,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 8.93 ,-,-,IQTR433716205,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
06/08/2017,Resverlogix Corp. (TSX:RVX),TSX:RVX,Public Offering,Closed, 9.91 ,-,-,IQTR434187228,Health Care (Primary),Canada (Primary),"Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Canada.","TSX:RVX
Company: Resverlogix Corp.
(IQT2590484) - Canada",-
06/07/2017,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 3.03 ,-,-,IQTR433505410,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
06/06/2017,Chartwell Retirement Residences (TSX:CSH.UN),TSX:CSH.UN,Private Placement,Closed, 200.0 ,-,-,IQTR433331409,Health Care (Primary),Canada (Primary),"Chartwell is an unincorporated, open-ended real estate trust which indirectly owns and operates a complete range of seniors housing communities, from independent supportive living through assisted living to long term care. It is the largest operator in the Canadian seniors living sector with over 200 quality retirement communities in four provinces. Chartwell is committed to its vision of Making People's Lives BETTER and to providing a happier, healthier and more fulfilling life experience for its residents.","TSX:CSH.UN
Company: Chartwell Retirement Residences
(IQT7768795) - Canada",-
06/01/2017,Kane Biotech Inc. (TSXV:KNE),TSXV:KNE,Private Placement,Closed, 4.14 ,-,-,IQTR432806400,Health Care (Primary),Canada (Primary),"Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.","TSXV:KNE
Company: Kane Biotech Inc.
(IQT5532100) - Canada",-
05/31/2017,Sirona Biochem Corp. (TSXV:SBM),TSXV:SBM,Private Placement,Closed, 0.587 ,-,-,IQTR432664844,Health Care (Primary),Canada (Primary),"Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.","TSXV:SBM
Company: Sirona Biochem Corp.
(IQT58893998) - Canada",-
05/31/2017,IMV Inc. (TSX:IMV),TSX:IMV,Public Offering,Closed, 10.0 ,-,-,IQTR432759883,Health Care (Primary),Canada (Primary),"IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company’s DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.","TSX:IMV
Company: IMV Inc.
(IQT71987179) - Canada",-
05/29/2017,Therma Bright Inc. (TSXV:THRM),TSXV:THRM,Private Placement,Closed, 0.318 ,-,-,IQTR432492172,Health Care (Primary),Canada (Primary),"Therma Bright Inc. develops and markets thermal therapy technology that provides topical relief to skin irritations resulting from insect bites, stings, and prevention of cold sores. It offers InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.","TSXV:THRM
Company: Therma Bright Inc.
(IQT2623116) - Canada",-
05/26/2017,Avicanna Inc. (TSX:AVCN),TSX:AVCN,Private Placement,Closed, 1.6 ,-,-,IQTR432235091,Health Care (Primary),Canada (Primary),"Avicanna Inc. focuses on the research and development, cultivation, manufacture, and commercialization of plant-derived cannabinoid-based products and extracts in North America, Latin America, Europe, and Asia. It intends to offer plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and extracts. The company was founded in 2016 and is headquartered in Toronto, Canada.","TSX:AVCN
Company: Avicanna Inc.
(IQT628278928) - Canada",-
05/25/2017,Element Lifestyle Retirement Inc. (TSXV:ELM),TSXV:ELM,Private Placement,Closed, 2.53 ,-,-,IQTR432138561,Health Care (Primary),Canada (Primary),"Element Lifestyle Retirement Inc. develops and operates senior retirement communities in British Columbia, Canada. It provides development consulting services, such as property selection, assembly and acquisition, building and community design, municipal approval and land entitlement processes, financing, marketing, sales and leasing, and construction project management. The company also offers long-term management services for the facilities, which include management of the administration, operation, and financing of retirement communities and physical facilities. Element Lifestyle Retirement Inc. was incorporated in 2007 and is headquartered in Vancouver, Canada.","TSXV:ELM
Company: Element Lifestyle Retirement Inc.
(IQT142268555) - Canada",-
05/25/2017,Trillium Therapeutics Inc. (TSX:TRIL),TSX:TRIL,Public Offering,Closed, 40.35 ,-,-,IQTR432199675,Health Care (Primary),Canada (Primary),"Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.","TSX:TRIL
Company: Trillium Therapeutics Inc.
(IQT13556077) - Canada",-
05/24/2017,Canadian International Pharma Corp. (TSXV:CIP.H),TSXV:CIP.H,Private Placement,Closed, 0.225 ,-,-,IQTR431999775,Health Care (Primary),Canada (Primary),"Canadian International Pharma Corp. focuses on the manufacture, distribution, and sale of generic and nutraceutical drugs in Canada and internationally. It also provides testing and measuring services for finished dosage forms of nutraceutical and pharmaceutical medications. The company was formerly known as Black Panther Mining Corp. and changed its name to Canadian International Pharma Corp. in June 2015. Canadian International Pharma Corp. is based in West Vancouver, Canada.","TSXV:CIP.H
Company: Canadian International Pharma Corp.
(IQT46045249) - Canada",-
05/24/2017,Oncolytics Biotech Inc. (TSX:ONC),TSX:ONC,Public Offering,Closed,-,-,-,IQTR432100699,Health Care (Primary),Canada (Primary),"Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.","TSX:ONC
Company: Oncolytics Biotech Inc.
(IQT2635856) - Canada",-
05/24/2017,Antibe Therapeutics Inc. (TSXV:ATE),TSXV:ATE,Public Offering,Closed, 4.98 ,-,-,IQTR432465524,Health Care (Primary),Canada (Primary),"Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company’s lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.","TSXV:ATE
Company: Antibe Therapeutics Inc.
(IQT241870185) - Canada",-
05/19/2017,Vigil Health Solutions Inc. (TSXV:VGL),TSXV:VGL,Merger/Acquisition,Closed, 0.338 ,NameSilo Technologies Corp. (OTCPK:URLO.F),-,IQTR431626267,Health Care (Primary),Canada (Primary),"Vigil Health Solutions Inc. develops, markets, and distributes hardware and software solutions for care plans and monitoring the aged in Canada and the United States. The company offers The Vigil Integrated Care Management System, which includes emergency call, nurse call, wireless call, fall management, wander management, perimeter monitoring, resident check in, and a non-invasive monitoring system for residents with Alzheimer’s and other forms of dementia. It also offers vigil memory care systems; vitality care systems; and cloud applications, as well as specialty monitoring and notification devices. The company serves customers, such as independent living, assisted living, memory care, skilled nursing and CCRCs/life plan communities. Vigil Health Solutions Inc. is headquartered in Victoria, Canada.","TSXV:VGL
Company: Vigil Health Solutions Inc.
(IQT2657746) - Canada",-
05/15/2017,Medexus Pharmaceuticals Inc. (TSXV:MDP),TSXV:MDP,Private Placement,Closed, 5.0 ,9346-4626 Québec Inc.,-,IQTR430938940,Health Care (Primary),Canada (Primary),"Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company’s primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Otixal, a prescription product for the treatment of acute otitis media with tympanostomy tubes in pediatric patients; Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; and Rupall, an allergy medication. It also offers Metoject Subcutaneous for the treatment of rheumatoid arthritis, psoriasis, and psoriatic arthritis; and distributes pharmaceutical products, such as Treosulfan and Gliolan. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is headquartered in Verdun, Canada.","TSXV:MDP
Company: Medexus Pharmaceuticals Inc.
(IQT253516634) - Canada",-
05/12/2017,Covalon Technologies Ltd. (TSXV:COV),TSXV:COV,Private Placement,Closed, 2.33 ,Goldfarb Corp.; ISYMAX Corp.,-,IQTR430744651,Health Care (Primary),Canada (Primary),"Covalon Technologies Ltd., an advanced medical technologies company, researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has three proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products that treat chronic and infected wounds, such as diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform, which is used in a family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. It sells wound care dressing, surgical and peri-operative, and infection management products under the Covalon brand name. The company also offers development contracts, licensing agreements, and distribution contracts services. It provides its technologies, products, and services to various health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.","TSXV:COV
Company: Covalon Technologies Ltd.
(IQT13433026) - Canada",-
05/09/2017,Biomark Diagnostics Inc (DB:20B),DB:20B,Private Placement,Closed, 1.05 ,-,-,IQTR430433082,Health Care (Primary),Canada (Primary),"Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a research collaboration with the University of Maryland School of Medicine related to the discovery and validation of biomarkers using a combinatorial technology approach. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",-,"CNSX:BUX
Company: Biomark Diagnostics Inc
(IQT275753722) - Canada"
05/01/2017,"Agility Health, Inc. (TSXV:AHI.H)",TSXV:AHI.H,Private Placement,Closed, 4.13 ,-,-,IQTR429567404,Health Care (Primary),Canada (Primary),"Agility Health, Inc. does not have significant operations. It focuses on identifying an active business. Previously, the company provided rehabilitation services through its clinics in Canada. Agility Health, Inc. was founded in 1968 and is headquartered in Hamilton, Canada.","TSXV:AHI.H
Company: Agility Health, Inc.
(IQT141105226) - Canada",-
04/27/2017,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 0.82 ,-,-,IQTR429034920,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
04/25/2017,Zecotek Photonics Inc. (TSXV:ZMS),TSXV:ZMS,Private Placement,Closed, 0.56 ,-,-,IQTR428726040,Health Care (Primary),Canada (Primary),"Zecotek Photonics Inc., a photonics technology company, develops various photonics technologies and products for commercial and research applications in medical, bio-science, high-energy physics, pharmaceutical research, material processing, engineering and industrial design, and multi-media markets. The company operates through three divisions: Zecotek Imaging China, Zecotek Optronics Systems, and Zecotek Autotronics. Its imaging systems include lutetium fine silicate scintillation crystals; solid-state micro-pixel avalanche photo diode photo detectors and transistors; and integrated detector modules. The company also develops glasses-free 3D displays; and 3D auto-stereoscopic displays, and 3D printers and related technologies for applications in healthcare, scientific, and industrial markets. Zecotek Photonics Inc. in Asia and North America. Its strategic partners primarily include Nucare Ltd., University of Washington, and University of California. The company was formerly known as Zecotek Medical Systems Inc. and changed its name to Zecotek Photonics Inc. in November 2007. Zecotek Photonics Inc. was incorporated in 1983 and is headquartered in Richmond, Canada.","TSXV:ZMS
Company: Zecotek Photonics Inc.
(IQT39242544) - Canada",-
04/21/2017,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 1.05 ,"Fulcher, N. W. Limited",-,IQTR428445816,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
04/13/2017,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 2.71 ,-,-,IQTR427755914,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
04/10/2017,Hemostemix Inc. (TSXV:HEM),TSXV:HEM,Private Placement,Closed, 5.31 ,-,-,IQTR427327181,Health Care (Primary),Canada (Primary),"Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cells products, such as synergetic cell populations, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.","TSXV:HEM
Company: Hemostemix Inc.
(IQT278407492) - Canada",-
04/10/2017,Innovotech Inc. (TSXV:IOT),TSXV:IOT,Private Placement,Closed, 0.4 ,Lonsdale Capital Corporation,-,IQTR427369313,Health Care (Primary),Canada (Primary),"Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States and internationally. The company offers InnovoSIL, an antimicrobial agents for coating onto or incorporation into medical devices; MBEC Assay, a screening assay used to determine the efficacy of antimicrobials against biofilms of various microorganisms; and Agress/AgreGuard, an environmentally friendly seed treatments and plant sprays to protect crops against both bacterial and fungal infections. It also provides implant medical devices; antibiotic, antimicrobial, and biocide resistance; bacteriophage, cytotoxicity, and in vitro antimicrobial testing; and analytical services. It serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food safety, transportation, and healthcare. Innovotech Inc. was incorporated in 2001 is headquartered in Edmonton, Canada.","TSXV:IOT
Company: Innovotech Inc.
(IQT5793712) - Canada",-
04/06/2017,Aurora Spine Corporation (TSXV:ASG),TSXV:ASG,Private Placement,Closed, 0.301 ,-,-,IQTR426960835,Health Care (Primary),Canada (Primary),"Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. The company offers interspinous process lumbar fusion devices for patients suffering from degenerative disc diseases; Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae and bone grows to complete the fusion process; sterile-packed titanium plasma spray coated spinal infusion implants for bone growth; and 3D Printed Stand Alone ALIF Cage, an integrated plate and spacer system that helps to preserve the natural anatomic profile, and provide spinal column support and stability. The company was incorporated in 2013 and is headquartered in Toronto, Canada.","TSXV:ASG
Company: Aurora Spine Corporation
(IQT245521185) - Canada",-
04/05/2017,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Closed, 0.4 ,Corner Market Capital Corporation,-,IQTR426771637,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
04/05/2017,IntelGenx Technologies Corp. (OTCPK:IGXT),OTCPK:IGXT,Public Offering,Closed, 6.84 ,-,-,IQTR426842271,Health Care (Primary),Canada (Primary),"IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer’s disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",-,"TSXV:IGX
Company: IntelGenx Technologies Corp.
(IQT59707332) - Canada"
03/31/2017,Zymeworks Inc. (NYSE:ZYME),NYSE:ZYME,Public Offering,Closed, 79.94 ,-,-,IQTR426421320,Health Care (Primary),Canada (Primary),"Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; and ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnership with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.",-,"TSX:ZYME
Company: Zymeworks Inc.
(IQT428079716) - Canada"
03/29/2017,Enlighta Inc. (TSXV:NLTA),TSXV:NLTA,Public Offering,Closed, 0.64 ,-,-,IQTR424996774,Health Care (Primary),Canada (Primary),"Enlighta Inc. operates as a healthcare and medical digital, green, and clean technology company. The company, through a joint venture with Fischer Institute of Physical Therapy and Performance, provides physical therapy services and rehabilitative medicine treatments. It also has a patent pending portfolio of 10 OTC nutraceutical formulations. The company was formerly known as HooXi Network Inc. and changed its name to Enlighta Inc. in July 2019. Enlighta Inc. is based in Richmond, Canada.","TSXV:NLTA
Company: Enlighta Inc.
(IQT253108413) - Canada",-
03/29/2017,Reliq Health Technologies Inc. (TSXV:RHT),TSXV:RHT,Private Placement,Closed, 0.762 ,-,-,IQTR428528845,Health Care (Primary),Canada (Primary),"Reliq Health Technologies Inc., a healthcare technology company, engages in the development of mobile software solutions for community care market. It offers iUGO Health technology platform, a hardware and software solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.","TSXV:RHT
Company: Reliq Health Technologies Inc.
(IQT26049870) - Canada",-
03/24/2017,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Private Placement,Closed, 25.0 ,"Thomvest Ventures, Inc.",-,IQTR424471862,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
03/24/2017,Vitalhub Corp. (TSXV:VHI),TSXV:VHI,Private Placement,Closed, 3.18 ,-,-,IQTR424487549,Health Care (Primary),Canada (Primary),"VitalHub Corp., together with its subsidiaries, develops and supports healthcare information systems in the mental health, long term care, community health service, and hospital sectors in Canada and the United States. Its technologies include blockchain, mobile and Web-based assessment, and electronic healthcare record solutions. The company is based in Toronto, Canada.","TSXV:VHI
Company: Vitalhub Corp.
(IQT411552553) - Canada",-
03/17/2017,Acerus Pharmaceuticals Corporation (TSX:ASP),TSX:ASP,Merger/Acquisition,Closed, 1.46 ,-,"Aytu BioScience, Inc. (NasdaqCM:AYTU)",IQTR423845520,Health Care (Primary),Canada (Primary),"Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.","TSX:ASP
Company: Acerus Pharmaceuticals Corporation
(IQT137641837) - Canada",-
03/16/2017,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 1.11 ,-,-,IQTR423719915,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
03/14/2017,ZoomMed Inc. (TSXV:ZMD.H),TSXV:ZMD.H,Private Placement,Closed, 0.5 ,"PCP GP, L.P.",-,IQTR423445518,Health Care (Primary),Canada (Primary),"ZoomMed Inc., together with its subsidiaries, develops and markets a range of computer applications designed for healthcare professionals primarily in the United States and the United Kingdom. The company builds and operates a clinical information exchange platform between physicians, pharmacists, and various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical companies, laboratories, physiotherapy clinics, and other organizations. It also offers ZRx Prescriber, a technological Web application that enables physicians to generate prescriptions. ZoomMed Inc. was incorporated in 2005 and is headquartered in Brossard, Canada.","TSXV:ZMD.H
Company: ZoomMed Inc.
(IQT22495974) - Canada",-
03/13/2017,Aurinia Pharmaceuticals Inc. (TSX:AUP),TSX:AUP,Public Offering,Closed, 202.91 ,-,-,IQTR423336873,Health Care (Primary),Canada (Primary),"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","TSX:AUP
Company: Aurinia Pharmaceuticals Inc.
(IQT2622592) - Canada",-
03/10/2017,WELL Health Technologies Corp. (TSXV:WELL),TSXV:WELL,Private Placement,Closed, 1.28 ,Impactreneur Capital Corp.,-,IQTR430987704,Health Care (Primary),Canada (Primary),"WELL Health Technologies Corp. owns and operates a portfolio of primary healthcare facilities. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. As at December 31, 2018, it operated 19 medical clinics. WELL Health Technologies Corp. is headquartered in Vancouver, Canada.","TSXV:WELL
Company: WELL Health Technologies Corp.
(IQT434799348) - Canada",-
03/09/2017,VentriPoint Diagnostics Ltd. (TSXV:VPT),TSXV:VPT,Private Placement,Closed, 3.36 ,-,-,IQTR422961918,Health Care (Primary),Canada (Primary),"Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe. The company offers Ventripoint Medical System, a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company is headquartered in Toronto, Canada.","TSXV:VPT
Company: VentriPoint Diagnostics Ltd.
(IQT37361106) - Canada",-
03/09/2017,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Closed, 1.08 ,-,-,IQTR423022635,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
03/09/2017,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed," 2,695.26 ",-,-,IQTR423542245,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
03/09/2017,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Public Offering,Closed," 1,684.54 ",-,-,IQTR423542256,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
03/08/2017,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 7.51 ,-,-,IQTR422876378,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
03/08/2017,Cardiol Therapeutics Inc. (TSX:CRDL),TSX:CRDL,Private Placement,Closed, 0.75 ,-,-,IQTR424954811,Health Care (Primary),Canada (Primary),"Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company develops CTX01, a proprietary formulation of pharmaceutical cannabidiol for the treatment of heart failure with preserved ejection fraction; CTX02, a proprietary formulation of methotrexate for the treatment of heart failure; and CTX03 is a proprietary nanoformulation of encapsulated Cyclosporine A for the treatment of heart failure. It also develops CRxIMT, an anti-tumor immunotherapy for the treatment of Glioblastoma Multiforme; and CardiolRx, a pharmaceutical cannabidiol product. The company was incorporated in 2017 and is headquartered in Oakville, Canada.","TSX:CRDL
Company: Cardiol Therapeutics Inc.
(IQT562976995) - Canada",-
03/06/2017,SQI Diagnostics Inc. (TSXV:SQD),TSXV:SQD,Private Placement,Closed, 3.65 ,-,-,IQTR422497766,Health Care (Primary),Canada (Primary),"SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.","TSXV:SQD
Company: SQI Diagnostics Inc.
(IQT34231255) - Canada",-
03/06/2017,Lexaria Bioscience Corp. (OTCPK:LXRP),OTCPK:LXRP,Private Placement,Closed, 2.31 ,-,-,IQTR422526454,Health Care (Primary),Canada (Primary),"Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.",-,"CNSX:LXX
Company: Lexaria Bioscience Corp.
(IQT241590134) - Canada"
03/03/2017,Aquarius Surgical Technologies Inc. (CNSX:ASTI),CNSX:ASTI,Private Placement,Closed, 4.41 ,-,-,IQTR422735322,Health Care (Primary),Canada (Primary),"Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America. It provides multi-diode laser systems and related fibre-optic delivery devices for minimally invasive treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance, as well as consumables. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.","CNSX:ASTI
Company: Aquarius Surgical Technologies Inc.
(IQT536082025) - Canada",-
03/02/2017,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Public Offering,Closed, 4.5 ,-,-,IQTR422251643,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
02/28/2017,Preferred Dental Technologies Inc. (CNSX:PDTI),CNSX:PDTI,Private Placement,Closed, 0.45 ,-,-,IQTR422032778,Health Care (Primary),Canada (Primary),"Preferred Dental Technologies Inc. develops and commercializes various technologies in the dental implant industry. It offers EAS components for custom dental abutments for dental implants. The company is headquartered in Winnipeg, Canada.","CNSX:PDTI
Company: Preferred Dental Technologies Inc.
(IQT529428534) - Canada",-
02/28/2017,Novoheart Holdings Inc. (TSXV:NVH),TSXV:NVH,Private Placement,Closed, 0.331 ,"Hong Kong Science and Technology Parks, Investment Arm",-,IQTR423309707,Health Care (Primary),Canada (Primary),"Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.","TSXV:NVH
Company: Novoheart Holdings Inc.
(IQT533927284) - Canada",-
02/27/2017,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 1.35 ,-,-,IQTR421797132,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
02/24/2017,Imagin Medical Inc. (CNSX:IME),CNSX:IME,Private Placement,Closed, 0.118 ,-,-,IQTR421787812,Health Care (Primary),Canada (Primary),"Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.","CNSX:IME
Company: Imagin Medical Inc.
(IQT302480186) - Canada",-
02/22/2017,Imagin Medical Inc. (CNSX:IME),CNSX:IME,Private Placement,Effective, 8.0 ,Alumina Partners LLC,-,IQTR421363515,Health Care (Primary),Canada (Primary),"Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.","CNSX:IME
Company: Imagin Medical Inc.
(IQT302480186) - Canada",-
02/21/2017,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 0.4 ,-,-,IQTR421199721,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
02/14/2017,Cronos Group Inc. (TSX:CRON),TSX:CRON,Public Offering,Closed, 15.08 ,-,-,IQTR420121010,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
02/09/2017,H-Source Holdings Ltd. (TSXV:HSI),TSXV:HSI,Private Placement,Closed, 3.22 ,-,-,IQTR419586856,Health Care (Primary),Canada (Primary),"H-Source Holdings Ltd., a technology company, operates in the healthcare industry. It offers a hospital-to-hospital transaction platform that provides a marketplace for members to buy, sell, and transfer excess inventory supplies and capital equipment with each other. The company’s platform allows members to conduct transactions within integrated delivery networks and group purchasing organizations. H-Source Holdings Ltd. is headquartered in Vancouver, Canada.","TSXV:HSI
Company: H-Source Holdings Ltd.
(IQT377711030) - Canada",-
02/07/2017,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 3.17 ,-,-,IQTR419311489,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
02/06/2017,Medicenna Therapeutics Corp. (TSX:MDNA),TSX:MDNA,Private Placement,Closed, 4.0 ,-,-,IQTR419222500,Health Care (Primary),Canada (Primary),"Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.","TSX:MDNA
Company: Medicenna Therapeutics Corp.
(IQT421396443) - Canada",-
02/02/2017,Acasti Pharma Inc. (TSXV:ACST),TSXV:ACST,Private Placement,Closed, 1.93 ,-,-,IQTR418926463,Health Care (Primary),Canada (Primary),"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","TSXV:ACST
Company: Acasti Pharma Inc.
(IQT129334454) - Canada",-
02/02/2017,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Closed, 2.72 ,-,-,IQTR419206286,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
01/31/2017,Sirona Biochem Corp. (TSXV:SBM),TSXV:SBM,Private Placement,Closed, 0.665 ,-,-,IQTR418671541,Health Care (Primary),Canada (Primary),"Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.","TSXV:SBM
Company: Sirona Biochem Corp.
(IQT58893998) - Canada",-
01/29/2017,"CardioComm Solutions, Inc. (TSXV:EKG)",TSXV:EKG,Private Placement,Closed, 0.076 ,-,-,IQTR418489235,Health Care (Primary),Canada (Primary),"CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company’s technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals, and call centers to access and manage patient information. The company’s software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a Web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 and EMR Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring, an ECG reading service. Additionally, CardioComm Solutions, Inc. provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. The company was incorporated in 1989 and is headquartered in Toronto, Canada.","TSXV:EKG
Company: CardioComm Solutions, Inc.
(IQT2598161) - Canada",-
01/27/2017,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Closed, 0.4 ,Corner Market Capital Corporation,-,IQTR418412571,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
01/20/2017,Apteryx Imaging Inc. (TSXV:XRAY),TSXV:XRAY,Private Placement,Closed, 14.45 ,-,-,IQTR417496170,Health Care (Primary),Canada (Primary),"Apteryx Imaging Inc. provides diagnostic imaging software and device technologies for dentists and oral health specialists. Its imaging software products include XrayVision 4 that provides image enhancement and analysis tools with open-architecture technology allowing integration with the imaging systems from various manufacturers; XVWeb, a DICOM server that accepts images from various DICOM-compliant imaging software; XVWeb 3D, a cloud solution for 3D dental imaging; XVlite, a dental imaging software package; and XrayVision DCV, a DICOM-based dental imaging suite. The company’s imaging hardware products comprise TUXEDO intraoral sensors; LED IC100 intraoral cameras; and RAYSCAN panoramic + cephalometric imaging solutions. It also offers VELscope Vx system, a device for the enhanced visualization of mucosal abnormalities, such as oral cancer and premalignant dysplasia; VELscope Vx imaging adapter for fluorescence and white-light clinical imaging; Vx VELcaps to prevent patient cross contamination; Vx VELsheaths, a single use plastic sheath to prevent patient cross contamination; and VELscope Vx Value Bundle, a portable handheld device used to conduct oral tissue examinations. Apteryx Imaging Inc. has a partnership agreement with 4th-IR AG to develop a suite of cloud-based AI solutions. The company was formerly known as LED Medical Diagnostics Inc. and changed its name to Apteryx Imaging Inc. in September 2019. Apteryx Imaging Inc. was founded in 2002 and is headquartered in Vancouver, Canada.","TSXV:XRAY
Company: Apteryx Imaging Inc.
(IQT143328534) - Canada",-
01/19/2017,"Agility Health, Inc. (TSXV:AHI.H)",TSXV:AHI.H,Private Placement,Closed, 0.5 ,-,-,IQTR417331128,Health Care (Primary),Canada (Primary),"Agility Health, Inc. does not have significant operations. It focuses on identifying an active business. Previously, the company provided rehabilitation services through its clinics in Canada. Agility Health, Inc. was founded in 1968 and is headquartered in Hamilton, Canada.","TSXV:AHI.H
Company: Agility Health, Inc.
(IQT141105226) - Canada",-
12/28/2016,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 1.82 ,-,-,IQTR414660850,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
12/22/2016,Aurinia Pharmaceuticals Inc. (TSX:AUP),TSX:AUP,Public Offering,Closed, 33.67 ,-,-,IQTR414375244,Health Care (Primary),Canada (Primary),"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","TSX:AUP
Company: Aurinia Pharmaceuticals Inc.
(IQT2622592) - Canada",-
12/21/2016,"CardioComm Solutions, Inc. (TSXV:EKG)",TSXV:EKG,Private Placement,Closed, 0.6 ,-,-,IQTR413909595,Health Care (Primary),Canada (Primary),"CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company’s technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals, and call centers to access and manage patient information. The company’s software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a Web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 and EMR Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring, an ECG reading service. Additionally, CardioComm Solutions, Inc. provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. The company was incorporated in 1989 and is headquartered in Toronto, Canada.","TSXV:EKG
Company: CardioComm Solutions, Inc.
(IQT2598161) - Canada",-
12/21/2016,Apteryx Imaging Inc. (TSXV:XRAY),TSXV:XRAY,Private Placement,Closed, 0.8 ,Stratigis Capital Advisors Inc.,-,IQTR413909853,Health Care (Primary),Canada (Primary),"Apteryx Imaging Inc. provides diagnostic imaging software and device technologies for dentists and oral health specialists. Its imaging software products include XrayVision 4 that provides image enhancement and analysis tools with open-architecture technology allowing integration with the imaging systems from various manufacturers; XVWeb, a DICOM server that accepts images from various DICOM-compliant imaging software; XVWeb 3D, a cloud solution for 3D dental imaging; XVlite, a dental imaging software package; and XrayVision DCV, a DICOM-based dental imaging suite. The company’s imaging hardware products comprise TUXEDO intraoral sensors; LED IC100 intraoral cameras; and RAYSCAN panoramic + cephalometric imaging solutions. It also offers VELscope Vx system, a device for the enhanced visualization of mucosal abnormalities, such as oral cancer and premalignant dysplasia; VELscope Vx imaging adapter for fluorescence and white-light clinical imaging; Vx VELcaps to prevent patient cross contamination; Vx VELsheaths, a single use plastic sheath to prevent patient cross contamination; and VELscope Vx Value Bundle, a portable handheld device used to conduct oral tissue examinations. Apteryx Imaging Inc. has a partnership agreement with 4th-IR AG to develop a suite of cloud-based AI solutions. The company was formerly known as LED Medical Diagnostics Inc. and changed its name to Apteryx Imaging Inc. in September 2019. Apteryx Imaging Inc. was founded in 2002 and is headquartered in Vancouver, Canada.","TSXV:XRAY
Company: Apteryx Imaging Inc.
(IQT143328534) - Canada",-
12/17/2016,"CardioComm Solutions, Inc. (TSXV:EKG)",TSXV:EKG,Private Placement,Closed, 0.5 ,-,-,IQTR413581398,Health Care (Primary),Canada (Primary),"CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company’s technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals, and call centers to access and manage patient information. The company’s software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a Web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 and EMR Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring, an ECG reading service. Additionally, CardioComm Solutions, Inc. provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. The company was incorporated in 1989 and is headquartered in Toronto, Canada.","TSXV:EKG
Company: CardioComm Solutions, Inc.
(IQT2598161) - Canada",-
12/16/2016,Antibe Therapeutics Inc. (TSXV:ATE),TSXV:ATE,Private Placement,Closed, 2.72 ,-,-,IQTR413333762,Health Care (Primary),Canada (Primary),"Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company’s lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.","TSXV:ATE
Company: Antibe Therapeutics Inc.
(IQT241870185) - Canada",-
12/15/2016,Appili Therapeutics Inc. (TSXV:APLI),TSXV:APLI,Private Placement,Closed, 2.88 ,Innovacorp,-,IQTR413941745,Health Care (Primary),Canada (Primary),"Appili Therapeutics Inc., a pharmaceutical company, acquires, develops, and commercializes therapeutics in the area of infectious disease in Canada. The company focuses on building and advancing a portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-1501, a taste-masked oral liquid formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was founded in 2015 and is headquartered in Halifax, Canada.","TSXV:APLI
Company: Appili Therapeutics Inc.
(IQT607127273) - Canada",-
12/06/2016,Knight Therapeutics Inc. (TSX:GUD),TSX:GUD,Public Offering,Closed, 87.0 ,-,-,IQTR412129372,Health Care (Primary),Canada (Primary),"Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; and NERLYNX for the treatment of HER2-positive breast cancer. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; and TX-004HR for moderate-to-severe dyspareunia and TX-001HR for moderate-to-severe vasomotor symptoms due to menopause. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. Further, the company develops TULSA-PRO, a medical device for prostate ablation. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.","TSX:GUD
Company: Knight Therapeutics Inc.
(IQT254910895) - Canada",-
12/05/2016,Acasti Pharma Inc. (TSXV:ACST),TSXV:ACST,Public Offering,Closed, 5.7 ,-,-,IQTR416187660,Health Care (Primary),Canada (Primary),"Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","TSXV:ACST
Company: Acasti Pharma Inc.
(IQT129334454) - Canada",-
12/02/2016,Neovasc Inc. (TSX:NVCN),TSX:NVCN,Private Placement,Closed, 9.3 ,Boston Scientific Corporation (NYSE:BSX),-,IQTR411843245,Health Care (Primary),Canada (Primary),"Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.","TSX:NVCN
Company: Neovasc Inc.
(IQT46472100) - Canada",-
12/02/2016,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Closed, 0.721 ,-,-,IQTR411940971,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
12/01/2016,Enlighta Inc. (TSXV:NLTA),TSXV:NLTA,Private Placement,Closed, 0.1 ,-,-,IQTR411737051,Health Care (Primary),Canada (Primary),"Enlighta Inc. operates as a healthcare and medical digital, green, and clean technology company. The company, through a joint venture with Fischer Institute of Physical Therapy and Performance, provides physical therapy services and rehabilitative medicine treatments. It also has a patent pending portfolio of 10 OTC nutraceutical formulations. The company was formerly known as HooXi Network Inc. and changed its name to Enlighta Inc. in July 2019. Enlighta Inc. is based in Richmond, Canada.","TSXV:NLTA
Company: Enlighta Inc.
(IQT253108413) - Canada",-
12/01/2016,Medicenna Therapeutics Corp. (TSX:MDNA),TSX:MDNA,Private Placement,Closed, 10.0 ,-,-,IQTR411762017,Health Care (Primary),Canada (Primary),"Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.","TSX:MDNA
Company: Medicenna Therapeutics Corp.
(IQT421396443) - Canada",-
11/30/2016,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Private Placement,Closed, 1.26 ,-,-,IQTR411636803,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
11/23/2016,IMV Inc. (TSX:IMV),TSX:IMV,Private Placement,Closed, 8.0 ,Ruffer LLP; CTI Life Sciences,-,IQTR410711356,Health Care (Primary),Canada (Primary),"IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company’s DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.","TSX:IMV
Company: IMV Inc.
(IQT71987179) - Canada",-
11/22/2016,Opsens Inc. (TSX:OPS),TSX:OPS,Public Offering,Closed, 13.0 ,-,-,IQTR410786367,Health Care (Primary),Canada (Primary),"Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for interventional cardiology, fractional flow reserve (FFR), oil and gas, and industrial applications. The company operates through two segments, Medical and Industrial. It primarily focuses on the measure of FFR in interventional cardiology. The company offers OptoWire, an advanced optical-based pressure guidewire that enhances the clinical outcome of patients with coronary artery disease; and OptoMonitor, which can be connected directly to the cath lab hemodynamic system that offers FFR module to display FFR on the cath lab monitor. It also provides design, installation, and field support services; and fiber optic point pressure and temperature sensors, distributed temperature sensors, specialized readout units, and specialized cables, as well as fiber optic sensors for infrastructure surveillance to the upstream and downstream oil and gas industry. In addition, the company provides fiber optic sensing solutions for industrial applications, including fiber optic temperature sensors, pressure sensors, strain sensors, displacement sensors, and extensometers, as well as signal conditioners/OEM boards. It serves various markets, such as life sciences, energy, defense and aerospace, geotechnical, civil engineering, scientific laboratory, and other markets. The company operates in the United States, Japan, Canada, and internationally. Opsens Inc. is headquartered in Québec, Canada.","TSX:OPS
Company: Opsens Inc.
(IQT29686435) - Canada",-
11/21/2016,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 0.7 ,Aconi Investments Corp. Ltd,-,IQTR410445631,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
11/18/2016,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Private Placement,Closed, 10.03 ,-,-,IQTR410525533,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
11/17/2016,Telo Genomics Corp. (TSXV:TELO),TSXV:TELO,Private Placement,Closed, 4.5 ,Knight Therapeutics Inc. (TSX:GUD),-,IQTR410098217,Health Care (Primary),Canada (Primary),"Telo Genomics Corp., a personalized medicine company, focuses on the development and commercialization of predictive technological products. Its proprietary software platform predicts the course of certain diseases and personalizes the treatment for individual patients. The company’s TeloView software platform measures the stage of the disease, rate of progression of the disease, how different diseases will respond to various therapies, and drug efficacy and toxicity. It is developing five diagnostic and prognostic products for cancers and neurological disorders, including Hodgkin’s lymphoma, prostate cancer, multiple myeloma, lung cancer, and Alzheimer’s diseases. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. is headquartered in Toronto, Canada.","TSXV:TELO
Company: Telo Genomics Corp.
(IQT401930792) - Canada",-
11/14/2016,Theratechnologies Inc. (TSX:TH),TSX:TH,Public Offering,Closed, 16.5 ,-,-,IQTR430010404,Health Care (Primary),Canada (Primary),"Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.","TSX:TH
Company: Theratechnologies Inc.
(IQT2657754) - Canada",-
11/09/2016,Aurinia Pharmaceuticals Inc. (TSX:AUP),TSX:AUP,Public Offering,Announced, 10.75 ,-,-,IQTR409418315,Health Care (Primary),Canada (Primary),"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","TSX:AUP
Company: Aurinia Pharmaceuticals Inc.
(IQT2622592) - Canada",-
11/07/2016,Zecotek Photonics Inc. (TSXV:ZMS),TSXV:ZMS,Private Placement,Closed, 1.76 ,-,-,IQTR408884531,Health Care (Primary),Canada (Primary),"Zecotek Photonics Inc., a photonics technology company, develops various photonics technologies and products for commercial and research applications in medical, bio-science, high-energy physics, pharmaceutical research, material processing, engineering and industrial design, and multi-media markets. The company operates through three divisions: Zecotek Imaging China, Zecotek Optronics Systems, and Zecotek Autotronics. Its imaging systems include lutetium fine silicate scintillation crystals; solid-state micro-pixel avalanche photo diode photo detectors and transistors; and integrated detector modules. The company also develops glasses-free 3D displays; and 3D auto-stereoscopic displays, and 3D printers and related technologies for applications in healthcare, scientific, and industrial markets. Zecotek Photonics Inc. in Asia and North America. Its strategic partners primarily include Nucare Ltd., University of Washington, and University of California. The company was formerly known as Zecotek Medical Systems Inc. and changed its name to Zecotek Photonics Inc. in November 2007. Zecotek Photonics Inc. was incorporated in 1983 and is headquartered in Richmond, Canada.","TSXV:ZMS
Company: Zecotek Photonics Inc.
(IQT39242544) - Canada",-
11/07/2016,Theralase Technologies Inc. (TSXV:TLT),TSXV:TLT,Public Offering,Closed, 4.27 ,-,-,IQTR409210086,Health Care (Primary),Canada (Primary),"Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Anti-Cancer Therapy and Medical Laser Technology. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.","TSXV:TLT
Company: Theralase Technologies Inc.
(IQT12454055) - Canada",-
10/17/2016,Profound Medical Corp. (TSX:PRN),TSX:PRN,Public Offering,Closed, 17.4 ,-,-,IQTR406834340,Health Care (Primary),Canada (Primary),"Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.","TSX:PRN
Company: Profound Medical Corp.
(IQT269189531) - Canada",-
10/13/2016,Reliq Health Technologies Inc. (TSXV:RHT),TSXV:RHT,Private Placement,Closed, 0.66 ,-,-,IQTR404699414,Health Care (Primary),Canada (Primary),"Reliq Health Technologies Inc., a healthcare technology company, engages in the development of mobile software solutions for community care market. It offers iUGO Health technology platform, a hardware and software solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.","TSXV:RHT
Company: Reliq Health Technologies Inc.
(IQT26049870) - Canada",-
10/13/2016,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Private Placement,Closed, 0.25 ,-,-,IQTR407670795,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
10/05/2016,ADVANZ PHARMA Corp. (TSX:ADVZ),TSX:ADVZ,Public Offering,Closed, 462.65 ,-,-,IQTR404970656,Health Care (Primary),Canada (Primary),"ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, ADVANZ PHARMA International and ADVANZ PHARMA North America. The ADVANZ PHARMA International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment’s products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; Zapain, a combination of codeine phosphate and paracetamol for severe pain reliefs, such as back pain, toothache, severe sprains and strains, and pain after operations. The ADVANZ PHARMA North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. The company sells its products through direct sales and local distribution relationships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.","TSX:ADVZ
Company: ADVANZ PHARMA Corp.
(IQT253396955) - Canada",-
09/30/2016,Enlighta Inc. (TSXV:NLTA),TSXV:NLTA,Private Placement,Closed, 0.584 ,-,-,IQTR403500107,Health Care (Primary),Canada (Primary),"Enlighta Inc. operates as a healthcare and medical digital, green, and clean technology company. The company, through a joint venture with Fischer Institute of Physical Therapy and Performance, provides physical therapy services and rehabilitative medicine treatments. It also has a patent pending portfolio of 10 OTC nutraceutical formulations. The company was formerly known as HooXi Network Inc. and changed its name to Enlighta Inc. in July 2019. Enlighta Inc. is based in Richmond, Canada.","TSXV:NLTA
Company: Enlighta Inc.
(IQT253108413) - Canada",-
09/29/2016,Lotus Ventures Inc. (CNSX:J),CNSX:J,Private Placement,Closed, 0.717 ,-,-,IQTR403287591,Health Care (Primary),Canada (Primary),"Lotus Ventures Inc. produces and sells medical marijuana. The company is based in Vancouver, Canada.","CNSX:J
Company: Lotus Ventures Inc.
(IQT274566928) - Canada",-
09/23/2016,VentriPoint Diagnostics Ltd. (TSXV:VPT),TSXV:VPT,Private Placement,Closed, 0.7 ,-,-,IQTR402624745,Health Care (Primary),Canada (Primary),"Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the United States, and Europe. The company offers Ventripoint Medical System, a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company is headquartered in Toronto, Canada.","TSXV:VPT
Company: VentriPoint Diagnostics Ltd.
(IQT37361106) - Canada",-
09/22/2016,Hemostemix Inc. (TSXV:HEM),TSXV:HEM,Private Placement,Effective, 0.5 ,-,-,IQTR402564260,Health Care (Primary),Canada (Primary),"Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cells products, such as synergetic cell populations, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.","TSXV:HEM
Company: Hemostemix Inc.
(IQT278407492) - Canada",-
09/15/2016,EGF Theramed Health Corp. (CNSX:TMED),CNSX:TMED,Private Placement,Closed, 0.5 ,-,-,IQTR384221400,Health Care (Primary),Canada (Primary),"EGF Theramed Health Corp. operates as a technology company that provides automated biomedical care online services for common health problems. It provides Fully Automated Signal Transduction, a medical device, which monitors blood pressure, as well as enables physiologically interactive health apps used in testing, tracking, and treating common health conditions. The company also offers Electro-Physiologically Interactive Computing (EPIC) system, an online system. Its EPIC serves people interested in normalizing blood pressure, blood glucose, and body weight and skin conditions. The company was formerly known as Theramed Health Corporation and changed its name to EGF Theramed Health Corp. in October 2019. EGF Theramed Health Corp. was incorporated in 2011 and is headquartered in Richmond, Canada.","CNSX:TMED
Company: EGF Theramed Health Corp.
(IQT246550060) - Canada",-
09/14/2016,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 4.26 ,-,-,IQTR384061443,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
09/13/2016,Imagin Medical Inc. (CNSX:IME),CNSX:IME,Private Placement,Closed, 0.696 ,-,-,IQTR383922577,Health Care (Primary),Canada (Primary),"Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company’s target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.","CNSX:IME
Company: Imagin Medical Inc.
(IQT302480186) - Canada",-
09/11/2016,"CardioComm Solutions, Inc. (TSXV:EKG)",TSXV:EKG,Private Placement,Closed, 0.135 ,-,-,IQTR383690847,Health Care (Primary),Canada (Primary),"CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company’s technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals, and call centers to access and manage patient information. The company’s software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a Web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 and EMR Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring, an ECG reading service. Additionally, CardioComm Solutions, Inc. provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. The company was incorporated in 1989 and is headquartered in Toronto, Canada.","TSXV:EKG
Company: CardioComm Solutions, Inc.
(IQT2598161) - Canada",-
09/08/2016,Vitalhub Corp. (TSXV:VHI),TSXV:VHI,Private Placement,Closed, 0.923 ,-,-,IQTR383267311,Health Care (Primary),Canada (Primary),"VitalHub Corp., together with its subsidiaries, develops and supports healthcare information systems in the mental health, long term care, community health service, and hospital sectors in Canada and the United States. Its technologies include blockchain, mobile and Web-based assessment, and electronic healthcare record solutions. The company is based in Toronto, Canada.","TSXV:VHI
Company: Vitalhub Corp.
(IQT411552553) - Canada",-
09/08/2016,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 10.25 ,-,-,IQTR383665677,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
09/06/2016,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Public Offering,Closed, 2.74 ,-,-,IQTR383027711,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
09/02/2016,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Closed, 0.816 ,-,-,IQTR382662345,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
08/24/2016,Canadian International Pharma Corp. (TSXV:CIP.H),TSXV:CIP.H,Private Placement,Effective, 0.1 ,Zimtu Capital Corp. (TSXV:ZC),-,IQTR381664363,Health Care (Primary),Canada (Primary),"Canadian International Pharma Corp. focuses on the manufacture, distribution, and sale of generic and nutraceutical drugs in Canada and internationally. It also provides testing and measuring services for finished dosage forms of nutraceutical and pharmaceutical medications. The company was formerly known as Black Panther Mining Corp. and changed its name to Canadian International Pharma Corp. in June 2015. Canadian International Pharma Corp. is based in West Vancouver, Canada.","TSXV:CIP.H
Company: Canadian International Pharma Corp.
(IQT46045249) - Canada",-
08/19/2016,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 1.0 ,-,-,IQTR381126425,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
08/12/2016,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 1.7 ,-,-,IQTR379898472,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
08/12/2016,Zecotek Photonics Inc. (TSXV:ZMS),TSXV:ZMS,Private Placement,Closed, 0.829 ,-,-,IQTR380641273,Health Care (Primary),Canada (Primary),"Zecotek Photonics Inc., a photonics technology company, develops various photonics technologies and products for commercial and research applications in medical, bio-science, high-energy physics, pharmaceutical research, material processing, engineering and industrial design, and multi-media markets. The company operates through three divisions: Zecotek Imaging China, Zecotek Optronics Systems, and Zecotek Autotronics. Its imaging systems include lutetium fine silicate scintillation crystals; solid-state micro-pixel avalanche photo diode photo detectors and transistors; and integrated detector modules. The company also develops glasses-free 3D displays; and 3D auto-stereoscopic displays, and 3D printers and related technologies for applications in healthcare, scientific, and industrial markets. Zecotek Photonics Inc. in Asia and North America. Its strategic partners primarily include Nucare Ltd., University of Washington, and University of California. The company was formerly known as Zecotek Medical Systems Inc. and changed its name to Zecotek Photonics Inc. in November 2007. Zecotek Photonics Inc. was incorporated in 1983 and is headquartered in Richmond, Canada.","TSXV:ZMS
Company: Zecotek Photonics Inc.
(IQT39242544) - Canada",-
08/11/2016,Imaging Dynamics Company Ltd. (TSXV:IDL),TSXV:IDL,Private Placement,Closed, 6.0 ,-,-,IQTR379731604,Health Care (Primary),Canada (Primary),"Imaging Dynamics Company Ltd., a medical technology company, provides digital radiography equipment worldwide. The company offers imaging detectors; and flat panel detectors under Aquarius8600 and VetnovaXion names. It also provides Magellan, a medical image processing software; and Sirius, a veterinary image processing software. In addition, the company provides 1600 Plus X-Series, a DR solution with a floor mounted U-arm multi-axis positioning device that includes X-ray tube, collimator, and generator; and veterinary DR systems. Further, it engages in the sale and servicing of equipment in the medical device industry. It offers products through dealers, distributors, and original equipment manufacturer partners. The company was formerly known as Imaging Dynamics Corporation and changed its name to Imaging Dynamics Company Ltd. in October 2001. Imaging Dynamics Company Ltd. was founded in 1995 and is headquartered in Calgary, Canada.","TSXV:IDL
Company: Imaging Dynamics Company Ltd.
(IQT2620120) - Canada",-
08/11/2016,HealthSpace Data Systems Ltd. (CNSX:HS),CNSX:HS,Private Placement,Closed, 3.46 ,-,-,IQTR379885947,Health Care (Primary),Canada (Primary),"HealthSpace Data Systems Ltd. develops and sells information and communication management systems for health inspection departments of federal, provincial, state, and municipal governments in Canada and the United States. Its products include HSCloud product, an enterprise software system for license, invoice, and inspection data for use by government agencies; HealthSpace Touch, an application designed for data collection, electronically capture signatures, and insert photos and email inspection reports for health inspectors; and HealthSpace EnviroIntel EHS Manager, an internet-based client/server application used to fill out forms, request information, and view data, including reports. The company also offers HealthSpace Cloud, a customizable cloud-based portal for managing applications, licenses, permits, and other data; and HealthSpace Data that provides environmental health reporting, analytics, and monitoring platform. HealthSpace Data Systems Ltd. was founded in 1998 and is headquartered in Chilliwack, Canada.","CNSX:HS
Company: HealthSpace Data Systems Ltd.
(IQT317841012) - Canada",-
08/03/2016,Ortho Regenerative Technologies Inc. (CNSX:ORTH),CNSX:ORTH,Private Placement,Closed, 0.905 ,-,-,IQTR378811189,Health Care (Primary),Canada (Primary),"Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a freeze-dried formulation for rotator cuff repair; and Ortho-M, a biopolymer for bilateral meniscus repair. It also develops Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.","CNSX:ORTH
Company: Ortho Regenerative Technologies Inc.
(IQT539889813) - Canada",-
07/29/2016,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 1.8 ,-,-,IQTR378397405,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
07/25/2016,Correvio Pharma Corp. (TSX:CORV),TSX:CORV,Public Offering,Closed, 39.62 ,-,-,IQTR377760887,Health Care (Primary),Canada (Primary),"Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.","TSX:CORV
Company: Correvio Pharma Corp.
(IQT2598163) - Canada",-
07/22/2016,Aurinia Pharmaceuticals Inc. (TSX:AUP),TSX:AUP,Public Offering,Announced, 13.18 ,-,-,IQTR377634238,Health Care (Primary),Canada (Primary),"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","TSX:AUP
Company: Aurinia Pharmaceuticals Inc.
(IQT2622592) - Canada",-
07/22/2016,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.19 ,-,-,IQTR377653370,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
07/21/2016,Knight Therapeutics Inc. (TSX:GUD),TSX:GUD,Private Placement,Effective, 5.0 ,-,-,IQTR376964681,Health Care (Primary),Canada (Primary),"Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; and NERLYNX for the treatment of HER2-positive breast cancer. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; and TX-004HR for moderate-to-severe dyspareunia and TX-001HR for moderate-to-severe vasomotor symptoms due to menopause. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. Further, the company develops TULSA-PRO, a medical device for prostate ablation. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.","TSX:GUD
Company: Knight Therapeutics Inc.
(IQT254910895) - Canada",-
07/21/2016,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Public Offering,Closed, 1.0 ,-,-,IQTR377163831,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
07/15/2016,Medexus Pharmaceuticals Inc. (TSXV:MDP),TSXV:MDP,Merger/Acquisition,Closed, 1.85 ,Knight Therapeutics Inc. (TSX:GUD),-,IQTR375070696,Health Care (Primary),Canada (Primary),"Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company’s primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Otixal, a prescription product for the treatment of acute otitis media with tympanostomy tubes in pediatric patients; Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; and Rupall, an allergy medication. It also offers Metoject Subcutaneous for the treatment of rheumatoid arthritis, psoriasis, and psoriatic arthritis; and distributes pharmaceutical products, such as Treosulfan and Gliolan. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is headquartered in Verdun, Canada.","TSXV:MDP
Company: Medexus Pharmaceuticals Inc.
(IQT253516634) - Canada",-
07/15/2016,Element Lifestyle Retirement Inc. (TSXV:ELM),TSXV:ELM,Private Placement,Closed, 0.71 ,-,-,IQTR375166701,Health Care (Primary),Canada (Primary),"Element Lifestyle Retirement Inc. develops and operates senior retirement communities in British Columbia, Canada. It provides development consulting services, such as property selection, assembly and acquisition, building and community design, municipal approval and land entitlement processes, financing, marketing, sales and leasing, and construction project management. The company also offers long-term management services for the facilities, which include management of the administration, operation, and financing of retirement communities and physical facilities. Element Lifestyle Retirement Inc. was incorporated in 2007 and is headquartered in Vancouver, Canada.","TSXV:ELM
Company: Element Lifestyle Retirement Inc.
(IQT142268555) - Canada",-
07/14/2016,Cronos Group Inc. (TSX:CRON),TSX:CRON,Private Placement,Closed, 15.0 ,-,-,IQTR374933032,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
07/14/2016,SQI Diagnostics Inc. (TSXV:SQD),TSXV:SQD,Public Offering,Announced, 3.12 ,-,-,IQTR374936479,Health Care (Primary),Canada (Primary),"SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.","TSXV:SQD
Company: SQI Diagnostics Inc.
(IQT34231255) - Canada",-
07/12/2016,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Merger/Acquisition,Closed,-,-,"Sequoia Fund, Inc. (MutualFund:SEQU.X); Ruane, Cunniff & Goldfarb Inc.",IQTR374242557,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
07/05/2016,Lexaria Bioscience Corp. (OTCPK:LXRP),OTCPK:LXRP,Private Placement,Closed, 0.38 ,-,-,IQTR371950146,Health Care (Primary),Canada (Primary),"Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.",-,"CNSX:LXX
Company: Lexaria Bioscience Corp.
(IQT241590134) - Canada"
07/04/2016,Apteryx Imaging Inc. (TSXV:XRAY),TSXV:XRAY,Private Placement,Closed, 0.5 ,Stratigis Capital Advisors Inc.; Bloom Burton Healthcare Lending Trust,-,IQTR371460144,Health Care (Primary),Canada (Primary),"Apteryx Imaging Inc. provides diagnostic imaging software and device technologies for dentists and oral health specialists. Its imaging software products include XrayVision 4 that provides image enhancement and analysis tools with open-architecture technology allowing integration with the imaging systems from various manufacturers; XVWeb, a DICOM server that accepts images from various DICOM-compliant imaging software; XVWeb 3D, a cloud solution for 3D dental imaging; XVlite, a dental imaging software package; and XrayVision DCV, a DICOM-based dental imaging suite. The company’s imaging hardware products comprise TUXEDO intraoral sensors; LED IC100 intraoral cameras; and RAYSCAN panoramic + cephalometric imaging solutions. It also offers VELscope Vx system, a device for the enhanced visualization of mucosal abnormalities, such as oral cancer and premalignant dysplasia; VELscope Vx imaging adapter for fluorescence and white-light clinical imaging; Vx VELcaps to prevent patient cross contamination; Vx VELsheaths, a single use plastic sheath to prevent patient cross contamination; and VELscope Vx Value Bundle, a portable handheld device used to conduct oral tissue examinations. Apteryx Imaging Inc. has a partnership agreement with 4th-IR AG to develop a suite of cloud-based AI solutions. The company was formerly known as LED Medical Diagnostics Inc. and changed its name to Apteryx Imaging Inc. in September 2019. Apteryx Imaging Inc. was founded in 2002 and is headquartered in Vancouver, Canada.","TSXV:XRAY
Company: Apteryx Imaging Inc.
(IQT143328534) - Canada",-
06/30/2016,KDA Group Inc. (TSXV:KDA),TSXV:KDA,Private Placement,Closed, 4.0 ,"PCP GP, L.P.",-,IQTR371385619,Health Care (Primary),Canada (Primary),"KDA Group Inc. provides pharmacy personnel replacement and vocational training services to health industry in the Province of Quebec, Canada. The company operates through Pharmacy Services and Pharmaceutical Solutions segments. It primarily offers replacement pharmacists and technical assistants. The company also provides consulting services to assist in optimizing pharmacy operations, including container-content verification delegation, optimization of laboratory operations, professional services and care plans, and inventory management. In addition, it is involved in the distribution of generic pharmaceutical products. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.","TSXV:KDA
Company: KDA Group Inc.
(IQT282005982) - Canada",-
06/27/2016,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Closed, 1.52 ,-,-,IQTR369102536,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
06/21/2016,Sernova Corp. (TSXV:SVA),TSXV:SVA,Private Placement,Closed, 4.2 ,-,-,IQTR367094270,Health Care (Primary),Canada (Primary),"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as hemophilia A and thyroid diseases. Sernova Corp. is headquartered in London, Canada.","TSXV:SVA
Company: Sernova Corp.
(IQT29198402) - Canada",-
06/21/2016,Enlighta Inc. (TSXV:NLTA),TSXV:NLTA,Private Placement,Closed, 0.1 ,-,-,IQTR368141764,Health Care (Primary),Canada (Primary),"Enlighta Inc. operates as a healthcare and medical digital, green, and clean technology company. The company, through a joint venture with Fischer Institute of Physical Therapy and Performance, provides physical therapy services and rehabilitative medicine treatments. It also has a patent pending portfolio of 10 OTC nutraceutical formulations. The company was formerly known as HooXi Network Inc. and changed its name to Enlighta Inc. in July 2019. Enlighta Inc. is based in Richmond, Canada.","TSXV:NLTA
Company: Enlighta Inc.
(IQT253108413) - Canada",-
06/15/2016,Aurinia Pharmaceuticals Inc. (TSX:AUP),TSX:AUP,Private Placement,Closed, 9.08 ,"ILJIN SNT Co., Ltd",-,IQTR365213198,Health Care (Primary),Canada (Primary),"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","TSX:AUP
Company: Aurinia Pharmaceuticals Inc.
(IQT2622592) - Canada",-
06/15/2016,Canadian International Pharma Corp. (TSXV:CIP.H),TSXV:CIP.H,Private Placement,Closed, 0.205 ,-,-,IQTR365402838,Health Care (Primary),Canada (Primary),"Canadian International Pharma Corp. focuses on the manufacture, distribution, and sale of generic and nutraceutical drugs in Canada and internationally. It also provides testing and measuring services for finished dosage forms of nutraceutical and pharmaceutical medications. The company was formerly known as Black Panther Mining Corp. and changed its name to Canadian International Pharma Corp. in June 2015. Canadian International Pharma Corp. is based in West Vancouver, Canada.","TSXV:CIP.H
Company: Canadian International Pharma Corp.
(IQT46045249) - Canada",-
06/14/2016,Arch Biopartners Inc. (OTCPK:ACHF.F),OTCPK:ACHF.F,Private Placement,Closed, 0.33 ,-,-,IQTR364917694,Health Care (Primary),Canada (Primary),"Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",-,"TSXV:ARCH
Company: Arch Biopartners Inc.
(IQT246708499) - Canada"
06/13/2016,Correvio Pharma Corp. (TSX:CORV),TSX:CORV,Private Placement,Closed, 40.0 ,-,-,IQTR365142484,Health Care (Primary),Canada (Primary),"Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.","TSX:CORV
Company: Correvio Pharma Corp.
(IQT2598163) - Canada",-
06/10/2016,Antibe Therapeutics Inc. (TSXV:ATE),TSXV:ATE,Private Placement,Closed, 1.46 ,-,-,IQTR347894449,Health Care (Primary),Canada (Primary),"Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company’s lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.","TSXV:ATE
Company: Antibe Therapeutics Inc.
(IQT241870185) - Canada",-
06/09/2016,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Effective, 5.0 ,Global Emerging Markets,-,IQTR347350960,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
06/07/2016,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.15 ,-,-,IQTR346749519,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
06/03/2016,Avivagen Inc. (TSXV:VIV),TSXV:VIV,Private Placement,Closed, 3.6 ,-,-,IQTR345591766,Health Care (Primary),Canada (Primary),"Avivagen Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal’s own health defenses. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. The company is headquartered in Ottawa, Canada.","TSXV:VIV
Company: Avivagen Inc.
(IQT23428260) - Canada",-
06/02/2016,Kane Biotech Inc. (TSXV:KNE),TSXV:KNE,Private Placement,Closed, 0.661 ,-,-,IQTR345299114,Health Care (Primary),Canada (Primary),"Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.","TSXV:KNE
Company: Kane Biotech Inc.
(IQT5532100) - Canada",-
05/31/2016,Aurora Spine Corporation (TSXV:ASG),TSXV:ASG,Private Placement,Closed, 0.505 ,-,-,IQTR344426779,Health Care (Primary),Canada (Primary),"Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. The company offers interspinous process lumbar fusion devices for patients suffering from degenerative disc diseases; Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae and bone grows to complete the fusion process; sterile-packed titanium plasma spray coated spinal infusion implants for bone growth; and 3D Printed Stand Alone ALIF Cage, an integrated plate and spacer system that helps to preserve the natural anatomic profile, and provide spinal column support and stability. The company was incorporated in 2013 and is headquartered in Toronto, Canada.","TSXV:ASG
Company: Aurora Spine Corporation
(IQT245521185) - Canada",-
05/31/2016,Lexaria Bioscience Corp. (OTCPK:LXRP),OTCPK:LXRP,Private Placement,Closed, 0.099 ,-,-,IQTR344485775,Health Care (Primary),Canada (Primary),"Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.",-,"CNSX:LXX
Company: Lexaria Bioscience Corp.
(IQT241590134) - Canada"
05/30/2016,MedX Health Corp (TSXV:MDX),TSXV:MDX,Private Placement,Closed, 1.5 ,-,-,IQTR344245278,Health Care (Primary),Canada (Primary),"MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in North America, Europe, and Asia. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, oralase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients’ mole and lesion scans can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.","TSXV:MDX
Company: MedX Health Corp
(IQT41570448) - Canada",-
05/29/2016,Titan Medical Inc. (TSX:TMD),TSX:TMD,Private Placement,Effective, 20.8 ,"Shanghai Jugu Equity Investment Fund Co., Ltd.",-,IQTR344810194,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
05/27/2016,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 0.207 ,-,-,IQTR343974984,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
05/27/2016,Lotus Ventures Inc. (CNSX:J),CNSX:J,Private Placement,Closed, 0.332 ,-,-,IQTR344323422,Health Care (Primary),Canada (Primary),"Lotus Ventures Inc. produces and sells medical marijuana. The company is based in Vancouver, Canada.","CNSX:J
Company: Lotus Ventures Inc.
(IQT274566928) - Canada",-
05/26/2016,Intellipharmaceutics International Inc. (TSX:IPCI),TSX:IPCI,Public Offering,Closed, 6.77 ,-,-,IQTR343437325,Health Care (Primary),Canada (Primary),"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.","TSX:IPCI
Company: Intellipharmaceutics International Inc.
(IQT79343703) - Canada",-
05/25/2016,Appili Therapeutics Inc. (TSXV:APLI),TSXV:APLI,Private Placement,Closed, 4.28 ,Innovacorp; Atlantic Canada Opportunities Agency; Bloom Burton & Co. Inc.; National Research Council of Canada's Industrial Research Assistance Program,-,IQTR342834260,Health Care (Primary),Canada (Primary),"Appili Therapeutics Inc., a pharmaceutical company, acquires, develops, and commercializes therapeutics in the area of infectious disease in Canada. The company focuses on building and advancing a portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-1501, a taste-masked oral liquid formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was founded in 2015 and is headquartered in Halifax, Canada.","TSXV:APLI
Company: Appili Therapeutics Inc.
(IQT607127273) - Canada",-
05/17/2016,Canadian International Pharma Corp. (TSXV:CIP.H),TSXV:CIP.H,Private Placement,Closed, 0.39 ,-,-,IQTR339664984,Health Care (Primary),Canada (Primary),"Canadian International Pharma Corp. focuses on the manufacture, distribution, and sale of generic and nutraceutical drugs in Canada and internationally. It also provides testing and measuring services for finished dosage forms of nutraceutical and pharmaceutical medications. The company was formerly known as Black Panther Mining Corp. and changed its name to Canadian International Pharma Corp. in June 2015. Canadian International Pharma Corp. is based in West Vancouver, Canada.","TSXV:CIP.H
Company: Canadian International Pharma Corp.
(IQT46045249) - Canada",-
05/17/2016,Opsens Inc. (TSX:OPS),TSX:OPS,Private Placement,Closed, 5.0 ,Lumira Ventures; Fiera Capital Corporation (TSX:FSZ); The Fiera Capital QSSP II Investment Fund Inc.,-,IQTR339843560,Health Care (Primary),Canada (Primary),"Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for interventional cardiology, fractional flow reserve (FFR), oil and gas, and industrial applications. The company operates through two segments, Medical and Industrial. It primarily focuses on the measure of FFR in interventional cardiology. The company offers OptoWire, an advanced optical-based pressure guidewire that enhances the clinical outcome of patients with coronary artery disease; and OptoMonitor, which can be connected directly to the cath lab hemodynamic system that offers FFR module to display FFR on the cath lab monitor. It also provides design, installation, and field support services; and fiber optic point pressure and temperature sensors, distributed temperature sensors, specialized readout units, and specialized cables, as well as fiber optic sensors for infrastructure surveillance to the upstream and downstream oil and gas industry. In addition, the company provides fiber optic sensing solutions for industrial applications, including fiber optic temperature sensors, pressure sensors, strain sensors, displacement sensors, and extensometers, as well as signal conditioners/OEM boards. It serves various markets, such as life sciences, energy, defense and aerospace, geotechnical, civil engineering, scientific laboratory, and other markets. The company operates in the United States, Japan, Canada, and internationally. Opsens Inc. is headquartered in Québec, Canada.","TSX:OPS
Company: Opsens Inc.
(IQT29686435) - Canada",-
05/17/2016,IMV Inc. (TSX:IMV),TSX:IMV,Private Placement,Closed, 8.0 ,CTI Life Sciences,-,IQTR339949771,Health Care (Primary),Canada (Primary),"IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company’s DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.","TSX:IMV
Company: IMV Inc.
(IQT71987179) - Canada",-
05/13/2016,Acerus Pharmaceuticals Corporation (TSX:ASP),TSX:ASP,Merger/Acquisition,Closed, 10.25 ,First Generation Capital Inc.,K2 & Associates Investment Management Inc.; West Face Capital Inc,IQTR338255931,Health Care (Primary),Canada (Primary),"Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.","TSX:ASP
Company: Acerus Pharmaceuticals Corporation
(IQT137641837) - Canada",-
05/11/2016,Sirona Biochem Corp. (TSXV:SBM),TSXV:SBM,Private Placement,Closed, 0.83 ,-,-,IQTR337516423,Health Care (Primary),Canada (Primary),"Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.","TSXV:SBM
Company: Sirona Biochem Corp.
(IQT58893998) - Canada",-
05/10/2016,Knight Therapeutics Inc. (TSX:GUD),TSX:GUD,Public Offering,Closed, 200.0 ,-,-,IQTR337311575,Health Care (Primary),Canada (Primary),"Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; and NERLYNX for the treatment of HER2-positive breast cancer. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; and TX-004HR for moderate-to-severe dyspareunia and TX-001HR for moderate-to-severe vasomotor symptoms due to menopause. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. Further, the company develops TULSA-PRO, a medical device for prostate ablation. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.","TSX:GUD
Company: Knight Therapeutics Inc.
(IQT254910895) - Canada",-
05/10/2016,Zecotek Photonics Inc. (TSXV:ZMS),TSXV:ZMS,Private Placement,Closed, 1.57 ,-,-,IQTR340761244,Health Care (Primary),Canada (Primary),"Zecotek Photonics Inc., a photonics technology company, develops various photonics technologies and products for commercial and research applications in medical, bio-science, high-energy physics, pharmaceutical research, material processing, engineering and industrial design, and multi-media markets. The company operates through three divisions: Zecotek Imaging China, Zecotek Optronics Systems, and Zecotek Autotronics. Its imaging systems include lutetium fine silicate scintillation crystals; solid-state micro-pixel avalanche photo diode photo detectors and transistors; and integrated detector modules. The company also develops glasses-free 3D displays; and 3D auto-stereoscopic displays, and 3D printers and related technologies for applications in healthcare, scientific, and industrial markets. Zecotek Photonics Inc. in Asia and North America. Its strategic partners primarily include Nucare Ltd., University of Washington, and University of California. The company was formerly known as Zecotek Medical Systems Inc. and changed its name to Zecotek Photonics Inc. in November 2007. Zecotek Photonics Inc. was incorporated in 1983 and is headquartered in Richmond, Canada.","TSXV:ZMS
Company: Zecotek Photonics Inc.
(IQT39242544) - Canada",-
05/09/2016,Cronos Group Inc. (TSX:CRON),TSX:CRON,Private Placement,Closed, 6.0 ,"Chesapeake Partners Management Co., Inc.",-,IQTR336023666,Health Care (Primary),Canada (Primary),"Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.","TSX:CRON
Company: Cronos Group Inc.
(IQT266973677) - Canada",-
05/05/2016,Eyecarrot Innovations Corp. (TSXV:EYC),TSXV:EYC,Private Placement,Closed, 1.62 ,-,-,IQTR334452375,Health Care (Primary),Canada (Primary),"Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.","TSXV:EYC
Company: Eyecarrot Innovations Corp.
(IQT202354752) - Canada",-
05/04/2016,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Public Offering,Closed, 60.14 ,-,-,IQTR335769091,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
05/02/2016,Premier Diversified Holdings Inc. (TSXV:PDH),TSXV:PDH,Private Placement,Closed, 1.02 ,Corner Market Capital Corporation,-,IQTR333582723,Health Care (Primary),Canada (Primary),"Premier Diversified Holdings Inc., through its subsidiaries, designs, finances, and operates medical diagnostic imaging centers in Canada. It operates through two segments, Investments and Operation of Diagnostic Centers. The company’s medical diagnostic imaging centers provide positron emission technology/computed tomography (PET-CT) scans. It operates PET-CT diagnostic scanning center in Burnaby, British Columbia. The company is headquartered in Burnaby, Canada.","TSXV:PDH
Company: Premier Diversified Holdings Inc.
(IQT246518802) - Canada",-
04/25/2016,Acerus Pharmaceuticals Corporation (TSX:ASP),TSX:ASP,Private Placement,Closed, 2.53 ,"Aytu BioScience, Inc. (NasdaqCM:AYTU)",-,IQTR331916268,Health Care (Primary),Canada (Primary),"Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.","TSX:ASP
Company: Acerus Pharmaceuticals Corporation
(IQT137641837) - Canada",-
04/25/2016,Med BioGene Inc. (TSXV:MBI.H),TSXV:MBI.H,Private Placement,Closed, 0.05 ,-,-,IQTR338323984,Health Care (Primary),Canada (Primary),"Med BioGene Inc., a life science company, focuses on the development and commercialization of genomic-based clinical tests for cancer. Its product is the GeneFx Lung, which tests early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy. Med BioGene Inc. has a collaboration agreement with the University Health Network in Toronto. The company was founded in 2002 and is headquartered in Vancouver, Canada.","TSXV:MBI.H
Company: Med BioGene Inc.
(IQT27127728) - Canada",-
04/22/2016,BriaCell Therapeutics Corp. (TSXV:BCT),TSXV:BCT,Private Placement,Closed, 1.28 ,-,-,IQTR331750456,Health Care (Primary),Canada (Primary),"BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada.","TSXV:BCT
Company: BriaCell Therapeutics Corp.
(IQT29557279) - Canada",-
04/20/2016,Hemostemix Inc. (TSXV:HEM),TSXV:HEM,Private Placement,Closed, 1.64 ,Drive Capital Corporation,-,IQTR331610243,Health Care (Primary),Canada (Primary),"Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cells products, such as synergetic cell populations, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.","TSXV:HEM
Company: Hemostemix Inc.
(IQT278407492) - Canada",-
04/18/2016,Sienna Senior Living Inc. (TSX:SIA),TSX:SIA,Public Offering,Closed, 120.3 ,-,-,IQTR331423668,Health Care (Primary),Canada (Primary),"Sienna Senior Living Inc., through its subsidiaries, provides senior housing and long-term care (LTC) services in Canada. It operates through LTC and Retirement segments. The company offers a range of seniors’ living options, including independent and assisted living, memory care, long-term care, and specialized programs and services, as well as provides management services. As of December 31, 2018, it owned and operated a total of 70 seniors’ living residences comprising 27 retirement residences, 35 LTC residences, and 8 seniors’ living residences. The company was formerly known as Leisureworld Senior Care Corporation and changed its name to Sienna Senior Living Inc. in May 2015. Sienna Senior Living Inc. was founded in 1972 and is headquartered in Markham, Canada.","TSX:SIA
Company: Sienna Senior Living Inc.
(IQT99930472) - Canada",-
04/15/2016,Helix BioPharma Corp. (TSX:HBP),TSX:HBP,Private Placement,Closed, 4.7 ,-,-,IQTR331301330,Health Care (Primary),Canada (Primary),"Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. It is developing L-DOS47 for the treatment of non-squamous small cell lung cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. The company is headquartered in Richmond Hill, Canada.","TSX:HBP
Company: Helix BioPharma Corp.
(IQT2618189) - Canada",-
04/07/2016,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Closed, 0.93 ,Dundee Resources Limited,-,IQTR330371489,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
04/04/2016,RepliCel Life Sciences Inc. (OTCPK:REPC.F),OTCPK:REPC.F,Private Placement,Closed, 0.378 ,-,-,IQTR330260392,Health Care (Primary),Canada (Primary),"RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",-,"TSXV:RP
Company: RepliCel Life Sciences Inc.
(IQT254079093) - Canada"
03/31/2016,H-Source Holdings Ltd. (TSXV:HSI),TSXV:HSI,Private Placement,Closed, 2.81 ,-,-,IQTR329694352,Health Care (Primary),Canada (Primary),"H-Source Holdings Ltd., a technology company, operates in the healthcare industry. It offers a hospital-to-hospital transaction platform that provides a marketplace for members to buy, sell, and transfer excess inventory supplies and capital equipment with each other. The company’s platform allows members to conduct transactions within integrated delivery networks and group purchasing organizations. H-Source Holdings Ltd. is headquartered in Vancouver, Canada.","TSXV:HSI
Company: H-Source Holdings Ltd.
(IQT377711030) - Canada",-
03/31/2016,Nexia Health Technologies Inc. (TSXV:NGH.H),TSXV:NGH.H,Private Placement,Closed, 1.0 ,-,-,IQTR329712607,Health Care (Primary),Canada (Primary),"Nexia Health Technologies Inc. does not have any significant operations. Previously, it was engaged in the development, sale, and support of application software and related services to customers in the healthcare industry in Canada and the United States. The company was formerly known as Nightingale Informatix Corporation and changed its name to Nexia Health Technologies Inc. in September 2016. Nexia Health Technologies Inc. was founded in 2002 and is based in Markham, Canada.","TSXV:NGH.H
Company: Nexia Health Technologies Inc.
(IQT23854791) - Canada",-
03/29/2016,Kane Biotech Inc. (TSXV:KNE),TSXV:KNE,Public Offering,Closed, 2.43 ,-,-,IQTR329434549,Health Care (Primary),Canada (Primary),"Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.","TSXV:KNE
Company: Kane Biotech Inc.
(IQT5532100) - Canada",-
03/29/2016,Cotinga Pharmaceuticals Inc. (TSXV:COT),TSXV:COT,Private Placement,Closed, 1.45 ,-,-,IQTR329514452,Health Care (Primary),Canada (Primary),"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","TSXV:COT
Company: Cotinga Pharmaceuticals Inc.
(IQT29927531) - Canada",-
03/22/2016,DIAGNOS Inc. (TSXV:ADK),TSXV:ADK,Private Placement,Effective, 0.533 ,TNG Capital Inc.; 9071 8776 Quebec Inc.,-,IQTR328919642,Health Care (Primary),Canada (Primary),"DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.","TSXV:ADK
Company: DIAGNOS Inc.
(IQT2605851) - Canada",-
03/21/2016,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Private Placement,Closed, 8.16 ,"Eventide Asset Management, LLC",-,IQTR328808401,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
03/21/2016,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 15.05 ,-,-,IQTR328839502,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
03/14/2016,StageZero Life Sciences Ltd. (TSX:SZLS),TSX:SZLS,Private Placement,Closed, 2.16 ,Alumina Partners LLC,-,IQTR328205304,Health Care (Primary),Canada (Primary),"StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.","TSX:SZLS
Company: StageZero Life Sciences Ltd.
(IQT29828484) - Canada",-
03/09/2016,Biomark Diagnostics Inc (DB:20B),DB:20B,Private Placement,Closed, 0.573 ,-,-,IQTR327812680,Health Care (Primary),Canada (Primary),"Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a research collaboration with the University of Maryland School of Medicine related to the discovery and validation of biomarkers using a combinatorial technology approach. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",-,"CNSX:BUX
Company: Biomark Diagnostics Inc
(IQT275753722) - Canada"
03/01/2016,Liminal BioSciences Inc. (TSX:LMNL),TSX:LMNL,Private Placement,Closed, 30.0 ,"Thomvest Ventures, Inc.",-,IQTR327061962,Health Care (Primary),Canada (Primary),"Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.","TSX:LMNL
Company: Liminal BioSciences Inc.
(IQT2640774) - Canada",-
02/25/2016,Oncolytics Biotech Inc. (TSX:ONC),TSX:ONC,Public Offering,Announced, 4.6 ,-,-,IQTR326758434,Health Care (Primary),Canada (Primary),"Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. It has collaboration with PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.","TSX:ONC
Company: Oncolytics Biotech Inc.
(IQT2635856) - Canada",-
02/23/2016,"ProMIS Neurosciences, Inc. (TSX:PMN)",TSX:PMN,Private Placement,Closed, 1.0 ,-,-,IQTR326376112,Health Care (Primary),Canada (Primary),"ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","TSX:PMN
Company: ProMIS Neurosciences, Inc.
(IQT24191293) - Canada",-
02/22/2016,EGF Theramed Health Corp. (CNSX:TMED),CNSX:TMED,Private Placement,Closed, 1.05 ,-,-,IQTR326267624,Health Care (Primary),Canada (Primary),"EGF Theramed Health Corp. operates as a technology company that provides automated biomedical care online services for common health problems. It provides Fully Automated Signal Transduction, a medical device, which monitors blood pressure, as well as enables physiologically interactive health apps used in testing, tracking, and treating common health conditions. The company also offers Electro-Physiologically Interactive Computing (EPIC) system, an online system. Its EPIC serves people interested in normalizing blood pressure, blood glucose, and body weight and skin conditions. The company was formerly known as Theramed Health Corporation and changed its name to EGF Theramed Health Corp. in October 2019. EGF Theramed Health Corp. was incorporated in 2011 and is headquartered in Richmond, Canada.","CNSX:TMED
Company: EGF Theramed Health Corp.
(IQT246550060) - Canada",-
02/18/2016,Spectral Medical Inc. (TSX:EDT),TSX:EDT,Private Placement,Closed, 0.854 ,-,-,IQTR327435101,Health Care (Primary),Canada (Primary),"Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops continuous renal replacement therapy, an open platform for other hemoperfusion cartridges. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.","TSX:EDT
Company: Spectral Medical Inc.
(IQT2651919) - Canada",-
02/16/2016,Bausch Health Companies Inc. (NYSE:BHC),NYSE:BHC,Merger/Acquisition,Closed,-,-,"Maverick Capital, Ltd.",IQTR325985607,Health Care (Primary),Canada (Primary),"Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.",-,"TSX:BHC
Company: Bausch Health Companies Inc.
(IQT2594579) - Canada"
02/12/2016,Lexaria Bioscience Corp. (OTCPK:LXRP),OTCPK:LXRP,Private Placement,Closed, 0.135 ,-,-,IQTR325994263,Health Care (Primary),Canada (Primary),"Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.",-,"CNSX:LXX
Company: Lexaria Bioscience Corp.
(IQT241590134) - Canada"
02/05/2016,Premier Health Group Inc. (CNSX:PHGI),CNSX:PHGI,Private Placement,Closed, 0.2 ,-,-,IQTR324986328,Health Care (Primary),Canada (Primary),"Premier Health Group Inc., together with its subsidiaries, operates and manages primary care clinics in Canada and the Dominican Republic. It operates four primary care clinics based in the Lower Mainland in British Columbia. The company also focuses on developing proprietary technology through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company was formerly known as Premier Health Services Inc. and changed its name to Premier Health Group Inc. in September 2015. Premier Health Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.","CNSX:PHGI
Company: Premier Health Group Inc.
(IQT316965305) - Canada",-
02/05/2016,Nova Leap Health Corp. (TSXV:NLH),TSXV:NLH,Public Offering,Closed, 0.35 ,-,-,IQTR325263018,Health Care (Primary),Canada (Primary),"Nova Leap Health Corp. provides personal home care and support services in the United States and Canada. Its services include companionship; cooking and meal preparation; dementia care; light housekeeping; respite care; transportation; personal care; medication reminders; and medication administration by nursing staff. The company serves clients in the states of Rhode Island, New Hampshire, Vermont, and Massachusetts. Nova Leap Health Corp. is headquartered in Halifax, Canada.","TSXV:NLH
Company: Nova Leap Health Corp.
(IQT327204283) - Canada",-
02/03/2016,Titan Medical Inc. (TSX:TMD),TSX:TMD,Public Offering,Closed, 10.5 ,-,-,IQTR324614200,Health Care (Primary),Canada (Primary),"Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.","TSX:TMD
Company: Titan Medical Inc.
(IQT47190779) - Canada",-
01/28/2016,Spectral Medical Inc. (TSX:EDT),TSX:EDT,Public Offering,Closed, 10.01 ,-,-,IQTR323667978,Health Care (Primary),Canada (Primary),"Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops continuous renal replacement therapy, an open platform for other hemoperfusion cartridges. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.","TSX:EDT
Company: Spectral Medical Inc.
(IQT2651919) - Canada",-
01/21/2016,Vaxil Bio Ltd. (TSXV:VXL),TSXV:VXL,Public Offering,Closed, 0.058 ,-,-,IQTR323104304,Health Care (Primary),Canada (Primary),"Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company’s lead product is ImMucin that has completed a Phase1/2 clinical trial, which is used for the treatment of multiple myeloma. It is also involved in developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.","TSXV:VXL
Company: Vaxil Bio Ltd.
(IQT115279018) - Canada",-
01/12/2016,Correvio Pharma Corp. (TSX:CORV),TSX:CORV,Public Offering,Announced, 28.55 ,-,-,IQTR322509744,Health Care (Primary),Canada (Primary),"Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.","TSX:CORV
Company: Correvio Pharma Corp.
(IQT2598163) - Canada",-
01/07/2016,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Public Offering,Closed, 1.75 ,-,-,IQTR321664618,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
01/07/2016,Aequus Pharmaceuticals Inc. (TSXV:AQS),TSXV:AQS,Private Placement,Closed, 0.899 ,-,-,IQTR321700726,Health Care (Primary),Canada (Primary),"Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistita, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation. It also offers Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. In addition, the company’s development stage product includes AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and depressive disorders; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid-based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; Mynosys Cellular Devices for distribution, sales and marketing of Zepto for cataract surgery; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.","TSXV:AQS
Company: Aequus Pharmaceuticals Inc.
(IQT288609605) - Canada",-
01/07/2016,Zymeworks Inc. (NYSE:ZYME),NYSE:ZYME,Private Placement,Closed, 86.97 ,BDC Capital Inc.; Celgene Corporation; Eli Lilly and Company (NYSE:LLY); Lumira Ventures; Fonds de solidarité FTQ; Perceptive Advisors LLC; CTI Life Sciences; Merlin Nexus LLC; Northleaf Capital Partners; Teralys Capital; Brace Pharma Capital,-,IQTR321714247,Health Care (Primary),Canada (Primary),"Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; and ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnership with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.",-,"TSX:ZYME
Company: Zymeworks Inc.
(IQT428079716) - Canada"
01/06/2016,ESSA Pharma Inc. (TSXV:EPI),TSXV:EPI,Private Placement,Closed, 21.57 ,"Deerfield Management Company, L.P.; Clarus Ventures, LLC",-,IQTR321476006,Health Care (Primary),Canada (Primary),"ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.","TSXV:EPI
Company: ESSA Pharma Inc.
(IQT282860074) - Canada",-
